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GRIN2A and GRIN2B encode the GluN2A and GluN2B subunits of the NMDA
receptor, a subtype of ionotropic glutamate receptor that displays voltage-dependent
block by Mg2+ and a high permeability to Ca2+. These receptors play important
roles in synaptogenesis, synaptic transmission and synaptic plasticity, as well as
contributing to neuronal loss and dysfunction in several neurological disorders.
Recently, individuals with a range of childhood onset epilepsies, intellectual disability
and other neurodevelopmental abnormalities have been found to carry heterozygous
gene-disrupting or protein-altering point mutations in GRIN2A and GRIN2B.
This thesis addresses the hypothesis that these point mutations cause
key functional disturbances to NMDA receptor properties that contribute to
neurodevelopmental disorders. To test this hypothesis, a group of related mutations
were selected for functional assessment in heterologous systems: four missense
mutations affecting residues in or near the subunit pore regions, all of which
are associated with epilepsy and intellectual disability. To model the impact of
gene disrupting mutations in GRIN2A, a preliminary analysis of the functional
consequences of GluN2A haploinsufficiency in a genetically modified rat was also
performed.
Three of the four missense mutations were found to be associated with profound
alterations in fundamental NMDA receptor properties: compared to wild type,
GluN2AN615K was found to reduce Mg2+ block, GluN2BN615I and GluN2BV618G to
cause potentiation by Mg2+, and GluN2AN615K and GluN2BN615I showed reduced
conductance. GluN2AR586K was not found to influence the parameters assessed.
When GluN2AN615K was expressed alongside wild type subunits in the same NMDA
receptor, it was found to have a dominant negative effect. Finally, I established
successful gene targeting in a new rat Grin2A knock-out model, and observed that
heterozygous neurons had lower GluN2A protein expression and current density,
making a good model to study human epilepsies associated with loss of a GRIN2A
allele.
This thesis provides evidence that three missense mutations in GRIN2A and
GRIN2B affect physiologically important properties of the NMDA receptor, and that
GluN2A haploinsufficiency influences important neural properties in vitro. This is
consistent with these mutations causing disease and highlights these and related




The N-methyl-D-aspartate receptor (NMDAR) is an important protein in the brain
that helps to transmit chemical signals between brain cells. Some people with brain
disorders like intellectual disability, autism and epilepsy, have mutations in their
genetic code for these receptors. It is probable that these mutations are at least part
of the cause of their disorder. However, it isn’t known exactly how the change in the
gene might lead to a change in brain function: the aim of this project was to investigate
this.
This project found that three mutations in the NMDAR cause big changes to how
the receptor functions, making it harder for brain cells to communicate with each
other. In the case of one of these mutations, the receptor’s functioning was altered
even when normal versions of the NMDAR genes were present too. This shows
that just one mutation is enough to affect the receptor’s behaviour. The way the
receptor’s functioning was affected by these mutations suggests that it will be less
able to participate in normal brain activities like learning and memory.
This project also designed an animal model which is missing one of its NMDAR
genes. This is similar to what is found in some people with epilepsy, who are also
missing a copy of this gene. Brain cells missing the gene showed some differences in
function which will be interesting to follow up in the future.
In summary, this project found that mutations in NMDARs, or removing a copy
of a NMDAR gene, cause changes in receptor and brain cell function consistent with
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1. Neurodevelopmental disorders are increasingly viewed as representing a continuum of
symptoms with shared disruptions in biological pathways and overlapping genetic and
environmental risk factors.
2. Hundreds of genes have been implicated in the aetiology of neurodevelopmental
disorders, including NMDAR subunits.
3. NMDARs are already known to participate in many crucial brain functions, including
synaptogenesis, synaptic transmission, synaptic plasticity, and neuronal survival.
4. NMDAR dysfunction has already been linked to a range of brain disorders.
5. Recent genetic evidence strongly implicates mutations in NMDARs as contributing to risk
for neurodevelopmental disorders.
6. Neurodevelopmental disorders associated with NMDARs influence cognition and
excitability.
7. Investigating the functional consequences of mutations in NMDAR subunits may highlight
key disruptions in biological pathways underlying neurodevelopmental disorders.
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1.2 Overview of pathogenesis of neurodevelopmental disorders
Mental disorders contribute substantially and increasingly to the global burden of disease
(Murray et al., 2015), however, therapeutic advance is limited by their largely unknown
pathogenesis. Although much time and effort in the past has been devoted to demarcating
subtypes of mental disorder, the emerging concept now is that many mental disorders
with onset in childhood and adolescence can be grouped together as a continuum of
neurodevelopmental disorder comprising intellectual disability, autism spectrum disorders,
schizophrenia and epilepsy. This theory is based partly on overlapping symptomatology
and substantial comorbidity but is mainly driven by evidence of shared genetic risk and
increasingly by evidence of shared biological underpinnings, as described below.
The increasing availability of whole exome sequencing data is opening up a new way
to investigate the pathogenenesis of mental disorders, along with other complex disease.
Most genetic risk for complex disease arises from multiple, common, inherited variants of
individual small effect, making it hard to identify potentially subtle pathogenic effects of a
given variant (see Figure 1.1). However, the ability to economically sequence the coding DNA
of large numbers of individuals has allowed many rare mutations to be identified in particular
disorders. Further, the parents of carriers of rare mutations can also be affordably screened,
allowing identification of mutations as de novo (arising during germline development, thus
present somatically in neither parent). These rarer mutations, particularly de novo ones, are
more likely than common inherited mutations to reduce reproductive fitness, hence contribute
a larger degree of risk for disorder to their carriers (Veltman and Brunner, 2012). This makes
investigating their functional consequences a potentially useful route into identifying key
pathological alterations underlying disease. This is the approach taken in this thesis.
Over the last five years, rare mutations in hundreds of genes have been implicated in
neurodevelopmental disorders: 700 genes and rising in intellectual disability (Vissers et al.,
2016), 400-1000 (predicted) in autism (Geschwind and State, 2015), > 100 in schizophrenia
(Ripke et al., 2014) and > 300 in epilepsy (Allen et al., 2013). Despite being individually rare, as
a group these mutations are estimated to be causal in up to 60% of severe intellectual disability
(Gilissen et al., 2014) and 25% of autism (Geschwind and State, 2015).
Identifying the key biological mechanisms affected by these multitudinous variations is
challenging. A common approach is to perform pathway analysis, where the rate of mutation
in a set of genes with related functions is compared to what would be expected by chance.
This approach is limited by incomplete understanding of the function of many genes and
the reliance on protein interactions identified in non-physiological contexts. Despite this,
there has been a degree of consistency in the biological pathways identified as important
in neurodevelopmental disorders, with chromatin remodelling, synapse development and
synaptic function all identified as frequently mutated pathways in intellectual disability (van
Bokhoven, 2011), autism (Geschwind and State, 2015), schizophrenia (O’Dushlaine et al., 2015)
and epilepsy (Myers and Mefford, 2015). Figure 1.2 shows some of the relationships between
proteins identified to carry mutations in intellectual disability, arranged to highlight the sort
of synaptic functions disrupted.
3
Figure 1.1: Genetic architecture of complex disease
The diagram shows a model for the genetic variants underlying mental disorder, and other
complex disease. An individual’s overall risk of disease will be influenced by multiple genetic
variants with a range of penetrances, and their environmental experiences. Whole exome and
whole genome sequencing is allowing the identification of a host of rare penetrant mutations
of medium to high penetrance (represented on the diagram as “Mendelian disease” and “low
frequency variants with intermediate penetrance”). Taken from Sullivan et al. (2012).
This array of dysfunctional genes and pathways identified in neurodevelopmental
disorders offers a wonderful opportunity to explore the mechanisms underlying these
disorders. However, it is also a daunting task - where to begin? Which genes matter and
which are coincidental? What are the important, disease-relevant, outcomes that should be
measured at the cellular, circuit and behavioural level? One way forward is to select a gene
or genes which have strong genetic evidence linking them to neurodevelopmental disorder,
and are also reasonably well characterised in terms of their products’ normal function. This
allows informed predictions to be made about the probable impact of mutations, facilitating
targeted investigation. Further, if the gene selected is known to be important for normal brain
function, this increases the biological plausibility of the hypothesis that mutations in it cause
neurodevelopmental disorders.
One such pair of genes are the type 2A and 2B subunits of the NMDA receptor, the subject
of the remainder of this thesis. In support of their importance, an overview of the discovery,
structure and normal functions of NMDARs is given in the next two sections, followed by a
brief overview of what is already known about NMDAR dysfunction in disease. The genetic
evidence linking NMDAR mutations to neurodevelopmental disorders is then considered
in detail, and a brief account provided of the clinical features of these putative “NMDAR
synaptopathies”. The introduction concludes with a statement of the aims of this thesis.
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Figure 1.2: Some of the post-synaptic proteins mutated in intellectual disability
The diagram shows a post-synaptic region of a neuron highlighting pathways in which proteins
have been found to be mutated in intellectual disability. Mutated proteins are shown in purple.
The blue circle marks GRIN2A and GRIN2B, the subject of the remainder of this thesis. Taken
from van Bokhoven (2011).
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1.3 Identification and classification of ionotropic glutamate receptors
This section provides a brief historical background to the identification of NMDARs, placing
them in context amongst related receptors.
The acidic amino acid L-glutamate was first considered as a neurotransmitter because of
its high concentrations in brain (Berl and Waelsch, 1958), and its ability to induce convulsions
(Hayashi, 1952), change electrical activity in rabbit cortex (“spreading depression” (van
Harreveld, 1959), cause contraction of crustacean muscle (van Harreveld, 1959), and evoke
action potentials in spinal neurons (Curtis et al., 1960).
Synthetic amino acids were used to demonstrate the existence of two populations of
receptors responding to excitatory amino acids in the spinal cord, with some being “aspartate-
preferring” (NMDA more potent) and some “glutamate-preferring” (kainate more potent)
(McCulloch et al., 1974). Selective antagonists were used to subdivide the “glutamate-
preferring” receptors further, with currents evoked by L-glutamate, or the partially selective
agonist quisqualate, showing block by the antagonist GDEE, but those evoked by kainate
showing insensitivity to GDEE (McLennan and Lodge, 1979). These three groups became
known as NMDA, quisqualate and kainate receptors, with quisqualate replaced by AMPA
once the latter was found to be more selective than quisqalate (which also activates
metabotropic glutamate receptors (Sladeczek et al., 1985)). Initially it was thought that NMDA
receptors were most likely to be activated by L-aspartate, and kainate and AMPA receptors
by L-glutamate. However, binding studies with the NMDAR selective antagonist D-AP5
demonstrated that L-glutamate was far more potent than L-aspartate at displacing D-AP5 from
NMDARs (Olverman et al., 1984), establishing L-glutamate as the key physiological activator
of NMDARs.
The development of AMPA and kainate receptor-specific antagonists such as CNQX
(Fletcher et al., 1988; Honore et al., 1988) allowed dissection of the contribution of different
glutamate receptor subtypes to synaptic responses. Excitatory post synaptic potentials
in X. laevis motoneurons were shown to be a summation of early, fast, non-NMDAR
receptor currents, and later, slower, NMDAR currents (Dale and Roberts, 1985). This work
demonstrated both that multiple types of glutamate receptor were present at the same
synapse, and showed that NMDARs mediated longer lasting currents than other glutamate
receptors.
A number of pharmacological differences between NMDARs extracted from different
brain regions led to the suggestion that NMDARs may be comprised of different subtypes with
different regional distributions (Reynolds and Palmer, 1991; Yoneda and Ogita, 1991). This
was confirmed following cloning of glutamate receptor subunits in the late 1980s and early
1990s (reviewed in Lodge (2009)) and summarised in Table 1.1. The first glutamate receptor to
be cloned was the AMPA receptor GluA1 subunit (initially thought to be a kainate receptor),
identified by screening of cDNA libraries via mRNA injection in X. laevis oocytes followed
by screening for glutamate-evoked currents (Hollmann et al., 1989). Sequence homology
was used to clone three further AMPA receptor subunits, and five kainate receptor subunits
were identified in this manner also. The first NMDAR subunit to be cloned, GluN1, again
6
required functional screening of cDNA libraries via oocytes (Moriyoshi et al., 1991). A further
four genes encoding type 2 NMDAR subunits were identified within two years, but the two
remaining NMDAR genes, encoding type 3 subunits, were not identified until 1995 and 2002.
In addition, two “orphan” subunits were identified in the early 1990s, GluD1 and GluD2,
which have substantial sequence homology with glutamate receptors yet are not known to
assemble into any functional channels. Despite this, they have some physiological role, as the
δ2 subunit is required for synaptic plasticity in the cerebellum and a gain of function mutation
in it causes ataxia (Zuo et al., 1997).
Table 1.1: Ionotropic glutamate receptor subunits
AMPA Kainate NMDA Delta
GluA1 GluK1 GluN1 GluD1






International Union of Basic and Clinical Pharmacology (IUPHAR) names.
Section summary
In summary, the NMDAR is one of a family of glutamate receptors, which together play an
important role in excitatory synaptic transmission in the central nervous system. Early work
found NMDARs to be distinguishable from other glutamate receptors by their pharmacology
and kinetics of synaptic responses. The next section provides more detail on further unique
properties of NMDARs, and how these contribute to their function.
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1.4 NMDAR structure and function
This section gives a brief overview of NMDAR subunit composition, functional domains,
regulation, and functional roles, highlighting key structural determinants where known. It
focusses on the 2A and 2B subunit of the receptor, as these are the subunits in which most
mutations have been found (see Section 1.6).
1.4.1 NMDAR overview
Ultimately the activity of NMDARs is thought to convert specific patterns of neural input
into sustained alterations in synaptic location and strength, underpinning cognition (Bliss
and Collingridge, 1993). They are well placed to do this because of an unusual set of
properties. Firstly, they have high permeability to Ca2+ (MacDermott et al., 1986). This is
important because Ca2+ is an important second messenger which is able to trigger signalling
cascades leading to alterations in synaptic plasticity and gene expression (West et al., 2001).
Secondly, they are “molecular coincidence detectors”: voltage-dependent block of their pore
by Mg2+ ions means their activation requires both the presence of glutamate and post-synaptic
depolarisation, to expel the Mg2+ ion (Mayer et al., 1984; Nowak et al., 1984). Thirdly, they
are made very sensitive to the extracellular environment by a range of modulatory sites
for endogenous regulators, and by the requirement for a co-agonist (glycine or D-serine)
(Johnson and Ascher, 1987; Mothet et al., 2000). Fourthly, they have slow deactivation rates,
facilitating temporal integration of synaptic currents (Erreger et al., 2005). Finally, they have
long cytoplasmic tails which contain sites for interaction with many other proteins in the post-
synaptic density (Husi et al., 2000), allowing a high degree of regulation and potentially even
non-ionotropic signal transduction (Gray et al., 2016).
1.4.2 NMDAR subunits
NMDARs are encoded by seven genes. NMDARs assemble as tetramers of two GluN1
subunits and two others, selected from four type two subunits (GluN2A-D) and two type
three subunits (GluN3A, B) (Paoletti et al., 2013). The GluN1 subunit has eight functionally
distinct splice variants (GluN1-1a-4a and GluN1-1b-4b). The GluN1-b isoforms contain an
extra 21 amino acids in the N terminus which reduce proton sensitivity (Traynelis et al.,
1995) and speed up deactivation rates (Rumbaugh et al., 2000). The GluN1-1-4 isoforms
are distinguished by different combinations of three short casettes in the C terminus which
influence trafficking (Horak and Wenthold, 2009). Glun1-1a and GluN1-2a are the commonest
forms expressed in the rat forebrain, although GluN1-1b is also found in particular regions of
cortex and hippocampus (Laurie and Seeburg, 1994). Although a number of splice variants
exist in the other subunits they are not known to be functionally important (Cull-Candy et al.,
2001). Recent X-ray crystallography structures showed the four subunits to arrange as a
“dimer of dimers” with the subunit types alternating, rather than neighbouring an identical
subunit (Karakas and Furukawa, 2014; Lee et al., 2014). If the two subunits partnering the
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GluN1 subunit are the same, the receptors are termed diheteromers. If they are different, they
are termed triheteromers.
Different subunit compositions lend different properties to NMDARs. NMDARs
containing GluN2A and GluN2B subunits form one broad group, GluN2C/D subunits
another, and GluN3A/B subunits a third. Figure 1.3 highlights the differences in subunit
properties between GluN2 subunits: NMDAR diheteromers containing GluN2A/B show
higher conductance, Ca2+ permeability, Mg2+ block, open probability and deactivation rate
than GluN2C/D diheteromers (Wyllie et al., 2013). All of these properties are important
in determining the integration of synaptic activity by NMDARs and thus the nature of any
synaptic plasticity that arises in response to a given input.
Open probability = 0.4(A), 0.1(B) Open probability = 0.01
Figure 1.3: Influence of subunit identity on NMDAR properties
The schematic groups NMDAR subunits by influence on key biophysical properties, modified
from Wyllie et al. (2013). The main and major sub-conductance level conductances are
provided. Values for open probability taken from Traynelis et al. (2010) and Dravid et al. (2008).
GluN3 diheteromeric NMDARs are very different to other NMDARs: activated by glycine,
not glutamate, with minimal Ca2+ conductance and no Mg2+ block, they are effectively
excitatory glycine receptors (Chatterton et al., 2002). Recently, the existence of GluN3
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diheteromers has been confirmed in optic nerve myelin (Pina-Crespo et al., 2010) and in
hippocampal cultures (Rozeboom et al., 2015). However, GluN3 subunits are thought
most likely to be expressed in vivo as triheteromers with GluN2 subunits. Such GluN2/3
triheteromers show reduced Ca2+ permeability, Mg2+ block, conductance and open probability
compared to GluN2 diheteromers (reviewed in Pachernegg et al. (2012)). Overall, knowledge
of the physiological roles of GluN3-containing NMDAR is considerably less advanced than
for GluN2 subunits.
1.4.3 NMDAR subunit domains
NMDAR subunits have four main functional domains (reviewed in Paoletti et al. (2013) and
Wyllie et al. (2013)), shown in Figure 1.4. The N terminus contains residues important in
subunit assembly, allosteric modulation and gating. The agonist binding domain is comprised
of two non-consecutive residue ranges termed S1 and S2, which interact to form a clam shell
confirmation to bind glycine, in the case of GluN1 and GluN3, or glutamate, in the case of
GluN2. The transmembrane domains form the pore, creating the ion selectivity filter and
mediating Mg2+ block. The C terminus contains residues important for trafficking, anchoring













































Figure 1.4: Function of NMDAR domains
The schematic shows principal NMDAR subunit domains: the dashed black lines represent the
N and C termini, the solid black lines the ligand binding domain (S1 and S2), the cylinders the
transmembrane domains (M1, M3, M4) and re-entrant loop (M2) and the dotted lines the M1-M2
and M2-M3 linker regions. The key functions of each domain are noted on the left. Glycine binds
GluN1 and GluN3 subunits, and glutamate binds GluN2 subunits. Common regulatory ions and
molecules are listed on the right, matched to approximate binding site. Whether they inhibit or
potentiate is marked by + or -. The degree of their influence varies with subunit identity. Some
key proteins which interact with the C terminus are listed on the bottom right. This list does not
include many proteins shown to interact with NMDAR C termini.
Sources: Paoletti et al. (2013), Traynelis et al. (2010), Wenthold et al. (2003).
1.4.4 NMDAR subunit expression
NMDARs show substantial spatial and temporal regulation of expression, with marked
differences between subunits. Detailed assessment of this has been performed using in situ
hybridisation in mice (Watanabe et al., 1992) and rats (Monyer et al., 1994). Consistent
with its obligatory role in all NMDARs, GluN1 is expressed ubiquitously from late gestation
onwards, increasing into adulthood. GluN2B subunits are expressed in late gestation in
all brain areas but gradually become confined to the forebrain by adulthood. In contrast,
GluN2A expression commences after birth and gradually increases until GluN2A subunits
are abundant throughout the brain. GluN2C is mainly expressed in the cerebellum and
olfactory bulb and expression does not commence until postnatal day 10. Similarly to GluN2B,
GluN2D expression commences prenatally, predominantly in the mid and hindbrain, but
reduces throughout adolescence until by adulthood it is expressed mainly in the midbrain
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at low levels. The expression of GluN3 subunits is also spatially and temporally restricted
(reviewed in Pachernegg et al. (2012)). GluN3A is expressed at high levels in the few days after
birth, particularly in layer V of the neocortex, before declining to very low levels in adulthood,
whereas GluN3B slowly increases following birth until it is expressed at highest levels in the
neocortex, hippocampus, cerebellum and motor neurons.
In humans, data are much scarcer due to the need for post-mortem tissue. However, the
overall trends are the same as those found in rodents. In situ hybridisation of fetal tissue (8-20
weeks gestation) identified high levels of GluN1, GluN2B and GluN2D mRNA in most brain
areas with detectable but low levels of GluN2A and GluN2C mRNA (Ritter et al., 2001). An
in situ hybridisation study of the hippocampus only at older ages (5 weeks post-natally to
adulthood) (Law et al., 2003) found GluN1 was expressed in neonates, with levels doubling
over the age of 6-12 months. GluN2B was expressed at highest levels in neonates, declining
over age 6-12 months to adult levels. GluN2A expression was stable from 1-3 months old
into adulthood. The dorsolateral prefrontal cortex was also found to show a pattern of
gradual increase in GluN1 mRNA and protein from gestation to adulthood (Henson et al.,
2008) whereas GluN3A expression was found to peak in infancy and then decline (Henson
et al., 2008). In contrast to these studies, immunoblotting of brains from 20 weeks gestation
to adulthood found levels of all NMDAR subunits investigated (GluN1, GluN2A, GluN2B,
GluN2C, GluN2D and GluN3A) to be highest prenatally (Jantzie et al., 2015). However, this
sample contained relatively few adults and a large proportion of fetuses born prematurely or
as stillbirths, which could conceivably influence NMDAR subunit expression. Taken together,
it seems that human brains primarily express GluN1, GluN2B and GluN2D prenatally, with
increases in GluN1 and GluN2A over childhood and adolescence, a decline in GluN2B over a
similar time period, and a peak in GluN3A in the first year of life.
In addition to the gross regional expression patterns described above, NMDAR subunit
expression varies between cell types and even by sub-cellular location. For example, within
the same cell, layer 5 pyramidal cells have been found to show different NMDAR subunit
compositions at synapses receiving input from local cortical circuits (mainly GluN2B) and
synapses receiving input from the opposite hemisphere (mainly GluN2A) (Kumar and
Huguenard, 2003). Further, there is a bias (not an absolute distinction) towards GluN2A being
found synaptically and GluN2B both synaptically and extra-synaptically (reviewed in Parsons
and Raymond (2014)).
1.4.5 NMDAR function: overview
What is the function of NMDARs in the central nervous system? They are clearly important as
global knock-out of GluN1 in mice results in death within 24 hours of birth, with pups showing
signs of respiratory difficulties and ataxia (Forrest et al., 1994; Li et al., 1994). The following
sections give very brief overviews of the key areas of brain function in which NMDARs
are known to be involved, highlighting the role of GluN2A and/or GluN2B subunits where
applicable.
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1.4.6 NMDAR function: synaptic transmission
NMDARs are cation permeable ion channels, allowing Na+ and Ca2+ to enter the cell and K+
to leave. Although their blockade by Mg2+ ions at resting membrane potentials makes them
unable to initiate neuronal excitation, they are able to further enhance excitation at an already
depolarised post-synaptic membrane (Collingridge et al., 1988). Their prolonged duration
of activation relative to other glutamate receptor sub-types allows them to make a unique
contribution to excitatory drive. The precise duration of depolarisation is very important
for the cyclical circuit activity underlying the generation of neural oscillations, and there is
evidence suggesting NMDARs are important in this process (see Figure 1.5). For example,
NMDAR pharmacological blockade or genetic deletion in interneurons alters the generation of
gamma oscillations in the cortex and hippocampus (reviewed in Gonzalez-Burgos and Lewis
(2012)) and modelling studies suggest NMDARs temporally constrain visual cortex responses
(Rangan et al., 2005) and thalamocortical responses to visual stimuli (Krukowski and Miller,
2001). A role in the generation of neural oscillations is important as coordinated neural activity
is thought to underpin key cognitive processes such as perception, attention and working
memory and be disrupted in subtle disorders of cognition such as autism and schizophrenia
(Uhlhaas and Singer, 2012).
There is some evidence suggesting GluN2A may be particularly important in driving
the inhibition required for coordinated neural activity, as parvalbumin positive interneurons
in culture show a five-fold higher GluN2A:GluN2B ratio than neighbouring pyramidal cells
(Kinney et al., 2006). Further, in Grin2a knock-out mice, NMDA evokes 50% less striatal GABA
release than in wild type animals (Miyamoto et al., 2001).
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Figure 1.5: Role of glutamate receptors in generation of gamma oscillations
The diagram shows a popular model for how high frequency (gamma) oscillations are generated
in neural networks. Pyramidal (P) cells stimulate excitatory glutamate receptors (AMPARs and
NMDARs) on parvalbumin (PV) positive basket cell interneurons which in turn inhibit pyramidal
cells via GABAA receptors. This negative feedback loop results in synchronised firing of groups
of pyramidal cells, and thus generation of detectable oscillations. Taken from Gonzalez-Burgos
and Lewis (2012).
1.4.7 NMDAR function: synaptic plasticity
In addition to NMDARs’ important roles in neurotransmission, they are also able to integrate
signals at synapses in a way that regulates synaptic abundance or strength. This is mediated
by their ability to act as molecular coincidence detectors (see Figure 1.6). As alterations in
synaptic strength are thought to underlie learning and memory (Kandel et al., 2014) the role of
NMDARs in these processes has received a great deal of attention. This subsection provides a
very brief account of this large and complex field.
The weakening or strengthening of synapses in response to activity is known as synaptic
plasticity (Kandel et al., 2014). In the hippocampus, high frequency stimulation leads to an
increase in subsequent response to stimulation (long term potentiation (LTP) (Bliss and Lomo,
1973)) whereas low frequency stimulation leads to a decrease in subsequent response (long
term depression (LTD) (Dudek and Bear, 1992; Mulkey and Malenka, 1992). NMDARs were
first identified as required for certain types of synaptic plasticity in the hippocampus, but are
now known to be important in plasticity in multiple brain regions, including cortex (Sawtell
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et al., 2003) and cerebellum (Rossi et al., 2002). However, not all forms of synaptic plasticity are
NMDAR dependent, for example, mossy fibre LTP in the hippocampus (Harris and Cotman,
1986), Purkinje cell LTD in the cerebellum (Ito et al., 1982) and metabotropic glutamate receptor
dependent LTD in the CA1 region of the hippocampus (Oliet et al., 1997).
The current paradigm for how NMDAR activity modulates synaptic strength has recently
been reviewed (Huganir and Nicoll, 2013; Kandel et al., 2014) and is summarised here and
in Figure 1.6. NMDARs are only activated when glutamate is released onto a synapse which
has recently been activated and thus has a depolarised post-synaptic membrane. A strongly
stimulated synapse results in a lot of NMDAR activation, and hence a lot of Ca2+ entry (leading
to LTP), a weakly stimulated synapse results in modest levels of NMDAR activation and hence
modest levels of Ca2+ entry (leading to LTD). The Ca2+ influx activates a range of intracellular
proteins (CAMKII and protein kinases for LTP, calcineurin and protein phosphatases for LTD).
These proteins then influence AMPAR trafficking to the membrane (increasing it in LTP,
decreasing it in LTD) and alter gene expression in a way that maintains this altered AMPAR
density. The alterations in gene expression can also lead to structural changes at the synapse,
with enlargement or reduction in dendritic spine volume. Although this is the current working
model for these processes, there are a number of challenges to various steps within it. In
particular, duration and location of Ca2+ transients have been suggested to be at least as
important as Ca2+ transient amplitude in controlling the direction of plasticity (reviewed in
Evans and Blackwell (2015)). It has also recently been suggested that LTD may be initiated by
metabotropic NMDAR signalling (reviewed in Gray et al. (2016)).
It seems paradoxical that the same receptor population could mediate synaptic plasticity
in opposing directions. An appealing idea to explain this is that different NMDAR subunits
underlie different types of plasticity (reviewed in Wyllie et al. (2013)). Pharmacological
studies seeking to address this using subunit specific antagonists initially appeared to suggest
that GluN2A was required for the initiation of LTP, and GluN2B for LTD. However, some
studies were limited by the use of the so-called GluN2A selective antagonist NVP-AAM077
at doses which also block GluN2B containing receptors (Frizelle et al., 2006)). Further, the
existence of triheteromeric receptors complicates the assessment of the role of the subunits
comprising them, as antagonists which strongly inhibit receptors containing a given subunit
diheteromerically may cause minimal inhibition of a receptor containing the same subunit
triheteromerically. Genetic studies, knocking out GluN2A or GluN2B in forebrain neurons,
show that loss of either subunit leads to deficits in LTP. The GluN2B C terminus appears to
be particularly important, as demonstrated by experiments where the C termini of GluN2A
and GluN2B subunits are swapped - GluN2B with a GluN2A C terminus is unable to support
the same forms of LTP as GluN2B with its native terminus. These experiments de-emphasise
the importance of receptor biophysical properties in mediating synaptic plasticity and instead
highlight the role of interactions with proteins such as CAMKII (which can bind the GluN2B
but not GluN2A C terminus). An emerging consensus is that the high Ca2+ flux offered
by GluN2A’s high open probability may work in concert with the CAMKII binding site in




Figure 1.6: NMDAR mediated synaptic plasticity
The schematic shows a model first published in 1988 describing how NMDAR can initiate LTP in
the hippocampus CA1 region (taken from Huganir and Nicoll (2013), with minor modifications).
Although this model has become much more detailed, the basic principles are the same now
as when it was first published. In A, glutamate release at a dendritic spine activates AMPARs
but not NMDARs, due to Mg2+ block. In B, the synapse has been exposed to high frequency
stimulation and the post-synaptic membrane is depolarised. This has expelled the positively
charged Mg2+ ions from the NMDAR pore. Now, when glutamate is released, both AMPARs
and NMDARs are activated, allowing Ca2+ to enter the spine and activate signalling proteins
which lead to LTP.
1.4.8 NMDAR function: synaptogenesis and synaptic pruning
The ultimate way to alter synaptic strength is to create or remove synapses: synaptogenesis
or synaptic pruning. NMDAR activity is also implicated in these processes. New synapses
are thought to arise as follows (Cline and Haas, 2008): folllowing an initial contact between
adhesion molecules on motile filopodia extending from two neurons’ axons or dendrites,
NMDARs are recruited to the post-synaptic membrane. These immature synapses are “silent”
as the release of glutamate will not activate them at resting membrane potentials. However,
when the post-synaptic neuron is depolarised, glutamate will activate NMDARs and allow
the recruitment of AMPARs and additional proteins necessary for synaptic scaffolding and
signalling (the post-synaptic density), via mechanisms similar to LTP. This is associated
with morphological changes in the neuron, with dendritic arbor development and synapse
formation/maturation thought to arise jointly (Cline and Haas, 2008). This process is
illustrated in Figure 1.7.
Both GluN2A and GluN2B have been found to be important in this process, with possible
opposing effects on the probability of functional synapse formation (Gambrill and Barria, 2011;
Gray et al., 2011). More recent evidence has also suggested a role for NMDARs in synaptic
pruning, particularly the GluN3A subunit (Kehoe et al., 2014; Zhang et al., 2013).
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Figure 1.7: NMDARs facilitate dendritic arbor development and synaptogenesis
The diagram shows a neuron with a simple dendritic tree and several immature excitatory
synapses where only NMDARs are present (“silent synapses”). After activation of NMDARs,
AMPARs are recruited to the maturing synapses and the dendritic tree becomes more complex.
Taken from Cline and Haas (2008).
1.4.9 NMDAR function: neuronal survival and death
The final function of NMDARs highlighted here is their role in neuronal survival and death. A
range of evidence suggests that some NMDAR activation is required for neuronal survival, but
too much results in cell death, with pro-survival signals arising mainly from synaptic NMDAR
activation and pro-death signals arising mainly from extrasynaptic NMDARs (reviewed in
Hardingham and Bading (2010), and see Figure 1.8).
The GluN2B subunit has a particularly important role in excitotoxicity as it is more likely
to be present extra-synaptically (Parsons and Raymond, 2014) and its C terminus has been
demonstrated to be more effective at transducing pro-death signals than that of GluN2A
(Martel et al., 2012). GluN2B is also the more important subunit in determining survival, with
GluN2B, but not GluN2A, required for survival of adult-born neurons (Kelsch et al., 2012).
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Figure 1.8: Influence of synaptic and extra-synaptic NMDAR activation on neuronal
survival
The diagram shows how insufficient activity at synaptic NMDAR is death promoting, with higher
activity levels promoting greater survival. In contrast, lack of activity at extrasynaptic NMDAR
has no effect on survival, but higher levels promote cell death. Taken from Hardingham and
Bading (2010).
Section summary
In summary, the NMDAR is an ionotropic glutamatergic neurotransmitter receptor with a
number of unusual properties that make it well suited for its functions in contributing to
coordinated neural activity, synaptic strength, synaptic abundance and neuronal survival.
Different subunits confer different properties on the receptor, allowing it to diversify its effects.
The GluN2A and GluN2B subunits are expressed in the forebrain and have important roles in
key NMDAR functions, and alterations in their expression or properties would be anticipated
to result in impairments in these brain functions.
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1.5 What non-genetic evidence links NMDARs to brain disorders?
NMDAR dysfunction had been linked to brain disorders for several years prior to the
emergence of genetic evidence. This section briefly considers what other lines of evidence
link NMDAR dysfunction to brain disorders. The disorders are split into those associated
with NMDAR overactivity and those associated with NMDAR underactivity.
The first group of disorders are those where NMDAR dysfunction may not trigger the
condition, but is an important component of pathogenesis. They comprise neurodegenerative
disorders (Alzheimer’s disease, Parkinson’s disease and Huntington’s disease) and responses
to tissue damage (stroke, traumatic brain injury, white matter injury and chronic pain). The
overall pattern is that there is a damaging degree of overexpression or overactivation of
NMDARs, predominantly those containing GluN2B subunits, resulting in cellular dysfunction
and often an increase in cell death (summarised in Paoletti et al. (2013)). Blockade of NMDAR
activation can alleviate symptoms, for example, the use of the NMDAR channel blocker
memantine for moderate-severe Alzheimer’s disease. These conditions highlight the potential
damage that activating mutations in NMDAR subunits could cause, although the effects may
not be as severe in the absence of other disrupted pathways or tissue damage.
The second group of disorders are those in which NMDAR underexpression or
underactivation may be one of the initial events triggering the disorder: schizophrenia, and
NMDAR auto-immune encephalitis. These disorders are of more relevance to disorders
arising from mutations in NMDARs, where NMDAR dysfunction would also be predicted
to be an initiating event, and so are considered in more detail below.
The NMDAR hypofunction theory of schizophrenia states that underactivation of
NMDARs contributes to the symptoms of schizophrenia. It was first mooted when it was
observed that the NMDAR channel blockers phenylcyclidine and ketamine caused symptoms
similar to schizophrenia (psychosis and cognitive deficits) in healthy controls and worsened
symptoms in those with schizophrenia (reviewed in Moghaddam and Krystal (2012)). Brain
imaging studies also demonstrate abnormalities in glutamate levels in schizophrenia, as
summarised in a recent meta-analysis (Merritt et al., 2016). Further, potentiation of NMDAR
function by increasing availability of its co-agonists has been found to be of benefit in treating
schizophrenia (reviewed in Hashimoto et al. (2013)). The hypoglutamatergic theory has been
refined to propose that loss of GluN2A subunits from parvalbumin positive interneurons in
particular may be a key step in schizophrenia pathogenesis. This theory is supported by
the finding that selective knock-out of NMDARs in hippocampal and cortical GABAergic
interneurons in mice leads to schizophrenia-like symptoms (Belforte et al., 2010) and by the
observation of reduced density of GluN2A-positive parvalbumin positive interneurons in the
pre-frontal cortex in schizophrenia post-mortem brains (Bitanihirwe et al., 2009).
In the last decade, the syndrome of NMDAR auto-immune encephalitis was recognised,
which presents initially with psychosis, memory deficits, seizures and language disintegration
(Dalmau et al., 2007). In this condition, patients generate antibodies against their own
NMDARs (with the epitope comprising residues 368 and 369 of GluN1), causing receptor
internalisation with a reduction in receptor density and NMDAR-mediated currents (reviewed
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in (Masdeu et al., 2016)). The majority of patients recover if the antibodies can be removed or
suppressed (Titulaer et al., 2013). This condition demonstrates that acute loss of NMDARs can
be associated with devastating but reversible changes in brain function.
Section summary
Alteration of NMDAR expression or function has been observed in a number of
neuropsychiatric disorders, and reversing the dysfunction has been shown to improve
symptoms. This supports the hypothesis that a genetic change resulting in altered NMDAR
expression or dysfunction could also cause neuropsychiatric disease, and also be potentially
modifiable.
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1.6 What genetic evidence links NMDARs to mental disorder?
1.6.1 Common variants
This section will focus on recently identified rare mutations in GRIN2A and GRIN2B. However,
common variants in GRIN2A and related genes have also been found to influence risk for
neurodevelopmental disorder. Early genetic evidence was provided by a genome wide
linkage study which found a significant association between autism and single nucleotide
polymorphisms in GRIN2A (Barnby et al., 2005). More recently, a genome wide association
study in schizophrenia also highlighted a locus near GRIN2A, and another near SRR (encoding
serine racemase, the enzyme that converts L-serine to the NMDAR co-agonist D-serine) as
influencing risk for schizophrenia (Ripke et al., 2014). The convergence of common and rare
variants in GRIN2A on risk for related neurodevelopmental disorders strengthens the evidence
that GRIN2A is contributing to the pathogenesis of these disorders.
1.6.2 Rare variants
The first study to identify exonic mutations in NMDAR subunits was that of Endele et al.
(2010) where a series of heterozygous point mutations and translocation break points in
GRIN2A and GRIN2B were identified in people with comorbid epilepsy and intellectual
disability. Over the next six years, this was followed by publication of over 100 other point
mutations, microdeletions, copy number variants and translocations affecting these two genes
and found heterozygously in people with a range of neurodevelopmental disorders. These
findings are summarised in Table 1.2, Table 1.3 and Figures 1.9-1.12 and discussed further
below. The majority of the mutations presented here have also been discussed in a review by
Burnashev and Szepetowski (2015).
Mutations in other NMDAR subunits have also been idenfitied. De novo missense
mutations in GRIN1 have been found in five cases of epileptic encephalopathy (Allen et al.,
2013; Ohba et al., 2015) and one of intellectual disability (Hamdan et al., 2011). Truncating
mutations in GRIN2C, GRIN3A and GRIN3B have been found in people with autism and
schizophrenia but are also found in controls so their relationship to disease is unclear (Myers
et al., 2011; Tarabeux et al., 2011). As mutations in other NMDAR subunits so far appear to be
much less common than those in GRIN2A and GRIN2B they are not considered further here.
Tables 1.2 and 1.3 show studies reporting GRIN2A and GRIN2B mutations. They highlight
two things: the range of disorders in which mutations in GRIN2A and GRIN2B have been
found, and the low prevalence of mutation within a given disorder. Mutations in GRIN2A
have so far been found mainly in epilepsy-aphasia syndromes, and in GRIN2B mainly in
autism, schizophrenia and intellectual disability. The highest prevalence of mutation are found
with GRIN2A in the more severe form of epilepsy-aphasia syndomes, where one study found
GRIN2A mutations in 100% of those with a family history of the disorder (Lesca et al., 2013)
and another in 18% of those with the most severe form of the disorder, with or without a
family history (Lemke et al., 2013). GRIN2B mutations so far have not been identified to be a
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major contributor to any one disorder: prevalences of mutation are at most 1 in 50 for people
with autism, schizophrenia or intellectual disability (considering studies assessing GRIN2B
mutations in > 100 cases). The true mutation frequency is likely to be lower, as the tables
give a falsely high impression of prevalence by not including studies which did not find any
GRIN2A or GRIN2B mutations.




Dyment et al. (2015) Refractory childhood epilepsy 22.2% (2/9)
Lesca et al. (2013) Epilepsy-aphasia syndromes 14.9% (17/114)
Lemke et al. (2013) Epilepsy-aphasia syndromes 8.6% (31/359)
Conroy et al. (2014) Landau Kleffner syndrome 7.7% (1/13)
Reutlinger et al. (2010) Epilepsy-aphasia syndromes 4.5% (3/66)
von Spiczak et al. (2011) Photosensitive generalised epilepsy 2.1% (1/48)
Dimassi et al. (2014) Rolandic epilepsy 2.1% (1/47)
Lesca et al. (2012) Epilepsy-aphasia syndromes 1.6% (1/61)
(LKS and CSWS only)
Carvill et al. (2013) Epileptic encephalopathies 0.8% (4/519)
DeVries and Patel (2013) Epilepsy and intellectual disability Case series, n = 2
Yuan et al. (2014) Epileptic encephalopathy Case report
Singh et al. (2015) Epileptic encephalopathy Case report
Fainberg et al. (2016) Landau Kleffner syndrome Case report
Other disorders
Bramswig et al. (2015) Coffin-Siris and Nicolaides-Baraitser syndromes 10.0% (1/10)
Endele et al. (2010) Intellectual disability 3.1% (4/127) and
and epilepsy/abnormal EEG 1 initial case
de Ligt et al. (2012) Intellectual disability 2.0% (2/100)
Tarabeux et al. (2011) Autism 1.4% (2/142)
Schizophrenia 2.1% (9/429)
Studies which have identified heterozygous mutations in GRIN2A in association with mental
disorder, ordered by frequency of mutation. Synonymous mutations or those found in controls
not included. LKS = Landau Kleffner syndrome, CSWS = continuous spikes and waves
during slow wave sleep. Coffin-Siris and Nicolaides-Baraitser syndromes are rare, closely
related syndromes where severe intellectual disability is associated with particular congenital
abnormalities.
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Figure 1.9 shows all heterozygous missense mutations identified in GRIN2A and GRIN2B,
however inherited. It is designed to highlight possible genotype:phenotype relationships.
Comparing across subunits, it would appear that overall there are fewer mutations identified
in GRIN2B. This may reflect its crucial role early in development, with mutations more likely to
result in death in utero. Alternatively, GRIN2B mutations may result in a phenotype which has
not yet been screened for GRIN2B variants. Mutations in GRIN2A are more often associated
with epilepsy than those in GRIN2B and GRIN2B mutations are more often associated with
intellectual disability than those in GRIN2A. However, there is substantial phenotypic overlap
(at least at the level of diagnoses) between mutations in either gene.
Comparing across protein domains, the epilepsy-associated mutations are predominantly
but not exclusively in the ligand binding and pore forming regions of the subunits, suggesting
an influence on ion entry, whereas the schizophrenia or autism associated mutations are
predominantly but not exclusively in the C or N terminals, suggesting an influence on
interactions with signalling or regulatory proteins.
There are some caveats regarding the tentative genotype:phenotype conclusions drawn
above. It is likely that at least some mutations found in patients are coincidental to their
disorder. Comparison between subunits is difficult as the number of people sequenced for a
given subunit varies (the mutations are derived from a mixture of whole exome and candidate
gene studies). Comparison between disorders is difficult as the number of people with a
given disorder sequenced varies (e.g. more people with epilepsy have been screened than
people with intellectual disability). Finally, the phenotypic categories used overlap to some
extent, and are sometimes based on incomplete information. For example, some people with
GRIN2B mutations associated with autism also have mild intellectual disability, and some
with intellectual disability have “autistic features”. In others with autism, the presence or
absence of intellectual disability is not reported. The approach used here has been to categorise
phenotypes in line with the authors who reported the mutations e.g. if the cohort sequenced
was selected for autism, the mutation is coded as this, regardless of intellectual disability.
Figure 1.10 shows only those missense mutations which were definitely inherited de novo.
With one exception, these all influence the ligand binding or pore forming domain of either
subunit. Of the nine missense mutations identified in the pore region, eight arose de novo
and one was of unknown inheritance. This is consistent with mutations arising in these areas
having more deleterious consequences than elsewhere, and thus being less likely to be passed
on via reproduction.
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Figure 1.9: Missense mutations identified in GRIN2A and GRIN2B
(A) This schematic shows the approximate location of heterozygous missense mutations within
functional domains of the NMDAR, coloured by neurodevelopmental phenotype. NMDAR
domains: the dashed black lines represent the N and C termini, the solid black lines the ligand
binding domain (S1 and S2), the cylinders the transmembrane domains (M1, M3, M4) and
re-entrant loop (M2) and the dotted lines the M2-M3 and M3-M4 linker regions (see Figure
1.4 for more information on functional domains). Synonymous mutations and those found in
databases of single nucleotide polymorphisms are not included. Some mutations have been
found multiple times in unrelated cases: R518H, A716T, D731N and N976S have all been
found twice in unrelated families with epilepsy-aphasia syndromes, V452M has been found in a
person with schizophrenia and a person with epileptic encephalopathy (who also carried a de
novo sodium channel mutation) and the T1064A mutation has been found in three individuals
(one with schizophrenia, one with epilepsy and one with intellectual disability with either EEG
abnormalities or epilepsy).
(B) As (A) but for GRIN2B. V18I has been identified twice, in unrelated people with
schizophrenia (inheritance unknown).
All mutations have been found heterozygously. The references for this figure are provided in
Tables 1.2 and 1.3. A modified version of this figure has been published (Hardingham and Do,
2016).
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O’Roak et al. (2011) Autism 5.0% (1/20)
Myers et al. (2011) Autism; 2.0% (2/102)
Schizophrenia; 2.2% (3/138)
Tarabeux et al. (2011) Autism; 0.7% (3/428);
Schizophrenia 1.6% (7/429)
Pan et al. (2015) Autism 0.7% (2/275)
Kenny et al. (2014) Autism; 0.7% (1/147);
Schizophrenia; 0/273
Williams et al. (2012) Schizophrenia 0.3% (2/690)
O’Roak et al. (2012b) Autism 0.3% (3/1,073)
O’Roak et al. (2012a) Autism 0.2% (4/2,446)
Talkowski et al. (2012) Autism and 0.03% (5/19,956) and
neurodevelopmental disorder 1 initial case
Intellectual disability
Hamdan et al. (2014) Intellectual disability 2.4% (1/41)
Endele et al. (2010) Intellectual disability 1.5% (7/468) and
2 initial cases
Freunscht et al. (2013) Intellectual disability 1.1% (1/93)
de Ligt et al. (2012) Intellectual disability 1.0% (1/100)
Dimassi et al. (2013) Intellectual disability Case series, n=3
with language delay
Adams et al. (2014) Intellectual disability Case report
Epilepsy syndromes
Lemke et al. (2014) Epilepsy 1.0% (4/404)
Allen et al. (2013) Epileptic encephalopathies 0.4% (1/264)
Studies which have identified heterozygous mutations in GRIN2B in association with mental
disorder, ordered by frequency of mutation. Synonymous mutations or those found in controls
not included.
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Figure 1.10: De novo missense mutations identified in GRIN2A and GRIN2B
(A) This schematic shows the approximate location of de novo heterozygous missense
mutations within functional domains of the NMDAR, coloured by neurodevelopmental
phenotype. NMDAR domains are depicted as in Figure 1.9. Synonymous mutations and those
found in databases of single nucleotide polymorphisms are not included.
(B) As (A) but for GRIN2B
All mutations have been found heterozygously. The references for this figure are provided in
Tables 1.2 and 1.3.
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Figure 1.11 shows heterozygous mutations which are predicted to result in absent or
truncated protein products: absent start codons, premature stop codons, deleted codons,
frameshifts, splice site mutations, microdeletions and copy number variants (deletions).
Although these mutations have been grouped together as “gene disrupting”, their
consequences may potentially be quite different - all can potentially prevent the protein from
being expressed, but some could alternatively result in proteins with altered function and
some could even result in normal proteins. For example, splice site mutations may not prevent
normal protein expression if an alternative splice site is available. Premature stop codons
may result in transcript degradation via nonsense-mediated decay (if the transcript terminates
more than 50 bp to 5’ of the final exon), but this is not certain to occur (Holbrook et al.,
2004). Thus any of the truncating mutations arising within the final exon, and potentially those
before, could conceivably be expressed and generate an almost complete protein, terminating
in novel residues in the case of frameshifts. The impact of the deletion of a single codon is also
hard to predict, with outcome likely to depend on the structural context.
When the impact of these potential gene disrupting mutations has been assessed, they
have mainly been found to reduce expression, as predicted. Two GRIN2B splice variants and
a GRIN2A premature stop codon were not shown to result in alternatively spliced products,
but a GRIN2B frameshift mutation was detected at the mRNA level (Endele et al., 2010). In
summary, the majority of the mutations shown in Figure 1.11 probably result in monoallelic
expression of the wild type allele but this is not definite for any of the mutations except those
that completely delete the gene or the small number which have been experimentally assessed.
Making the assumption that the majority of these potentially gene disrupting mutations
do indeed result in monoallelic expression, what can be inferred about the consequences of
only one functional GRIN2A or GRIN2B allele? Firstly, the presence of neurodevelopmental
disorders in their carriers suggests that this results in haploinsufficiency - one copy of a subunit
is not enough (in contrast to the majority of genes). Secondly, all the GRIN2A disrupting
mutations are associated with epilepsy, with the vast majority (23/29) of that being in the form
of epilepsy-aphasia syndromes. In the case of GRIN2B, gene disuption is associated with a
fairly even split of either autism or intellectual disability (or a combination). These phenotypic
associations are less diverse than what was seen with missense mutations, reflecting the
simpler proposed mechanism - an absence of protein, rather than a range of proteins with
altered functions.
The final mutation diagram shows probable gene disrupting events which are known to
have arisen de novo (Figure 1.12). Interestingly, very few of the GRIN2A disrupting events
arose de novo whereas the majority of the GRIN2B disrupting events did. This suggests that
the consequences of GRIN2B disruption may be more deleterious than that of GRIN2A, with
disrupting mutations not passed on through reproduction.
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Figure 1.11: Gene disrupting mutations identified in GRIN2A and GRIN2B
(A) This schematic shows mutations in GRIN2A likely to result in an absent or truncated
protein, coloured by neurodevelopmental phenotype. NMDAR domains are depicted as in
Figure 1.9. Bars mark premature stop codons, frameshifts, and a deleted codon, marked at
their approximate locations. Those prior to the start of the final exon encode mRNA transcripts at
risk of nonsense-mediated decay and hence no protein product. Crosses indicate more severe
gene disruption (loss of start codon, splice site mutation, microdeletions partially or completely
deleting the gene, copy number deletions, and a translocation disruption).
(B) As (A) but for GRIN2B. In addition, a GRIN2B copy number deletion has been identified in
a person with an unspecified neurodevelopmental disorder (Talkowski et al., 2012) but has not
been marked on the figure (because of the uncertain phenotype).
All mutations have been found heterozygously. The references for this figure are provided in
Tables 1.2 and 1.3.
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Figure 1.12: De novo gene disrupting mutations identified in GRIN2A and GRIN2B
(A) This schematic shows de novo mutations in GRIN2A likely to result in an absent or truncated
protein, coloured by neurodevelopmental phenotype. NMDAR domains are depicted as in
Figure 1.9. The bar marks a frameshift mutation associated with severe intellectual disability and
epilepsy. Crosses indicate three microdeletions, all associated with epilepsy-aphasia syndrome.
(B) As (A) but for GRIN2B. The bars mark two frameshifts and two premature stop codons,
marked at their approximate locations. They are all prior to the start of the final exon and so
encode mRNA transcripts at risk of nonsense-mediated decay and hence no protein product.
Crosses indicate more severe gene disruption (splice site mutations, and three microdeletions
partially or completely deleting GRIN2B).
All mutations have been found heterozygously. The references for this figure are provided in
Tables 1.2 and 1.3.
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Too much GRIN2B may also be problematic. Several partial or complete chromosomal
arm (12p) duplications including GRIN2B have been identified. All duplications also involve
multiple other contiguous genes. In partial arm duplications involving GRIN2B, all carriers
had intellectual disability but only one out of 20 cases were reported to have seizures (Poirsier
et al., 2014; Talkowski et al., 2012). Thus, it is possible that GluN2B function is sensitive to
gene dosage, and too much causes intellectual disability. This has implications for therapeutic
strategies which might seek to increase the activity of wild type NMDARs: too much activity
may also be a problem. However, the possibility that other genes in the duplicated regions
cause the phenotype is a real one.
In summary, almost 100 mutations have been identified in GRIN2A in people with
neurodevelopmental disorder (15 de novo), and almost 50 in GRIN2B (23 de novo), all likely
to result in either a protein of altered function or an absent protein. But is this to be expected?
Mutations do arise spontaneously - is the association with neurodevelopmental disorders just
a chance finding?
There are two ways to approach this. In the case of inherited mutations, the cosegregation
of disorder with mutation can be assessed. If a mutation is always associated with a phenotype
in its carriers (cosegregation), this strengthens the evidence that it (or a locus nearby) is causing
the phenotype. Conversely, if a mutation does not cause a phenotype in all its carriers,
it is either not relevant to disease, or of low penetrance. Inherited mutations in GRIN2A
and GRIN2B show both patterns, suggesting that in some cases at least the association with
neurodevelopmental disorder is not a chance finding. Inherited mutations also highlight the
variation in phenotype of carriers of identical mutations, suggesting that the consequences
of a mutation are modified by stochastic developmental events, other gene variants, and/or
environmental factors.
The second approach is statistical: assessing the probability of seeing the observed number
of mutations in a group vs an expected number. In the case of GRIN2A, Lemke et al. (2014)
compared the proportion of people with idiopathic focal epilepsy and heterozygous GRIN2A
mutations (7.5%) with the proportion of people without epilepsy but with heterozygous
GRIN2A mutations (0.6%) and found the rate of mutation in GRIN2A to be significantly higher
than expected by chance. In the case of de novo mutations in GRIN2B O’Roak et al. (2012a)
compared the rate of de novo mutation in GRIN2B against that simulated to occur by chance
based on gene specific mutation rates and sequence information (the low rate of de novo
mutation makes using control groups impractical), and found de novo mutations in GRIN2B
to arise in autism at rates significantly above chance.
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Section summary
This section has reviewed genetic evidence for the association of NMDAR GluN2A and
GluN2B subunits with mental disorder. A large and statistically above chance number of
mutations in individuals with neurodevelopmental disorder have been identified in the last six
years, with mutations in GRIN2A predominantly associated with epilepsy-aphasia syndrome
and mutations in GRIN2B with intellectual disability and autism. Further, a genome wide
association study identified a locus near GRIN2A as impacting on risk for schizophrenia. There
is therefore strong genetic evidence that alterations in GluN2A and GluN2B expression or
properties are associated with mental disorder.
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1.7 Description of phenotypes associated with mutations in GRIN2A
and GRIN2B
The previous section introduced a lot of diagnostic terms, including some which refer to
rare disorders, and some where the terminology is used variably by different authors. This
section therefore gives an account of the key features of each class of disorder associated with
mutations in GRIN2A or GRIN2B.
1.7.1 Epilepsy-aphasia syndromes
Epilepsy is the recurrent experience of seizures: defined by the International League Against
Epilepsy (ILAE) as “a transient occurrence of signs and/or symptoms due to abnormal
excessive or synchronous neuronal activity in the brain” (Fisher et al., 2014). It has a prevalence
of around 0.6% (Forsgren et al., 2005).
Epilepsy-aphasia syndromes comprise a broad spectrum of disorders which all include
childhood onset language difficulties associated with an abnormal EEG or epilepsy during
sleep. The key features are (Loddenkemper et al., 2011):
1. Age specific presentation, with onset around age 4-5 years old and stabilisation,
improvement or even resolution around the age of puberty
2. EEG discharges that increase and generalise during sleep (classically prolonged spike
and wave activity during non-REM sleep)
3. Neuropsychological deficits or regression, in milder forms involving language
regression only and in more severe forms global intellectual impairment
Epilepsy-aphasia syndromes form a spectrum, with some authors treating either extreme
as independent of the intermediate disorders. This is not supported by the genetic evidence
presented in the previous section. In this thesis, the spectrum of epilepsy-aphasia syndrome
used is that suggested by Tsai et al. (2013): continuous spikes and waves during slow
wave sleep, Landau Kleffner syndrome, intermediate epilepsy-aphasia disorder and benign
childhood epilepsy with centrotemporal spikes, also known as rolandic epilepsy. Figure 1.13 is
a Venn diagram showing the relationship between disorders. Table 1.4 describes key features
of the two disorders at the mildest and at the most severe end of the spectrum (where the
majority of GRIN2A mutations are found). The table highlights the difference in severity of
cognitive deficits, EEG abnormalities and outcomes across the spectrum.
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Figure 1.13: Disorders included in the epilepsy-aphasia spectrum
This figure shows the relationship of disorders on the epilepsy-aphasia spectrum, taken from
Tsai et al. (2013) (text modified to increase legibility). The disorders vary along axes of
cognition and EEG features/associated epilepsy. The mildest disorder is benign epilepsy
with centrotemporal spikes (BECTS). which has mild epilepsy and mild defects in language
dysfunction. The most severe end is continuous spike and wave during sleep (CSWS), where
patients have a marked global cognitive impairment and frequent seizures.
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Table 1.4: Key features of disorders on the epilepsy-aphasia spectrum
Disorder CSWS LKS BECTS
Other names ECSWS, CSWSS, EAS EAS BCE, Rolandic epilepsy
Prevalence Rare Rare Common
(0.2% childhood epilepsy) (10-15% childhood epilepsy)
Family history 10% 3% 18-36%
Sex 63% male 68% male Slight male preponderance
Age of onset 5-7 years, 20% >9 years 5-7 years, 5% >9 years 7-9 years peak, range 1-14 years
Age of improvement Puberty Puberty Puberty
Prognosis Poor. 50% can live independently. Quite poor. 50% “normal life”. If aphasic for Good. Either normal or very mild
>1-2 years, lifelong language dysfunction. ongoing impairments.
Language Reduction in or complete loss of speech As CSWS Normal or mild difficulties
Auditory agnosia (e.g. poor spelling, reading aloud)
(to non-verbal stimuli also) or listening comprehension)
Other cognition Severe and global impairment Moderate Normal or mild difficulties in attention,
Severe decline IQ Inattention and hyperactivity visuospatial skills, picture naming




Seizure prevalence 100% 70% 100%
Commonest seizure type Unilateral motor, Simple partial motor (e.g. eye blinking, Simple partial motor
generalised tonic-clonic head drops, minor automatisms) (e.g. twitches, anarthria).
EEG while awake Focal or bilateral anterior spikes Bilateral temporal spikes Centrotemporal spikes
EEG while asleep >85% of non-REM sleep continuous Commonly (<85%) continuous Commonly (<85%) continuous
spike and wave spike and wave spike and wave
Structural brain abnormalities 30-60% (perinatal vascular lesions, 13% Up to 30% (atrophy, cortical dysplasias,
cortical malformations, white matter abnormalities)
atrophy, abnormal myelination)
Abbreviations: (E)CSW(S)S = (Epileptic encephalopathy with) continuous spikes and waves during slow wave sleep, LKS = Landau Kleffner syndrome, BECTS = benign
epilepsy with centrotemporal spikes, EAS = Epilepsy aphasia spectrum disorders, BCE = Benign childhood epilepsy.
Sources: Smith and Hoeppner (2003), Loddenkemper et al. (2011), Tsai et al. (2013), Fejerman and Caraballo (2007), Kramer et al. (1998), Larsson and Eeg-Olofsson (2006), Shinnar et al. (1999).
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1.7.2 Epileptic encephalopathies
The more severe forms of epilepsy-aphasia syndromes are often referred to as epileptic
encephalopathies. Epileptic encephalopathies are defined by the ILAE as epileptic disorders
where “the epileptic activity itself may contribute to severe cognitive and behavioral
impairments above and beyond what might be expected from the underlying pathology
alone” (Berg et al., 2010). Of course, without knowing the underlying pathology, this is a
difficult definition to apply in practice. It is often used more broadly to apply to any disorder in
which epilepsy is associated with severe intellectual disability, although some authors regard
this as a misuse of the term (Shao and Stafstrom, 2016).
Epileptic encephalopathies are an even more diverse group of disorders than epilepsy-
aphasia syndromes. They include a number of eponymous syndromes with characteristic
seizure types, such as infantile spasms in West syndrome and febrile seizures in Dravet
syndrome (Galanopoulou and Moshe, 2015). The disorders are individually rare; the
commonest (West syndrome) affects 0.02% of children under 10 years old (Cowan, 2002).
Some improvement may be seen in adolescence (Panayiotopoulos, 2005), but the outcome
for epileptic encephalopathies is generally poor with high support needs (Cowan, 2002).
Although an increasing number of genetic causes are being identified (McTague et al., 2016),
hypoxia or infection around the time of birth, and congenital brain malformations are also
frequent causes (Panayiotopoulos, 2005).
1.7.3 Intellectual disability
Intellectual disability, formerly known as learning disability or mental retardation, is defined
as an intelligence quotient < 70 associated with impairments in adaptive functioning, and
with onset before age 18 (WHO, 1992). The prevalence is around 1% (Maulik et al., 2011). It
is associated with an increased risk of other psychiatric disorders, such as schizophrenia (Deb
et al., 2001), and also an increased risk of epilepsy (Lhatoo and Sander, 2001). As with the
other disorders discussed so far, intellectual disability refers to a spectrum of severity, with
the mildest forms causing mild impairment in day to day living and the most severe forms
requiring 24 hour care. The causes are also highly diverse, with both genetic (e.g. Down’s
syndrome) and environmental factors (e.g. birth complications) contributing (van Bokhoven,
2011).
1.7.4 Schizophrenia
Schizophrenia is a psychotic disorder characterised by hallucinations, delusions or disordered
thought processes (WHO, 1992). Symptoms typically first manifest in late adolescence, or
the early 20s. The prevalence is around 0.7% (McGrath et al., 2008). It is associated with an
increased risk of epilepsy (Hyde and Weinberger, 1997) and lower premorbid IQ (Woodberry
et al., 2008). Although some patients have a good functional outcome, the majority show a
gradually declining course (Hegarty et al., 1994) with a 16 year reduction in life expectancy
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(Laursen, 2011). Heritability is around 80% (Sullivan et al., 2003), with environmental risk
factors including cannabis (Large et al., 2011) and early life adversity (Varese et al., 2012).
1.7.5 Autism
Autism is a syndrome of social impairment, communication impairment and repetitive or
stereotyped behaviours with onset before 3 years old (WHO, 1992). The prevalence is around
0.6% (Elsabbagh et al., 2012). Comorbid epilepsy and intellectual disability is common
(Kielinen et al., 2004). Heritability is around 80%, with environmental risk factors including
birth complications (Ronald and Hoekstra, 2011). There is a wide range of severities and
outcomes, with lower IQ predicting poorer outcome (Farley et al., 2009).
Section summary
Mutations in NMDAR GluN2A and GluN2B subunits are found in people with a range
of frequently comorbid neurodevelopmental disorders, mainly of childhood onset, often
influencing electrical activity in the brain and always influencing cognition, particularly
language and social cognition. The symptoms caused by an acute reduction in NMDAR
function (as seen with the use of channel blockers or in NMDAR encephalitis) partially
mirror those found in carriers of NMDAR mutations. The fact that both putative and
confirmed mechanisms of altered NMDAR function show converging consequences supports
the hypothesis that the mutations are indeed influencing NMDAR function in a way that
increases risk for mental disorder.
The functional outcomes for these NMDAR-associated neurodevelopmental disorders are
variable, but a large proportion of people will require assistance with day to day living and
experience a reduction in life expectancy. Although NMDAR mutations are rare, and not
the predominant cause for any of the disorders with which they are associated, the disorders
overall are common and represent a large burden of disability in society. This increases the
value of any general pathophysiological insights which can be achieved through investigating
the NMDAR related forms of the disorders.
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1.8 Thesis aims
This introduction has summarised evidence that neurodevelopmental disorders arise from a
genetically heterogenous set of disruptions in shared biological pathways. NMDAR subunits
are amongst the hundreds of genes mutated. However, unlike many of the genes implicated,
NMDAR subunits are already known to have a range of important brain functions, and
to be dysfunctional in neuropsychiatric conditions. NMDAR subunits therefore represent
biologically plausible, experimentally tractable genes with which to investigate the nature of
neural changes which may contribute to neurodevelopmental disorder.
The overall aim of this thesis is thus to better understand the aetiology of mental
disorders through investigating the functional consequences of disease-associated mutations
in the NMDAR subunits GluN2A and GluN2B. This thesis hypothesises that mutations in
NMDAR subunits alter their function in a way that contributes to their carriers’ risk of
neurodevelopmental disorder.
To address this hypothesis fully, it is necessary to assess the impact of NMDAR mutations
at a range of levels of functional organisation: subunit, receptor, cell, circuit, and eventually,
whole organism. The aims of each chapter of this thesis are therefore as follows:
The first results chapter aims to assess the impact of four NMDAR mutations at the subunit
level by expressing mutant NMDAR subunits in heterologous systems.
The second results chapter aims to assess the impact of three NMDAR mutations at the
receptor level, by expressing mutant NMDAR subunits in heterologous systems, with control
over receptor subunit composition.
The third results chapter aims to assess the impact of gene disrupting mutations in






2.1 Preparation of DNA constructs
Table 2.1 lists the NMDAR constructs used in this study, and their origin. Details of the
techniques used to modify the cDNA sequences follow the table.
Table 2.1: Wild type and mutant constructs
cDNA Vector Origin
Chapter 3
hGluN1-1a (NP 015566) pCI-neo Gift from Dr Kasper Hansen
hGluN2AWT(NP 000824) pCI-neo Gift from Dr Kasper Hansen and Dr Hongjie Yuan
hGluN2AR586K pCI-neo Gift from Dr Kasper Hansen and Dr Hongjie Yua
hGluN2AN615K pCI-neo Site-directed mutagenesis (In-Fusion)
hGluN2BWT pRK5 Gift from Prof Robert Harvey
hGluN2BN615I pRK5 Gift from Prof Robert Harvey
hGluN2BV618G pRK5 Gift from Prof Robert Harvey
hGluN2BD101A pRK5 Site-directed mutagenesis (In-Fusion)
hGluN2BD101A, N615I pRK5 Site-directed mutagenesis (In-Fusion)
hGluN2BD101A, V618G pRK5 Site-directed mutagenesis (In-Fusion)
Chapter 4
rGluN1-1a eGFP (U08261) pCI-neo Gift from Dr Kasper Hansen
rGluN2AWT(D13211) pCI-neo Gift from Dr Kasper Hansen
rGluN2AN615K pCI-neo Ligation
rGluN2AC1 pCI-neo Gift from Dr Kasper Hansen
rGluN2AC2 pCI-neo Gift from Dr Kasper Hansen
rGluN2AC1N615K pCI-neo Site-directed mutagenesis (In-Fusion)
rGluN2AC2N615K pCI-neo Ligation
rGluN2BWT(U11419) pCI-neo Gift from Dr Kasper Hansen
rGluN2BN615I pCI-neo Site-directed mutagenesis (Quikchange)
rGluN2BV618G pCI-neo Site-directed mutagenesis (Quikchange)
rGluN2BAC1 pCI-neo Gift from Dr Kasper Hansen
rGluN2BAC2 pCI-neo Gift from Dr Kasper Hansen
rGluN2BAC1N615I pCI-neo Site-directed mutagenesis (In-Fusion)
rGluN2BAC2N615I pCI-neo Site-directed mutagenesis (In-Fusion)
rGluN2BAC1V618G pCI-neo Site-directed mutagenesis (In-Fusion)
rGluN2BAC2V618G pCI-neo Site-directed mutagenesis (In-Fusion)
Genbank accession code given in brackets (where deposited). Dr Kasper Hansen is based at the
University of Montana, Dr Hongjie Yuan at the University of Emory and Prof Robert Harvey at University
College London.
2.1.1 Site-directed mutagenesis techniques
2.1.1.1 In-Fusion Method
Site-directed mutagenesis was performed via PCR with overlapping mutagenizing
oligonucleotides (see Table 2.2) using a thermostable Pfu high fidelity DNA polymerase (New
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England Biolabs, Ipswich, MA, USA). The PCR product was recircularised into a viable
plasmid using an InFusion HD kit (Clontech, Mountain View, CA, USA). The double-stranded
mutant DNA was transformed into TOP10 Competent Cells (Life Tech, Grand Island, NY,
USA). Clones were amplified before DNA was extracted using QIAPrep Spin MiniPrep Kit
(Qiagen, Venlo, Netherlands) as per the manufacturer’s instructions. The mutations were
verified by Sanger sequencing through the entire cDNA.
Table 2.2: Mutagenising primers used with In-Fusion method
Protein product Forward primer (5’-3’) Reverse primer (5’-3’)
hGluN2AcC1845A (pN615K) TTCAATAAATCCGTGCCTGTCCAGAAT GCACGGATTTATTGAACACCAGGCCC
rGluN2AcT1845A (pN615K) CTTCAACAAATCTGTGCCTGTCCAGAAT GCACAGATTTGTTGAAGACCAGGCCCCA
hGluN2BcA304C (pD101A) TTTGCTGCTGACACAGACCAGGAA TGTGTCAGCAGCAAACACCACC
rGluN2B cA1834T (pN615I) GGTGTTTATCAACTCCGTACCTGTGCAG CGGAGTTGATAAACACCAGACCCCAGAG
rGluN2BcT1852G (pV618G) CAACTCCGGACCTGTGCAGAACCCAAAG GCACAGGTCCGGAGTTGTTAAACACCAG
Substituted nucleotides are marked in bold.
2.1.1.2 QuikChange Method
Site-directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis
Kit method (Agilent Technologies, Santa Clara, CA, USA). Firstly, PCR was performed with
overlapping mutagenizing oligonucleotides using a thermostable PfuTurbo DNA polymerase
(see Table 2.3). The PCR product was then treated with the endonuclease Dpn I, which digests
methylated parental DNA but leaves intact newly synthesized mutated DNA. The remaining
mutant DNA was transformed into chemically competent cells by heat shock. Clones were
amplified before DNA was extracted using GenElute MiniPrep (Sigma-Aldrich, St Louis, MO,
USA) as per the manufacturer’s instructions. The mutations were verified by sequencing
across the point mutation and a region of the modified C terminus.
Table 2.3: Mutagenising primers used with QuikChange
Protein product Forward primer (5’-3’) Reverse primer (5’-3’)
rGluN2BN615I GGTCTGGTGTTTATCAACTCCGTACCTG CAGGTACGGAGTTGATAAACACCAGACC
rGluN2BV618G GTGTTTAACAACTCCGGACCTGTGCAGAACCC GGGTTCTGCACAGGTCCGGAGTTGTTAAACAC
Substituted nucleotides are marked in bold.
2.1.1.3 DNA ligation
rGluN2A, rGluN2AC2 and rGluN2AC1N615K were digested with restriction enzymes Bsp120I
and Sal1 for 1 hour at 37 °C. The relevant bands were then extracted using the illustra GFX
PCR DNA and Gel Band Purification Kit (GE Healthcare, Buckinghamshire, UK) as per
manufacturer’s instructions before being ligated overnight at 16 °C with T4 DNA ligase and
buffer (New England Biolabs). The product was used to transform chemically competent cells
by heat shock. Resulting clones were amplified before DNA was extracted using GenElute
MiniPrep (Sigma-Aldrich) as per the manufacturer’s instructions. The mutations were verified
by sequencing across the point mutation and a region of the modified C terminus.
41
2.2 Techniques used with oocytes
2.2.1 cRNA synthesis and receptor expression
cRNA for wild type and mutants was synthesized from linearized plasmid DNA as runoff
transcripts using the T7 polymerase mMessage machine RNA synthesis kit (Life Technologies
Ltd, Paisley, UK). Each oocyte was injected with 3.7-9 ng of cRNA, comprising a 1:1 molar
ratio of GluN1 and GluN2A cRNAs diluted in RNAse free water.
Stage VVI Xenopus laevis oocytes were obtained from the UK Xenopus centre (Portsmouth,
UK) and from Diaclean (CastropRauxel, Germany), collagenased (200 units/ml for 60
minutes), then manually defolliculated prior to injection. After injection oocytes were placed
in separate wells of 24-well plates containing a modified Barth’s solution with composition
(in mM): 88 NaCl, 1 KCl, 2.4 NaHCO3, 0.82 MgCl2, 0.44 CaCl2, 0.33 Ca(NO3)2, 15 Tris-HCl,
adjusted to pH 7.35 with NaOH. This solution was supplemented with 50 IU/ml penicillin,
50 mg/ml streptomycin and 50mg/ml tetracycline. Oocytes were placed in an incubator
(16-21°C) for 24-48 hours to encourage receptor expression and subsequently stored at 4 °C.
Recordings were made 48-96 hours post injection.
2.2.2 Two-electrode voltage-clamp recordings
Two-electrode voltage-clamp (TEVC) recordings were made at room temperature (18-21°C)
from oocytes that were placed in a solution that contained (in mM): 115 NaCl, 2.5 KCl,
10 HEPES, 1.8 BaCl2, 0.01 EDTA; pH 7.35 with NaOH. Recordings were made using a
GeneClamp 500B amplifier (Molecular Devices, Union City, CA, USA). Current and voltage
electrodes were made from thin-walled borosilicate glass (GC150TF-7.5, Harvard Apparatus,
Kent, UK) using a PP-830 electrode puller (Narashige Instruments, Japan). Filling with 3 M
KCl gave resistances of between 0.2 and 1.5 MΩ. Application of solutions was determined
manually. Data were filtered at 10 Hz and digitized at 100 Hz via a 1401 plus analogue-digital
interface (Cambridge Electronic Design, Cambridge, UK) using WinEDR software (Strathclyde
Electrophysiology Software, Strathclyde University, UK). Oocytes were voltage-clamped at
–40, –60 or –80 mV. Recordings were rejected if the holding current (in nA) was greater than
three times the holding potential (in mV) or if the holding current drifted by more than 10% of
the agonist response across the course of the experiment.
The liquid-liquid junction potential for two-electrode voltage-clamp recordings was
calculated to be +1 mV (using the open access software provided by (Marino et al., 2014)).
All other internal/external pairings in this thesis were calculated to be between +16 to +17 mV
(using Clampex software (Molecular Devices)).
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2.2.3 Single-channel voltage-clamp recordings
Single-channel voltage-clamp recordings were made at room temperature (18-21°C) from
outside-out patches pulled from oocytes that were placed in a solution that contained (in mM):
125 NaCl, 3 KCl, 1.25 NaH2PO4, 20 HEPES, 0.85 CaCl2, 0.01 EDTA; pH 7.35 with NaOH. Steady
state recordings were made in the presence of 30 µM glutamate and 30 µM glycine. Recording
durations varied from 30 seconds to 5 minutes. Prior to recording vitelline membranes were
removed from oocytes placed in a hypertonic solution that contained (in mM): 200 sodium
methyl sulphate, 20 KCl, 10 HEPES, 1 MgCl2, pH 7.4 with NaOH. Recordings were made using
an AxoPatch 1D amplifier (Molecular Devices). Electrodes were made using thick walled
borosilicate glass (GC150F-7.5, Harvard Apparatus) using a P-87 electrode puller (Sutter
Instrument, Novato, CA, USA) and their tips fire polished to give resistances of 7 to 12 MΩ
when filled with internal solution containing (in mM): 2.5 NaCl, 141 K-gluconate, 10 HEPES,
11 EGTA; pH 7.4 with KOH. Electrodes tips were coated in silicone elastomer (“sylgard
184”, Dow Corning, Wiesbaden, Germany) to reduce capacitance. Application of solutions
was controlled manually. Data were prefiltered at 2 kHz (–3 dB, 8th order Bessel filter) and
digitized at 20 kHz via a Micro 1401 analogue-digital interface (Cambridge Electronic Design)
using WinEDR software (Strathclyde Electrophysiology Software). Patches were voltage-
clamped at -60 or –100 mV.
WinEDR v3.3.7 was used to idealise the traces (using a transition threshold of 50% of the
unitary conductance level and a 100 µs open and shut resolution), to fit Gaussian curves
to amplitude histograms and to fit multiple exponential curves to dwell time durations (all
curves fitted using iterative maximum likelihoods). Any openings where more than one
channel was open simultaneously were discarded. Conductance was calculated by dividing
the current amplitude by the holding potential.
43
2.3 Techniques used with HEK293 and HEK293T cells
2.3.1 Culture
For single channel recordings (Chapter 3), human embryonic kidney 293 cells (HEK293) cells
were cultured in Dulbeccos Modified Eagle Medium with GlutaMax-I supplemented with 10%
foetal calf serum, and 1% antibiotic/antimycotic. Cells were passaged twice weekly and plated
onto cover slips precoated in poly-D-lysine (0.05 mg/ml) to give a density of 10-30% on the
day of recording.
For triheteromer experiments (Chapter 4), HEK293 cells containing the SV40 large
T–antigen (HEK293T cells) were cultured in Dulbeccos Modified Eagle Medium with
GlutaMax-I (Invitrogen, Carlsbad, CA, USA) supplemented with 10% dialyzed fetal bovine
serum (Invitrogen, Waltham, MA, USA), 10 U/ml penicillin, and 10 µg/ml). HEK293T
cells were chosen for their propensity to grow singly rather than in clumps, facilitating
electrophysiological experiments involving rapid solution application. Cells were passaged
twice weekly and plated onto cover slips precoated in poly-D-lysine (0.1 mg/ml) to give a
density of 10-30% on the day of recording.
2.3.2 Transient transfection
For single channel recordings (Chapter 3), HEK293 cells were transfected using Lipofectamine
2000 (hereafter referred to as lipofectamine). For one well of a 24-well plate, plasmids
containing hGluN1-1a, the hGluN2 subunits of interest and eGFP were mixed in a 1:2:1 mass
ratio to give 500 ng total DNA in 25 µl opti-MEM and added to 2 µl lipofectamine in 25 µl opti-
MEM. After 20 minutes at room temperature, 50 µl of transfection mix was added dropwise
to each well. After 2-5 hours the media was replaced with fresh media containing NMDAR
antagonists (10 µM D-AP5 and 1 µM 5,7-dichlorokynurenic acid) to avoid NMDAR mediated
excitotoxicity. Recordings were made approximately 24-48 hours post transfection.
For triheteromer experiments (Chapter 4), HEK293T cells were transfected using the
calcium phosphate precipitation method. Plasmids containing rGluN1-1a eGFP and the
rGluN2 subunits of interest were mixed in a 1:1 mass ratio and diluted to 200 ng/µl with
water. To transfect 4 wells of a 24-well plate, 10 µl of cDNA was mixed with 25 µl of 1 M CaCl2
and 100 µl of 2xBES (50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4, pH 6.95), then mixed
by pipetting. After 10-15 minutes, 50 µl of this mixture was added dropwise to each well.
After 4-6 hours the media was replaced with fresh media supplemented with NMDA receptor
antagonists (1 mM D-AP5 and 1 mM 7-CKA to avoid NMDAR excitotoxicity. Recordings were
made approximately 24 hours post transfection.
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2.3.3 Whole-cell voltage-clamp recordings
Transfected cells were identified by eGFP expression (excitation at 470 nm, coolLED pE-
100 (coolLED Ltd, Andover, UK)). Whole-cell patch-clamp recordings were performed using
an Axopatch 200B amplifer (Molecular Devices) at room temperature (21°C), with low-pass
filter set to 100 kHz. The signal was then filtered using an 8 kHz 8–pole low-pass filter
(–3 dB Bessel; Frequency Devices, Ottawa, IL, USA), and digitized at 20 kHz using a Digidata
1440A analogue-digital interface (Axon Instruments, Union City, CA) using Clampex software
(Molecular Devices). Patch-pipettes were made from thin-walled borosilicate glass (TW150F-
4, World Precision Instruments (Sarasota, FL, USA)) using a P-1000 puller (Sutter Instruments)
to give a resistance of 4-5 MΩ when filled with an internal solution containing (in mM): 141
K-gluconate, 2.5 NaCl, 10 HEPES, 11 EGTA; pH 7.3 with KOH (300 mOsm). The extracellular
solution was composed of (in mM) 150 NaCl, 10 HEPES, 3 KCl, 0.5 CaCl2, 0.01 EDTA, 20
D-mannitol (pH 7.4 with NaOH). Rapid solution exchange (open tip solution exchange had
10-90% rise times of 0.7-0.9 ms) was achieved using a two-barrel theta-glass pipette controlled
by a piezoelectric translator (Siskiyou Corporation, Grants Pass, OR).
Cells with glutamate evoked responses of less than 100 pA or greater than 1000 pA were
rejected, to reduce error from noise and to avoid leak of undesired subunit pairings (see
Chapter 4).
Amplitudes of whole-cell currents were analysed using Clampfit (Molecular Devices).
To calculate glutamate deactivation rates and Mg2+ on and off rates, multi-component
exponential decay curves were fitted to macroscopic response time courses in ChanneLab
software (www.synaptosoft.com; Synaptosoft, Decatur, GA).
τweighted was calculated as: % amplitudefast * τ fast + % amplitudeslow * τslow.
2.3.4 Single-channel voltage-clamp recordings
Single-channel voltage-clamp recordings were made at room temperature (18-21°C) from cell
attached patches formed on HEK293 cells placed in a solution that contained (in mM): 150
NaCl, 2.8 KCl, 10 HEPES, 2 CaCl2, 10 glucose, 0.1 glycine; pH 7.35 using NaOH (300-330
mOsm). Patches were recorded from at a range of holding potentials. Transfected cells were
identified by eGFP expression (excitation at 470 nm, coolLED pE-100 (coolLED Ltd)). Patch-
pipettes were made from thick-walled borosilicate glass (GC150F-7.5, Harvard Apparatus)
using a P-87 puller (Sutter Instruments) to give a resistance of 6-12 MΩ when filled with
the external solution plus agonist (NMDA (33-500 µM)). Currents were recorded using an
Axopatch 200B amplifier (Molecular Devices). Data were filtered at 2 kHz and digitized at 20
kHz via a National Instruments BNC-2090A analogue-digital interface (National Instruments,
Newbury, UK) using WinEDR software (Strathclyde Electrophysiology Software).
WinEDR v3 was used to idealise the traces (using a transition threshold of 50% of the
unitary conductance level and a 100 µs open and shut resolution), to fit Gaussian curves
to amplitude histograms and to fit multiple exponential curves to dwell time durations (all
curves fitted using iterative maximum likelihoods). Any openings where more than one
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channel was open simultaneously were discarded from dwell time and amplitude analyses. To
improve accuracy of amplitude estimates, a 1 ms minimum open time duration was applied.
Because the membrane potential was not known, the patch potential was unknown. Therefore
recordings were made at a range of holding potentials and the current plotted: the slope gave
the conductance.
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2.4 Techniques used with cultured primary mouse and rat cortical
neurons
2.4.1 Culture
Culturing was a modified version of Furshpan and Potter (1989). Brains from E17.5 CD1
mice or E20.5 Long-Evans Hooded rats (sex not determined) were microdissected in medium
containing (in mM): 8.8 Na2SO4, 27 K2SO4, 5.3 MgCl2, 0.23 CaCl2, 0.9 HEPES, 0.001% Phenol
Red, 18 D-glucose, 0.0005 kynurenic acid, adjusted to pH 7.35 with NaOH. Cortices were
incubated at 37°C for 40 minutes in papain enzyme (36,000 USP units/ml) (Worthington
Biochemical Corporation, Lakewood, NJ, USA) then washed and triturated in NeuroBasal A
medium (supplemented with 1% rat serum (Harlan laboratories, Indianapolis, IN, USA), 1 x B-
27 supplement, 1% antibacterial/antimycotic and 1 mM glutamine). The cell suspension was
diluted in opti-MEM (supplemented with 20 mM glucose and 1% antibacterial/antimycotic)
to give an end concentration of 1 hemisphere per 7 ml, and 0.5 ml/coverslip plated onto
13 mm diameter coverslips precoated with poly-D-lysine (1.33% w/v in H20) and laminin
(0.5% w/v) (Roche, Basel, Switzerland) in 24-well plates. Plates were kept at 37°C in a
humidified 5% CO2 incubator for 2.5 hours before replacement of the cell suspension with
supplemented NeuroBasal A. On DIV 4, 1 ml/well of supplemented NeuroBasal A containing
9.6 µM cytosine β -D-arabinofuranoside hydrochloride was added to the cells.
2.4.2 Quantitative PCR
RNA was isolated from cultured neurons using the Roche High Pure RNA Isolation Kit
(including DNase treatment), according to manufacturer’s instructions (Roche, Hertfordshire,
UK). 3 wells from a 24-well plate were pooled for each animal. cDNA was synthesized
from 13 µg RNA using a Transcriptor First Strand cDNA Synthesis Kit (Roche), according
to manufacturer’s instructions, then stored at –20°C. For real time PCR (RT-PCR), cDNA was
diluted to the equivalent of 6 ng of initial RNA per 15 µl qPCR reaction, per gene of interest.
Real-time PCR was performed in a Stratagene Mx3000P QPCR System (Agilent Technologies,
Waldbronn, Germany), using the FS universal SYBR Green MasterRox mix (Roche), according
to manufacturer’s instructions. The required amount of template was mixed with water, SYBR
Green MasterRox mix and forward and reverse primers (200 nM each final concentration, see
Table 2.4 for sequences) to the required reaction volume. Technical replicates as well as no
template and no RT negative controls were included. The qRT-PCR cycling programme was
10 min at 95°C, then 40 cycles of 30 sec at 95°C, 40 sec at 60°C with detection of fluorescence
and 1 min at 72°C, followed by 1 cycle (for dissociation curve) of 1 min at 95°C and 30 sec at
55°C with a ramp up to 30 sec at 95°C (ramp rate: 0.2°C/sec) with continuous detection of
fluorescence on the 55-95°C ramp. Data were normalised to GADPH expression.
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Table 2.4: Primers used for qPCR
Forward primer (5’-3’) Reverse primer (5’-3’)
rGrin2A (exon 1-2) AGCCAGAGACCCCGCTAC TGGGGTGCACCTGGTAAC
rGADPH AGAAGGCTGGGGCTCACC AGTTGGTGGTGCAGGATGC
2.4.3 Immunoblotting
Neurons were lysed in 1.5x LDS sample buffer and sample reducing agent (NuPage, Life
Technologies) and boiled at 100°C for 10 min. Approximately 20 µg of protein was loaded
onto a precast gradient gel (4-12% Bis-Tris gel, Nupage, Life Technologies) and subjected to
electrophoresis. Western blotting onto a PVDF membrane was then performed using the
Xcell Surelock system (Invitrogen) according to the manufacturer’s instructions. Following the
protein transfer, the PVDF membranes were blocked for 1 hour at room temperature with 5%
(w/v) non-fat dried milk in TBS with 0.1% Tween 20. The membranes were incubated at 4°C
overnight with the primary antibodies diluted in blocking solution: Anti GluN2A N-terminus
(Invitrogen 480031, 1 in 2000, rabbit) and anti β actin (Abcam 8227, 1 in 50,000, rabbit).
For visualisation of immunoblots, HRP-based secondary antibodies were used followed by
chemiluminescent detection on Kodak X-Omat film. A range of exposures were taken to
ensure bands were not saturated. Loading was normalized using β actin as a loading control
(run on the same blot). Immunoblots were digitally scanned and densitometric analysis was
performed using Image J (Schneider et al., 2012). In some cases, lanes from non-adjacent lanes
are spliced together, but the lanes are always from the same blot, processed in the same way,
and the splicing point is clearly marked.
2.4.4 Transient transfection
Neurons were transfected on DIV 7 or 8 with plasmids containing cDNA for wild type and
mutant GluN2A or GluN2B, or the inert control β globin, using lipofectamine in serum
free non-trophic transfection medium composed of 10% minimum essential media (MEM)
(+Earles, -L-glutamine), 88% Salt-Glucose-Glycine (SGG) (comprising in mM 114 NaCl, 26
NaHCO3, 5.3 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 1 glycine, 30 D-glucose, 0.5 sodium pyruvate,
with phenol red 0.001%) supplemented with 1% antibiotic/antimycotic and 1% insulin–
transferrin–selenium supplement. For each cover slip 2.3 µl of lipofectamine was mixed with
575 ng plasmid DNA comprising a 2:1 mass ratio of GluN2A/GluN2B and eGFP cDNA.
Cotransfection rate was 96% (data not shown). Electrophysiological recordings were made
48 hours post transfection.
2.4.5 Viral transduction
Neurons were transfected on DIV 3 with 1.1e8 viral transduction units (1 µl/well of a 24-
well plate) of an adeno-associated virus (serotype 2) expressing a Cre-eGFP fusion protein
driven by the CMV promoter. Transduction efficiency was approximately 80%, determined at
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DIV18 by assessing the proportion of cells expressing eGFP. The virus was purchased from the
University of North Carolina Gene Therapy Center Vector Core.
2.4.6 Whole-cell voltage-clamp recordings
2.4.6.1 Assessing Mg2+ block and ifenprodil sensitivity
Recordings were made at room temperature (18–21°C ) with neurons superfused (at a flow
rate of 2 mL/min) with external recording solution as used in Section 2.3.4 except with
the addition of 300 nM TTX to prevent action potentials by blocking voltage-gated sodium
channels. Transfected cells were identified by eGFP expression as in Section 2.3.4. 150 µM
NMDA was applied briefly twice to elicit desensitisation then until steady state (around 10
seconds) at which point 1 mM MgCl2 was co-applied until steady state. Experiments were then
repeated after perfusion with 3 µM ifenprodil for one minute. Application of solutions was
controlled manually. Patch-pipettes were made from thick-walled borosilicate glass (GC150F-
7.5, Harvard Apparatus) using a P-87 puller (Sutter Instruments) to give a resistance of 2-4 MΩ
when filled with the same internal solution as Section 2.3.3. Currents were recorded using an
Axopatch 200B amplifier (Molecular Devices). Data were filtered at 2 kHz and digitized at≥ 20
kHz via a National Instruments BNC-2090A analogue-digital interface (National Instruments)
using WinEDR software. Neurons were voltage-clamped at –65 mV, and recordings were
rejected if the holding current was greater than 150 pA or if the series resistance was greater
than 30 MΩ, or increased by greater than 20% during the course of the recording. Capacitance
was calculated by calculating the area under the current response to a 5 mV test pulse plotted
against time (giving the charge) and dividing by the voltage of the test pulse. Current density
was then calculated as current / capacitance.
2.4.6.2 Assessing spermine potentiation
Neurons were initially voltage-clamped at –65mV using the internal solution and external
described in Section 2.4.6.1. The neurons were then voltage-clamped at –30 mV and switched
to a recording solution composed of (in mM): 70 NaCl, 60 choline chloride, 2.8 KCl, 20 HEPES,
10 glucose, 0.1 glycine, pH 6.5 with NaOH. 100 µM DTPA was also included otherwise rapid
desensitization of the spermine potentiation was seen. The low external sodium concentration
resulted in small currents, reducing the likelihood of large currents escaping voltage–clamp
and biasing the potentiation seen. NMDA currents were evoked (as described in Section
2.4.6.1) then potentiated by 100 µM and 200 µM spermine consecutively. 200 µM spermine
was originally included as an internal control: both 100 µM and 200 µM spermine are on
the linear part of the dose-response and an approximate 2–fold increase in potentiation was
expected jumping from 100 µM to 200 µM spermine. Only the % potentiation at 100 µM
spermine was chosen for analysis. Only cells with NMDA-evoked currents greater than 40 pA
(in low sodium external) were included. The equipment and settings used were as Section
2.4.6.1 except data were filtered at 5 kHz and digitised at 20 kHz.
49
2.4.6.3 Recording miniature excitatory post synaptic currents (mEPSCs)
Solutions, equipment and settings were as Section 2.4.6.1 except bicuculline 50 µM was added
to the external solution (to block GABAA receptors) and data were filtered at 2 kHz and
digitised at 20 kHz.
Additionally, to allow calculation of excitation:inhibition ratios, a subset of recordings
were made using the same internal solution as for miniature inhibitory post synaptic potentials
(see below).
Recordings were made for 10 minutes and analysed offline to obtain average data using
Stimfit software (Guzman et al., 2014). Exemplar events were fitted with tri–exponential
functions, then the fit parameters used as templates to extract all remaining events (using
template scaling), with thresholds of 7.5 ms minimum between events, a T50 (time from peak
to 50% of response) of 1 ms minimum and an amplitude at least three times the standard
deviation of the neighbouring baseline.
2.4.6.4 Recording miniature inhibitory post synaptic currents (mIPSCs)
Recordings were made as for mEPSCs (Section 2.4.6.3) but with the AMPA receptor antagonist
20 µM CNQX present in the recording solution rather than bicuculline. To enhance the
amplitude of mIPSCs, neurons were voltage-clamped at 0 mV, and a Cs-gluconate based
internal used to block voltage-gated potassium channels (the internal used contained (in mM):
140 Cs-gluconate, 4 CsCl, 10 HEPES, 0.2 EGTA, 2 ATP magnesium salt, 2 ATP sodium salt, 0.3
GTP sodium salt, 0.1% Biocytin).
Recordings were analysed as for excitatory events, except that the minimum T50 threshold
was increased to 3 ms, reflecting the slower time course of mIPSCs. For calculation of EPSC
to IPSC ratios, average amplitude and frequency were calculated for each cell with paired
recordings and expressed as a ratio.
2.4.7 Calcium imaging
DIV 17 neurons were transferred to a recording solution as used in Section 2.3.4 and loaded
with 11 mM Fluo3 AM (from a stock solution of 2.2 mM Fluo3 dissolved in anhydrous
dimethylsulfoxide containing 20% (w/v) Pluronic detergent) for 30 min at 37°C. Cells were
washed with solution until a stable baseline was achieved, then drugs of interest applied. To
calibrate images, Fluo-3 was saturated by adding 50 µM ionomycin to the perfusion chamber
(to obtain Fmax) and quenched with 20 µM MnCl2 + 50 µM ionomycin to levels corresponding
to 100 nM Ca2+ (Minta et al., 1989), which was in turn used to calculate Fmin. Free Ca2+
concentrations were calculated from the fluorescence signal (F) according to the equation
[Ca2+] = Kd(F – Fmin)/(Fmax – F), and expressed as a multiple of the Kd of Fluo-3 (which is
approximately 390 nM). Fluo3 fluorescence images (excitation 480 ± 20 nm, emission 527
± 15 nm) were taken at one frame every second using a Leica DFC 360FX camera (Leica
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Microsystems, Mannheim, Germany) through a x 10 dry objective (HC PL Fluotar 10x/0.3 Ph1,
Leica) on an upright microscope (DMI 6000B, Leica) with a heated (37°C) stage. Fluorescence
excitation was provided by a mercury lamp in combination with an excitation filter cube. Data
were collected using Leica LAS AF v4.0.0 software.
Basal calcium levels were calculated by averaging [Ca2+] during the 50 s prior to
bicuculline application. Bicuculline-evoked spike frequency was calculated as the number of
spikes separated by a return to within 5% of baseline divided by the total period of bicuculline
application. To account for baseline drift, baseline intensity was calculated as a moving
median, considering the 20 s either side of a given point, except where a burst of very frequent
spikes occurred, where baseline values neighbouring the spike cluster were used instead. 50
cells were analysed per cover slip.
Cell density was assessed by counting the number of cells visible in a field of view 480 µm
by 640 µm (307 µm2).
2.4.8 Induction of excitotoxicity
To apply an excitotoxic insult, neurons were first deprived of growth factors by being placed
overnight into a medium containing 10% MEM, 89% SGG medium and 1% antibacterial/anti-
mycotic (see Section 2.4.4 for SGG media composition). Neurons were then treated with
NMDA at the indicated concentrations for 1 hour, after which medium was changed to
NMDA-free. After a further 23 hours, neurons were fixed (in 3% paraformaldehyde and
4% sucrose in phosphate buffered saline) and stained with DAPI contained in Vectashield
mounting medium (Vector Labs, Peterborough, UK). Cell death was quantified by counting
(blind to genotype) the number of shrunken, pyknotic nuclei as a percentage of the total.
Approximately 200–400 cells were analysed per condition, per replicate.
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2.5 Generation and validation of genetically modified rat
2.5.1 Generation of rat models
Single cell Long Evans Hooded rat embryos underwent pronuclear microinjection of mRNA
encoding the enzyme Cas9, single guide RNAs (sgRNA) binding to 5’ and 3’ of exon 8 of
Grin2A, and a pUC57 plasmid containing 2142 bp of donor DNA (see Figure 2.1)) before being
implanted into pseudopregnant mothers. The resulting live births were screened by PCR for
either insertion of donor DNA via homology directed repair or genomic deletions due to repair
by non-homologous end joining of double stranded breaks targeted to either side of exon 8.
Separate founder mutants containing LoxP sites either side of exon 8, and a 1065 bp deletion
spanning exon 8 (which encodes key pore forming domains of GluN2A) were identified using
restriction digests, and confirmed by sequencing. The sgRNA design and generation of the
founder animals was performed by Horizon Discovery Group plc (St Loius, MO, USA).
Grin2A with 
floxed exon 8
Exon 8Exon 8 Exon 8
Double strand breaks 







Donor DNA with LoxP sites
A. Floxed allele generation
Exon 8 Exon 8
Double strand breaks 





Wild type Grin2A Grin2A without 
exon 8
B. Knock out generation
(1) (2)
Figure 2.1: Crispr/Cas9 strategy for generation of rat models
2.5.2 Sequencing of rat models
Confirmation by Sanger sequencing was performed by PCR amplification of a genomic region
spanning the donor DNA section and including endogenous DNA to 5’ and 3’. This was
achieved using a high processivity enzyme (Pfu high fidelity DNA polymerase (New England
Biolabs)) and a nested PCR approach (see Table 2.5). The region was initially amplified from
genomic DNA with one pair of primers, then DNA oligomers and salts removed from the
PCR product (using a PCR Clean-up kit (MaCherey-Nagel, Düren, Germany), used as per
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manufacturer’s instructions), then a second PCR run with primers internal to the first pair.
Finally, the segment was sequenced with further internal primers. Settings for the first PCR
were: 2 minutes at 96°C, then 35 cycles of 20 s at 96°C, 30 s at 65°C and 3 min at 72°C, then
10 min at 72°C. Settings for the second PCR were as for the first, but with only 25 cycles (to
reduce amplification of non-specific products).
Table 2.5: Primers used for nested PCR
Primer pair 1 Primer pair 2
Forward primer (5’-3’) TACTCAGGACATGGGGAGGG AAGGCAGAGAGAGAGACAAAG
Reverse primer (5’-3’) CTTCCCCCGCCTAAAACG TTACTTCTCCTGCTAAAAACTCG
WT band 2351 bp 2267 bp
Floxed exon band 2429 bp 2347 bp
Deleted exon band 1286 bp 1202 bp
2.5.3 Genotyping
Genomic DNA was extracted by heating a tissue sample (ear notch or pellet from 1.5 ml cell
suspension) in 600 µl of 50 mM NaOH at 100°C for 30 minutes, with mixing by inversion after
15 minutes. 50 ul of 1 M Tris HCl (pH 6.8) was added before centrifuging at 13,000 rpm for
10 minutes at 4°C. 5 µl of supernatant was then amplified by PCR with Taq DNA polymerase
(Qiagen). PCR settings were: 5 min at 95°C, then 35 cycles of 30 s at 95°C, 30 s at 58°C and
1 min at 68°C, then 5 min at 68°C. See Table 2.6 for primers and band sizes.
Table 2.6: Genotyping primers and expected band sizes
Rat model Floxed exon 8 Deleted exon 8
Primer pair 1
Forward primer (5’-3’) AGGGAAGAAGGGAACAGGAG AGGGAAGAAGGGAACAGGAG
Reverse primer (5’-3’) ATGGCAGTTCCCAGTAGCAT TCTCTGGGATTCAGTGCAGA
WT band 369 bp 1387 bp (not seen)
Mutant band 409 bp 322 bp
Primer pair 2
Forward primer (5’-3’) – AAGGCAGAGAGAGAGACAAAG
Reverse primer (5’-3’) – ATGGCAGTTCCCAGTAGCAT
WT band 493 bp
Mutant band No band
2.5.4 Immunoblotting
Rats were terminally anaesthetised by inhalation of isofluorane 100% w/w (Abbot
Laboratories, Maidenhead, Berkshire, UK) before being decapitated. Brains were
microdissected in ice cold cutting solution (comprised of, in mM: 86 NaCl, 1.2 NaH2PO4,
2.5 KCl, 25 NaHCO3, 75 sucrose, 25 glucose, 0.5 CaCl2, 7 MgCl2) and regions of interest
flash frozen and stored at –80°C. Samples were later manually homogenised in a RIPA buffer
(comprised of: 150 mM NaCl, 1% NP–40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris
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(pH 8.0), protease inhibitors). Samples were centrifuged for 5 minutes at 13,000 rpm in a 4°C
centrifuge and the supernatant used for experiments. A BCA assay was performed to allow
equal masses of protein to be loaded. Samples were denatured by heating with 100 mM DTT
and 2% SDS for ten minutes at 80°C. From the point of gel loading, samples were treated as
described in Section 2.4.3.
2.6 Materials
Bicuculline, CNQX, 5,7-Dichlorokynurenic acid, D-AP5, EGTA, ifenprodil, ionomycin,
NMDA, spermine and tetrodotoxin citrate were purchased from Tocris (Bristol, UK). Media,
media supplements, lipofectamine 2000, foetal bovine serum, antibiotic/antimycotic, B-27
and Fluo-3 were purchased from Invitrogen (Paisley, UK). The remaining substances were
purchased from Sigma-Aldrich (Dorset, UK) unless stated otherwise in the text.
2.7 Statistical analysis
Data in tables are presented as mean ± standard error of the mean (SEM). Bar graphs depict
individual cells (circles), means (bars) and SEM (arrows).
R (v 3.1.2) (R Core Team, 2014) was used to perform statistical tests. Comparisons between
multiple means are performed by ANOVA. Comparisons between two means are performed
by independent, two-tailed, Welch t–tests (which do not assume equal variance between
groups) unless otherwise stated. Correction for multiple comparisons is made using the
Bonferroni method. The significance level used was p <0.05. In tables and figures, * indicates
p <0.05, ** indicates p <0.01 and *** indicates p <0.001.
2.8 Ethics
Animal breeding, maintenance and procedures were performed in accordance with UK
Animal Scientific Procedures Act (1986) under project license number 60/4290.
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CHAPTER3
Three missense mutations alter
important NMDAR properties
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3.1 Chapter summary and key findings
1. The GluN2AN615K mutation significantly alter potency of a range of NMDAR channel
blockers, including Mg2+. It also reduces Mg2+ block and current density in cultured neurons,
and reduces single channel conductance.
2. The GluN2AR586K mutation has no effect on Mg2+ block, current density or single channel
conductance.
3. The GluN2BN615I mutation reduces Mg2+ block and current density in cultured neurons. It
also reduces single channel conductance.
4. The GluN2BV618G mutation reduces Mg2+ block and current density in cultured neurons.
5. The alteration of important physiological NMDAR properties seen with the mutations
GluN2AN615K, GluN2BN615I and GluN2BV618G supports their role in disease causation.
6. The absence of altered properties associated with GluN2AR586K does not support a role in
disease causation, but does not exclude it.
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3.2 Introduction
Over 100 mutations have been identified in NMDAR subunits in people with a range of
neurodevelopmental disorders (see Section 1.6). Although this thesis hypothesises that some
of these mutations will contribute to their carriers’ disorders, it is unlikely that they all
do. Some missense mutations may cause no or minimal alteration to NMDAR properties,
and some may cause alterations which are easily compensated for by existing homeostatic
mechanisms. Screening mutations for functional consequences is a time consuming, resource
intensive process. It is therefore necessary to select a subset of mutations which are a priority
for investigation. As the overall aim of this thesis was to generate knowledge about key
biological pathways underlying the pathophysiology of severe mental disorders, mutations
which had large effects on receptor properties were desirable, rather than mutations with
subtle or context-specific effects.
With the aim of identifying mutations likely to have a large influence on NMDAR
properties, the first factor considered was the mode of genetic inheritance. De novo mutations
are more likely to be associated with highly deleterious phenotypes than inherited mutations
(Veltman and Brunner, 2012) and hence be the sole or major cause of disorders in their carriers,
and hence have large effects on receptor properties. The second selection criterion was the
nature of the phenotype. Neurodevelopmental disorders cover a broad spectrum of symptoms
and severity. Disorders which are highly disabling and of early onset are more likely to be
caused by mutations which cause a large change in receptor properties. The third criterion
was existing knowledge about the mutated domain. Mutations in a domain already known
to be important for receptor function are likely to have important consequences. Fourthly,
mutations which resulted in substitution of an amino acid with one from a different class
(e.g. hydrophilic versus hydrophobic) were prioritised, as being more likely to alter receptor
properties. Finally, mutations which have had some functional investigation already and have
been shown to impact on receptor properties are good candidates for further investigation.
With these factors in mind, four missense point mutations were selected for study in this
chapter (see Table 3.1). Three of the four arose de novo, are associated with an early onset
and severe phenotype of epileptic encephalopathy and affect the pore region of the NMDAR,
with two of the mutations modifying residues previously identified as important for Mg2+
block (the “N” and “N+1” site asparagines (Burnashev et al., 1992; Mori et al., 1992; Sakurada
et al., 1993; Wollmuth et al., 1998)). Figure 3.1 highlights the location of the “N” site. The
fourth mutation (GluN2AR586K) was chosen because of its proximity to the mutations above
(affecting a residue in the intracellular loop linking the M1 and M2 pore regions), although less
is known about the function of this receptor domain. Also, this mutation has weaker genetic
evidence of causality in that it was inherited maternally (no information about the mother’s
phenotype was reported).
The two mutations affecting the pore of GluN2B were both found in individuals with a
particular sub-type of epileptic encephalopathy: West syndrome. There are three cardinal
features of West syndrome: seizures termed “infantile spasms” where the trunk flexes
or extends, a characteristic EEG pattern between seizures called “hypsarrhythmia” where
chaotic, multifocal high amplitude spikes are seen, and intellectual disability or other
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neurodevelopmental difficulties (Galanopoulou and Moshe, 2015). The mutations were
associated with all of these features in their carriers, and in addition, with “autistic like
behaviour” in the case of GluN2BN615I (Lemke et al., 2014). The mutation affecting the pore of
GluN2A was found in a child with a similar phenotype of frequent myoclonies (muscle jerks)
and severe intellectual disability, but an EEG different to West syndrome (generalised slowing
with bilateral independent posterior spikes) (Endele et al., 2010). The GluN2AR586K mutation
was also identified by Endele et al. (2010) but was less well characterised. It was found in a
person in a cohort selected to have an unspecified degree of intellectual disability and either
epilepsy and/or an abnormal EEG.
Figure 3.1: The “N” site shown in GluN2B crystal structure
This figure shows the crystal structure of the NMDAR GluN2B subunit transmembrane region,
taken from Lee et al. (2014). The green and blue dots denote a solvent accessible pathway
through the pore, with green dots indicating a pore radius less than 2.3 Ångströms. The “N” site
asparagine is denoted here as a sphere labelled N612 (equivalent to N615 in the unmodified
protein). The “N+1” site neighbours it. It can be seen that these residues are near the narrowest
part of the pore. Although not shown here, the GluN2A pore structure is thought to be very
similar.
Having identified a group of interesting mutations to investigate, it was necessary to
prioritise properties to screen. This was done partly by making predictions from existing
structure-function knowledge, partly by seeking to extend work done by other groups, and
partly in response to results obtained during this study. Given that three of the four mutations
influenced the pore, and had been found to affect Mg2+ block by others (Endele et al., 2010;
Lemke et al., 2014), Mg2+ block and conductance were obvious properties to investigate (and
whole cell current density, which is influenced by conductance amongst other things). Some
work had already been done on the impact of GluN2AN615K on channel blocker potency
(Pierson et al., 2014) so this study sought to replicate and extend these findings by repeating
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Table 3.1: Mutations selected for study
Mutation GluN2AN615K GluN2BN615I GluN2BV618G GluN2AR586K
Inheritance de novo de novo de novo Maternal
(phenotype unknown)
Disorder Epileptic Epileptic Epileptic Intellectual disability
encephalopathy encephalopathy encephalopathy and epilepsy*
(West syndrome) (West syndrome)
Position Pore (“N+1”) site Pore (“N” site) Pore M1-M2 linker
in protein region
Existing Mg2+ block ↓; Mg2+ block ↓; Mg2+ block ↓; None
functional Ca2+ permeability ↓ [1] Ca2+ permeability ↑ [3] Ca2+ permeability ↑ [3]
work Memantine potency ↓;
Amantadine potency ↓;
Dextromethorphan potency ↑ [2]
First Endele et al. (2010) Lemke et al. (2014) Lemke et al. (2014) Endele et al. (2010)
report
[1]: (Endele et al., 2010), [2]: (Pierson et al., 2014), [3]: (Lemke et al., 2014).
*GluN2AR586K associated with abnormal EEG or epilepsy: detailed description of phenotype not reported
(Endele et al., 2010).
the experiments at a range of holding potentials and including the additional channel blocker
ketamine.
Uniquely, this study assessed the functional consequences of the mutations in cultured
neurons. This is important as conceivably differences in trafficking, regulation or post-
translational modifications could lead to differences in mutant subunit properties in neurons
which would not be identified in systems which do not endogenously express NMDAR.
However, endogenous expression of NMDAR is also a disadvantage, as it means that receptor
populations will be a mixture of wild type and mutant receptors, complicating interpretation.
To confirm expression of GluN2B mutant subunits, an additional mutation was introduced
to artificially reduce their sensitivity to a GluN2B selective antagonist (discussed further in
Section 3.4).
This chapter describes the assessment of Mg2+ block and current density for the mutant
NMDAR subunits GluN2AN615K, GluN2AR586K, GluN2BN615I and GluN2BV618G expressed in
cultured neurons. Conductance and channel state dwell times were assessed for GluN2AN615K,
GluN2AR586K and GluN2BN615I expressed in oocytes and HEK293 cells. The chapter begins
with an assessment of the impact of GluN2AN615K on channel blocker potency in oocytes.
The overall finding of this chapter is that the three mutations GluN2AN615K, GluN2BN615I
and GluN2BV618G all significantly impact important receptor properties, consistent with a role
in causing the epileptic encephalopathies experienced by their carriers.
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3.3 Expression of mutant diheteromers in oocytes
3.3.1 The GluN2AN615K mutation reduces Mg2+ block and alters potency of NMDAR
channel blockers
Previous work with the GluN2AN615K mutation expressed in X. laevis oocytes identified a
near absence of Mg2+ block at holding potentials of –70 mV (Endele et al., 2010). This study
sought to extend these findings by comparing inhibition of glutamate-evoked currents by
both Mg2+ and by small molecule channel blockers (memantine, amantadine, ketamine and
dextromethorphan) in X. laevis oocytes expressing NMDAR containing wild type GluN2A
and GluN2AN615K using two-electrode voltage-clamp at holding potentials of –40 mV, –60 mV
and –80 mV. In addition, experiments with memantine and amantadine were performed in the
presence and absence of Mg2+ in order to identify any alterations in channel blocker potency
associated with the presence of an approximately physiological concentration of Mg2+.
The first finding was that Mg2+ block was reduced in NMDARs containing GluN2AN615K
compared to wild type GluN2A at all holding potentials (see Table 3.2 and Figures 3.2 and 3.3).
Furthermore, block by memantine and amantadine was also reduced in NMDAR containing
GluN2AN615K compared to wild type GluN2A (Table 3.2, Figures 3.2 and 3.3). This reduction
in blockade remained even in the presence of Mg2+.
The GluN2AN615K mutation also reduced block by ketamine at the majority of holding
potentials tested (Table 3.2 and Figure 3.4) whereas block by dextromethorphan was increased
at the majority of holding potentials tested (Table 3.2 and Figure 3.5).
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Table 3.2: Summary values for channel blockers in oocytes
GluN2A GluN2AN615K GluN2A GluN2AN615K
Memantine (10 µM) Amantadine (100 µM)
n 9 7 9 7
–40 mV 59 ± 2 11 ± 1 29 ± 4 9 ± 1
–60 mV 76 ± 2 27 ± 3 45 ± 4 17 ± 1
–80 mV 76 ± 2 28 ± 2 51 ± 5 17 ± 1
Mg2+ (1 mM)
n 9 7
–40 mV 66 ± 4 0 ± 1
–60 mV 89 ± 1 7 ± 2
–80 mV 93 ± 2 2 ± 2
Memantine & Mg2+ Amantadine & Mg2+
n 9 7 9 7
–40 mV 81 ± 2 10 ± 2 72 ± 3 6 ± 1
–60 mV 94 ± 1 29 ± 3 91 ± 1 20 ± 4
–80 mV 95 ± 3 27 ± 1 96 ± 1 18 ± 3
Ketamine (10 µM) Dextromethorphan (10 µM)
n 9 6 7 8
–40 mV 65 ± 2 50 ± 3 24 ± 2 42 ± 8
–60 mV 79 ± 2 73 ± 1 45 ± 2 55 ± 3
–80 mV 85 ± 1 79 ± 1 57 ± 3 67 ± 3




































Figure 3.2: NMDARs containing GluN2AN615K show reduced Mg2+ and memantine block
(A) Representative whole–cell voltage–clamp recordings from oocytes expressing 2A wild type
NMDARs, showing inhibition by memantine (10 µM), Mg2+ (1 mM) and the two combined.
Holding potential –60 mV. Responses are normalised to the peak amplitude.
(B) As for (A) but oocytes expressing 2AN615K NMDARs.
(C) The line chart shows % inhibition by the channel blockers at three holding potentials (–40
mV, –60 mV, –80 mV). Stars indicate significance level of comparison of GluN2AN615K means
with wild type means for each combination of channel blockers (same significance at all holding
potentials). A three-way repeated measures ANOVA showed main effects of subunit (F(1,14)
= 897, p < 4.3e–14), channel blocker (F(2, 28) = 301, p < 2e–16), and holding potential (F(2,
28) = 58, p < 1.2e–10) with a significant three-way interaction (F(4, 56) = 26, p < 3.3e-12 ).
Planned post-hoc t–tests (Bonferroni corrected) showed that at –40 mV, 2AN615K subunits were
associated with lower block than wild type for Mg2+ (t(8.8) = 19.1 , pcorr = 1.5e-7 ), memantine
(t(10.7) = 19.4 , pcorr < 9.5e-9 ), and the two combined (t(13.6) = 24.1 , pcorr =1.3e-11). This
pattern was also seen at –60 mV for Mg2+ (t(7.4) = 23.2, pcorr 3̄.2e-7), memantine (t(10.1) =
17.0, pcorr = 8.8e-8) and the two combined (t(6.4) = 15.7, pcorr = 2.2e-5), and at –80 mV for
Mg2+ (t(10.8) = 32.7, pcorr = 3.2e-11), memantine (t(13.6) = 18.7, pcorr = 3.9e-10 ) and the two
combined (t(11.1) = 22.1, pcorr = 1.5e-9).



































Figure 3.3: NMDARs containing GluN2AN615K show reduced Mg2+ and amantadine block
(A) Representative whole–cell voltage–clamp recordings from oocytes expressing 2A wild type
NMDARs, showing inhibition by amantadine (100 µM), Mg2+ (1 mM) and the two combined.
Holding potential –60 mV. Responses are normalised to the peak amplitude.
(B) As for (A) but oocytes expressing 2AN615K NMDARs.
(C) The line chart shows % inhibition by the channel blockers at three holding potentials (–40
mV, –60 mV, –80 mV). Stars indicate significance level of comparison of GluN2AN615K means
with wild type means for each combination of channel blockers. A three-way repeated measures
ANOVA showed main effects of subunit (F(1,14) = 509, p < 2.1e–12), channel blocker (F(2,28)
= 170, p < 2.3e–16), and holding potential (F(2, 28) = 64, p < 3.3e–11) with a significant three-
way interaction (F(4, 56) = 5.5, p < 0.0008). Planned post-hoc t–tests (Bonferroni corrected)
showed that at –40 mV, 2AN615K subunits were associated with lower block than wild type for
Mg2+ (t(8.3) = 15.7 , pcorr = 1.5e-6), amantadine (t(9.2) = 5.4 , pcorr = 0.0036 ), and the two
combined (t(10.5) = 18.6 , pcorr =2e-8). This pattern was also seen at –60 mV for Mg2+ (t(13.7)
= 40.0, pcorr 1̄.3e-14), amantadine (t(10.3) = 7.3, pcorr = 0.0002) and the two combined (t(7.2) =
19.2, pcorr = 1.8e-6), and at –80 mV for Mg2+ (t(13.9) =52.3, pcorr = 2e-15), amantadine (t(9.2) =
6.4, pcorr = 0.001 ) and the two combined (t(7.2) = 24.2, pcorr = 3.3e-7 ).





























Figure 3.4: NMDARs containing GluN2AN615K show reduced block by ketamine
(A) Representative whole–cell voltage–clamp recordings from oocytes expressing 2A wild type
NMDARs, showing inhibition by ketamine (10 µM). Holding potential –60 mV. Responses are
normalised to the peak amplitude.
(B) As for (A) but oocytes expressing 2AN615K NMDARs.
(C) The line chart shows % inhibition by ketamine (10 µM) at three holding potentials (–40 mV,
–60 mV, –80 mV). Stars indicate significance level of comparison of GluN2AN615K means with
wild type means at each holding potential. A two-way repeated measures ANOVA showed main
effects of subunit (F(1,15) = 19.8, p = 0.0005) and holding potential (F(2,30) = 125, p < 3e–15)
with a significant interaction (F(2, 30) = 5.5, p = 0.009). Planned post-hoc t–tests (Bonferroni
corrected) showed that 2AN615K subunits were associated with lower block by ketamine than
seen in wild type at holding potentials of –40 mV (t(8.3) = 4.2, pcorr = 0.0086) and at –80 mV
(t(14.2) = 3.5, pcorr = 0.0097) but not at –60 mV (t(14.9) = 2.6, pcorr = 0.058).




























Figure 3.5: NMDARs containing GluN2AN615K show increased block by dextromethorphan
(A) Representative whole-cell voltage-clamp recordings from oocytes expressing 2A wild
type NMDARs, showing inhibition by dextromethorphan (10 µM). Holding potential –60 mV.
Responses are normalised to the peak amplitude.
(B) As for (A) but oocytes expressing 2AN615K NMDARs.
(C) The bar chart shows % inhibition by dextromethorphan (10 µM) at three holding potentials
(–40 mV, –60 mV, –80 mV). Stars indicate significance level of comparison of GluN2AN615K
means with wild type means at each holding potential. A two-way repeated measures ANOVA
showed main effects of subunit (F(1,13) = 15.5, p = 0.002) and holding potential (F(2,26) =
245, p < 2e–16) with a significant interaction (F(2, 26) = 7.4, p = 0.003). Planned post-hoc
t–tests (Bonferroni corrected) showed that 2AN615K subunits were associated with higher block
by dextromethorphan than seen in wild type at holding potentials of –40 mV (t(12.8) = 6.3, pcorr =
9e–5) and at –60 mV (t(12.6) = 2.8, pcorr = 0.043) but not at –80 mV (t(12.3) = 2.4, pcorr = 0.109).
See Table 3.2 for samples sizes and summary values.
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3.3.2 The GluN2AR586K mutation does not affect Mg2+ block
The GluN2AR586K mutation was investigated next. In contrast to the GluN2AN615K mutation,


























Figure 3.6: NMDARs containing GluN2AR586K have normal Mg2+ block
(A) Representative whole–cell voltage–clamp recordings from oocytes expressing 2A wild type
NMDARs, showing inhibition by Mg2+ (1 mM). Holding potential –60 mV. Responses are
normalised to the peak amplitude.
(B) As for (A) but oocytes expressing 2AR586K NMDARs.
(C) The bar charts show % inhibition by Mg2+ (1 mM) at a holding potential of –60 mV. A t–test
showed no significant difference between Mg2+ block in NMDARs containing wild type (92 ± 3
%, n=3) or 2AR586K (90 ± 2 %, n=5) subunits.
Some of the data in this figure was collected by Pete Parker, a medical undergraduate
completing a summer project with me.
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3.4 Expression of mutant subunits in neurons
Oocytes are extremely useful vehicles for expression of recombinant ion channels because they
allow expression of a known population of receptors in a standardised fashion. However, to
be relevant to disease, any alteration in NMDAR properties should also be observed in cells
in which NMDARs are normally expressed: predominantly forebrain neurons (in the case of
the GluN2A and GluN2B subunits). Conceivably, neuron-specific trafficking and regulation
pathways could result in no expression of mutant subunits or some compensatory effect, such
as increased expression of other subunits. This section therefore used cultured primary mouse
cortical neurons as a highly relevant system in which to overexpress mutant subunits and
assess their impact, if any, on NMDAR properties.
The interpretation of results in neurons is complicated by each cell giving a NMDA-
evoked response which arises in part from endogenous NMDAR subunits and in part from
transfected subunits. The age of culture used (DIV 9) was chosen so that virtually all the
endogenous GluN2 subunits were GluN2B (McKay et al., 2012) (and see also Figure 5.12 in
Chapter 5). The GluN2B selective antagonist ifenprodil could therefore be used to suppress
the contribution of endogenous NMDARs and to confirm the transfection of the subunit of
interest. In the case of mutations affecting GluN2A subunits, expression could be confirmed
simply by ifenprodil sensitivity of less than around 80%, as GluN2B diheteromers show 80%
block but GluN2A diheteromers minimal block at the concentration of ifenprodil used (3 µM)
(Williams, 1993). To confirm expression of mutations affecting GluN2B subunits, however, an
additional mutation was required to artificially reduce their ifenprodil sensitivity: the D101A
point mutation. This mutation reduces ifenprodil sensitivity of GluN2B diheteromers to 9%
(Perin-Dureau et al., 2002). Subunits carrying this mutation are denoted here as GluN2B(ins).
In addition to confirming expression of transfected subunits, application of ifenprodil also
allowed asessment of NMDAR properties from a population where an increased proportion
contained the mutant subunit of interest. Therefore, where there are differences in parameters
with and without ifenprodil, ifenprodil insensitive wild type and mutant subunits have been
compared in the presence of ifenprodil, maximising the contribution of these subunits to the
whole-cell currents.
The final general point about the methodological approach taken in this section is that the
most relevant control for transfected cells are other transfected cells. This is both because
the act of transfection has a detrimental impact on cells’ health (Sandbichler et al., 2013),
and because the characteristics of cells selected for patching may vary between transfected
cells (where there is a limited number to choose from) and untransfected cells (where there
are many cells to choose from). The data shown here therefore includes two controls,
untransfected cells and cells transfected with an inert protein (β globin), but statistical
comparisons for NMDAR subunit transfections are made only with β globin transfected cells.
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3.4.1 The GluN2AN615K mutation reduces Mg2+ block and current density in neurons
Cultured primary mouse cortical neurons were transiently transfected with GluN2AN615K,
wild type GluN2A and the inert control β globin. First, NMDA-evoked currents were assessed
using whole-cell patch-clamping, and % inhibition by a physiological concentration of Mg2+
assessed. Next, cells were exposed to ifenprodil for a minimum of 1 minute (to allow
full inhibition to develop) and NMDA-evoked currents and Mg2+ inhibition assessed again.
Representative traces are shown in Figure 3.7.
Figure 3.8 and Table 3.3 show ifenprodil sensitivity. It can be seen that cells transfected
with either GluN2A subunit type (wild type or mutant) show lower ifenprodil sensitivity than
































Figure 3.7: Representative traces from neurons transfected with wild type GluN2A or
GluN2AN615K
(A) Representative whole-cell voltage-clamp recording from untransfected DIV 9 neurons,
showing inhibition of current evoked by saturating NMDA (150 µM) by Mg2+ (1 mM) before
and after one minute of ifenprodil (3 µM) application. Holding potential –65 mV. Responses are
normalised to the peak amplitude.
(B-D) As for (A) but neurons transfected with an inert control (β globin), 2A or 2AN615K NMDAR
subunits respectively.
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Table 3.3: Summary values for Mg2+ block, current density and ifenprodil inhibition associated
with expression of GluN2A and GluN2B mutant subunits in neurons
Mg2+ block Mg2+ block Current density Current density Ifenprodil n
(%) (%) + Ifenprodil (pA/pF) (pA/pF) + Ifenprodil inhibition (%)
Untransfected* 94 ± 1 99 ± 1 52 ± 5 13 ± 2 76 ± 2 15
Globin* 97 ± 1 103 ± 2 45 ± 4 11 ± 1 75 ± 2 15
GluN2A 93 ± 1 95 ±1 58 ± 5 38 ± 4 32 ± 3 15
GluN2AN615K 52 ± 5 31 ± 5 40 ± 4 23 ± 3 43 ± 4 15
GluN2AR586K 92 ± 2 93 ± 1 62 ± 6 47 ± 5 25 ± 3 12
GluN2B 94 ± 2 103 ± 1 56 ± 6 10 ± 1 84 ± 2 11
GluN2B(ins) 95 ± 2 97 ± 2 40 ± 4 23 ± 3 45 ± 3 21
GluN2BN615I 77 ± 6 92 ± 5 31 ± 4 8 ± 2 74 ± 3 11
GluN2BN615I (ins) 86 ± 3 76 ± 3 33 ± 5 12 ± 1 60 ± 2 12
GluN2BV618G 85 ± 3 91 ± 2 40 ± 3 7 ± 1 72 ± 2 11
GluN2BV618G (ins) 90 ± 1 89 ± 3 36 ± 5 11 ± 2 67 ± 3 12
* Summary values represent cells from recording days shared with GluN2AN615K subunits. Other







































Figure 3.8: Ifenprodil inhibition is reduced in neurons transfected with wild type GluN2A
or GluN2AN615K
The bar chart shows % inhibition by ifenprodil (3 µM) for untransfected neurons, neurons
transfected with an inert control (β globin), 2A and 2AN615K NMDAR subunits. A one-way
ANOVA showed a significant main effect of transfected subunit (F(3,56) = 54.5, p < 2e–16.
Planned post-hoc independent t–tests showed no significant difference in ifenprodil sensitivity
between untransfected neurons and neurons transfected with β globin. However, there was
a highly significant reduction in ifenprodil sensitivity in neurons transfected with 2A (t(21.9) =
10.7, pcorr = 1.4e–9) and 2AN615K (t(20.0) = 7.2, pcorr = 2.5e–6) when compared to a β globin
transfection. Finally, there was no significant difference between neurons transfected with 2A
and 2AN615K subunits.
Figure 3.9 and Table 3.3 show Mg2+ block, in the presence and absence of ifenprodil. The
key message of this figure is that there is no difference in Mg2+ block between untransfected
cells, cells transfected with β globin or cells transfected with wild type GluN2A, but there
was a marked reduction in Mg2+ block in cells transfected with GluN2AN615Kcompared to
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wild type GluN2A, in the presence or absence of ifenprodil. A two-way ANOVA identified a
significant group by ifenprodil interaction (see figure legend) whereby Mg2+ block was greater
in the presence of ifenprodil in the case of untransfected cells and lower in the presence
of ifenprodil for cells transfected with GluN2AN615K. This second finding is important as it
shows that increasing the proportion of the response arising from mutant receptors increases
the degree of alteration in receptor property observed. The finding in untransfected cells was
not replicated with cells recorded on other days (Figures 3.17 and 3.21) and likely reflects
incomplete wash out of NMDA from previous applications (this also allowed some cells to





































No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.9: Mg2+ block is reduced in neurons transfected with GluN2AN615K
The plot shows % inhibition by Mg2+ (1 mM) before and after ifenprodil (3 µM) application for
untransfected neurons and neurons transfected with an inert control (β globin), 2A or 2AN615K
NMDAR subunits. A two-way repeated measures ANOVA showed main effects of transfected
construct (F(3,56) = 108, p < 2e–16) and ifenprodill (F(1,56) = 12.3, p = 0.0009) with a
significant interaction (F(3,56) = 75, p < 2e–16 ). Planned post-hoc paired t–tests (Bonferroni
corrected) showed that ifenprodil was associated with a small but significant increase in Mg2+
block in untransfected neurons (t(14) = 3.5, pcorr = 0.027), no difference in Mg2+ block in neurons
transfected with β globin or 2A , and a significant reduction in Mg2+ block in neurons transfected
with 2AN615K (t(14) = 13.1, pcorr = 2.5e–8). Further post-hoc independent t–tests were used
to compare transfected constructs in the absence of ifenprodil; these showed no significant
difference in Mg2+ block between untransfected neurons and neurons transfected with β globin
or 2A , but a significant reduction in Mg2+ block in neurons transfected with 2AN615K (t(16.7) =
8.2, pcorr = 2.6e–6). Finally, 2A and 2AN615K were compared in the presence of ifenprodil, again
demonstrating a significant reduction in Mg2+ block associated with 2AN615K (t(15.4) = 12.1,
pcorr = 2.2e–8).
See Table 3.3 for samples sizes and summary values.
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Figure 3.10 and Table 3.3 show current density. The most prominent feature of these
data is the substantial reduction in current density seen in all groups following application
of ifenprodil. This reflects blockade of endogenous GluN2B-containing NMDARs. However,
it is also evident that the cells transfected with GluN2A subunits show higher current density
than the other groups (reflecting their lower ifenprodil sensitivity): there was no difference
in current density post ifenprodil comparing untransfected and β globin transfected cells, but
wild type GluN2A showed higher currents. Interestingly, cells transfected with GluN2AN615K































No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.10: Current density is reduced in neurons transfected with GluN2AN615K
The plot shows current density before and after ifenprodil (3 µM) application for untransfected
neurons and neurons transfected with an inert control (β globin), 2A or 2AN615K NMDAR
subunits. A two-way repeated measures ANOVA showed main effects of transfected construct
(F(3,56) = 6.9, p = 0.0005) and ifenprodill (F(1,56) = 312, p < 2e–16) with a significant
interaction (F(3, 56) = 12, p= 3.6e–6). Planned post-hoc paired t–tests (Bonferroni corrected)
showed that ifenprodil was associated with a significant reduction in current density with all
groups: untransfected neurons (t(14) = 12.1, pcorr = 9.8e–7), β globin (t(14) = 9.8, pcorr = 9.8e–
7), 2A (t(14) = 6.1, pcorr = 0.0002) and 2AN615K (t(14) = 7.0, pcorr = 4.7e–5). Further post-hoc
independent t–tests were used to compare transfected constructs in the presence of ifenprodil
(as this is when the GluN2A subunits contributed the highest proportion to whole-cell currents);
these showed no significant difference in current density between untransfected neurons and
neurons transfected with β globin, but a significant increase in current density in neurons
transfected with 2A (t(17.1) = 7.4, pcorr = 8.0e–6). Finally, 2A and 2AN615K were compared in
the presence of ifenprodil, demonstrating a significant reduction in current density associated
with 2AN615K (t(27.8) = 3.3, pcorr = 0.023).
See Table 3.3 for samples sizes and summary values.
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3.4.2 The GluN2AR586K mutation has no effect on Mg2+ block or current density
The next mutation to be investigated was the GluN2AR586K mutation. The same experiments
were performed as with the GluN2AN615K mutation (Figure 3.11). As with the GluN2AN615K
mutation, expression of the mutant subunits was confirmed by reduced ifenprodil sensitivity
(Figure 3.12). In contrast to GluN2AN615K, there was no difference in Mg2+ block between
wild type GluN2A and GluN2AR586K transfected cells (Figure 3.13). The subset of β globin
controls used for this series of experiments had an unusually high Mg2+ block, resulting in
significant differences from untransfected and wild type GluN2A transfected cells. However,
this pattern was not replicated with other data sets (Figures 3.9, 3.17, 3.21) and so is unlikely
















Figure 3.11: Representative traces from neurons transfected with wild type GluN2A or
GluN2AR586K
(A) Representative whole-cell voltage-clamp recording from DIV 9 neurons transfected with 2A,
showing inhibition by Mg2+ (1 mM) before and after one minute of ifenprodil (3 µM) application.
Holding potential –65 mV. Responses are normalised to the peak amplitude.
(B) As for (A) but neurons transfected with 2AR586K NMDAR subunits.
Figure 3.14 shows current density. Again, all groups showed a marked reduction in current
density in the presence of ifenprodil, with wild type GluN2A transfected cells showing higher
current density than β globin transfected cells, in the presence of ifenprodil. However, there








































Figure 3.12: Ifenprodil inhibition is reduced in neurons transfected with wild type GluN2A
or GluN2AR586K
The bar chart shows % inhibition by ifenprodil (3 µM) for untransfected neurons, neurons
transfected with an inert control (globin), 2A and 2AR586K NMDAR subunits. A one-way repeated
measures ANOVA showed a significant main effect of transfected subunit (F(3,40) = 78.4, p <
2e–16). Planned post-hoc independent t-tests showed no significant difference in ifenprodil
sensitivity between untransfected neurons and neurons transfected with β globin. However,
there was a highly significant reduction in ifenprodil sensitivity in neurons transfected with 2A
(t(15.7) = 12.6, pcorr = 5.0e–9) and 2AN615K (t(18.3) = 13.8, pcorr = 1.6e–10) when compared to
a β globin transfection. Finally, there was no significant difference between neurons transfected
with 2A or 2AR586K subunits.

































No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.13: Mg2+ block is normal in neurons transfected with GluN2AR586K
The plot shows % inhibition by Mg2+ (1 mM) before and after ifenprodil (3 µM) application for
untransfected neurons and neurons transfected with an inert control (β globin), 2A or 2AR586K
NMDAR subunits. A two-way repeated measures ANOVA showed main effects of transfected
construct (F(3,40) = 4.2, p = 0.011) and ifenprodil (F(1,40) = 20.1, p = 6.1e–5) with a non-
significant interaction. Planned post-hoc independent t–tests were used to compare transfected
constructs with results in the presence/absence of ifenprodil combined; these showed a small
but significant increase in Mg2+ block in neurons transfected with β globin when compared to
untransfected neurons (t(40.0) = 4.3, pcorr = 0.026) and neurons transfected with 2A (t(40.0) =
4.3, pcorr = 0.00045). There was no difference in Mg2+ block in cells transfected with 2AR586K
compared to 2A .






































*** *** ** ***
n.s. *** n.s.
No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.14: Current density is unaffected in neurons transfected with GluN2AR586K
The plot shows current density before and after ifenprodil (3 µM) application for untransfected
neurons and neurons transfected with an inert control (β globin), 2A or 2AR586K NMDAR
subunits. A 2 way repeated measures ANOVA showed main effects of transfected construct
(F(3,40) = 6.4, p = 0.0012) and ifenprodill (F(1,40) = 210, p < 2e–16) with a significant
interaction (F(3, 40) = 14, p= 2.1e–6). Planned post-hoc paired t–tests (Bonferroni corrected)
showed that ifenprodil was associated with a significant reduction in current density with all
groups: untransfected neurons (t(10) = 8.5, pcorr = 4.9e–5), β globin (t(9) = 8.2, pcorr = 0.00012,
2A (t(10) = 5.5, pcorr = 0.0018 and 2AR586K (t(11) = 6.4, pcorr = 0.00035). Further post-hoc
independent t–tests were used to compare transfected constructs in the presence of ifenprodil;
these showed no significant difference in current density between untransfected neurons and
neurons transfected with β globin, but a significant increase in current density in neurons
transfected with 2A (t(11.9) = 6.8, pcorr = 0.00015). Finally, 2A and 2AR586K were compared
in the presence of ifenprodil, demonstrating no difference in current density.
See Table 3.3 for samples sizes and summary values.
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3.4.3 The GluN2BN615I mutation reduces Mg2+ block and current density
GluN2B mutations were examined next. Experiments comparing wild type GluN2B with
GluN2BN615I were peformed alongside ifenprodil insensitive versions of each subunit:
GluN2B(ins) and GluN2BN615I (ins) (Figure 3.15). This was to allow confirmation of mutant
expression, and to allow better assessment of the mutant subunit’s impact on NMDAR
properties by inhibition of endogenous, ifenprodil sensitive, NMDARs (for more details, see

































Figure 3.15: Representative traces from neurons transfected with wild type GluN2B or
GluN2BN615I, wild type and ifenprodil insensitive forms
(A) Representative whole-cell voltage-clamp recording from DIV 9 neuron transfected with 2B,
showing inhibition by Mg2+ (1 mM) before and after one minute of ifenprodil (3 µM) application.
Holding potential –65 mV. Responses are normalised to the peak amplitude.
(B-D) As for (A) but neurons transfected with 2BN615I, 2B(ins) or 2BN615I (ins) NMDAR subunits
respectively.
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Figure 3.16 and Table 3.3 show ifenprodil sensitivity. The primary finding is that the
ifenprodil insensitive forms show lower ifenprodil sensitivity than their standard sensitivity
counterparts, confirming expression. Also of note is that the GluN2BN615I (ins) mutant shows
greater ifenprodil sensitivity than cells transfected with GluN2B(ins) subunits. This may reflect
lower expression, or it may reflect a reduction in current density in the mutant which gives a


















































Figure 3.16: Ifenprodil inhibition is reduced in neurons transfected with ifenprodil
insensitive forms of wild type GluN2B and GluN2BN615I
The bar chart shows % inhibition by ifenprodil (3 µM) for untransfected neurons and neurons
transfected with an inert control (β globin), 2B, 2B(ins), 2BN615I or 2BN615I (ins) NMDAR subunits.
A one-way ANOVA showed a significant main effect of transfected subunit (F(5,71) = 22.2, p <
2.6e-13). Planned post-hoc independent t-tests showed no significant difference in ifenprodil
sensitivity between untransfected neurons and neurons transfected with β globin or 2B.
However, there was a highly significant reduction in ifenprodil sensitivity in neurons transfected
with 2B(ins) vs 2B (t(21.9) = 10.7, pcorr = 8.0e-10), and between 2BN615I and 2BN615I (ins) (t(16.8)
= 3.3, pcorr = 0.030). Neurons transfected with 2BN615I (ins) showed significantly higher ifenprodil
sensitivity than those transfected with 2B(ins) (t(30.1) = 3.7, pcorr = 0.0066), but there was no
significant difference comparing wild type and mutant forms without altered ifenprodil sensitivity.
Figure 3.17 and Table 3.3 show Mg2+ block. The key finding is that Mg2+ block is
reduced in cells transfected with GluN2BN615I (ins) compared to GluN2B(ins), in the presence of
ifenprodil. In contrast to this finding, Mg2+ block did not vary between wild type and mutant
transfections without modified ifenprodil sensitivity. This may reflect the lower proportion
of current contributed by mutant subunits in the absence of ifenprodil. A two-way ANOVA
identified a significant group by ifenprodil interaction (see figure legend) whereby Mg2+ block
was greater in the presence of ifenprodil in the case of cells transfected with 2B and 2BN615I
but lower in the presence of ifenprodil for cells transfected with GluN2BN615I (ins). The latter
finding shows that increasing the proportion of the response arising from mutant receptors
increases the degree of alteration in receptor property observed. The increase in Mg2+ block
seen with ifenprodil for the unmodified subunits probably reflects the lack of complete NMDA















































n.s. n.s. ** * n.s. **
n.s. n.s. n.s. ***
No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.17: Mg2+ block is reduced in neurons transfected with ifenprodil insensitive
GluN2BN615I
The plot shows % inhibition by Mg2+ (1 mM) before and after ifenprodil (3 µM) application
for untransfected neurons and neurons transfected with an inert control (β globin), 2B, 2B(ins),
2BN615I or 2BN615I (ins) NMDAR subunits. A two-way repeated measures ANOVA showed main
effects of transfected construct (F(5,71) = 11.3, p < 5e–8) and ifenprodill (F(1,71) = 128.1, p =
6.3e–5) with a significant interaction (F(5, 71) = 17.6, p < 2.7e–11). Planned post-hoc paired
t–tests (Bonferroni corrected) showed that ifenprodil was associated with a small but significant
increase in Mg2+ block in 2B neurons (t(10) = 4.6, pcorr = 0.0097), no difference in Mg2+ block
in untransfected neurons or neurons transfected with β globin or 2B(ins) , but a significant
increase in Mg2+ block in neurons transfected with 2BN615I (t(10) = 4.4, pcorr = 0.014) and a
significant decrease in neurons transfected with 2BN615I (ins) (t(11) = 4.6, pcorr = 0.0078). Further
post-hoc independent t–tests were used to compare transfected constructs in the absence of
ifenprodil; these showed no significant difference in Mg2+ block between untransfected neurons
and neurons transfected with β globin, 2B or 2BN615I . Finally, 2B(ins) and 2BN615I (ins) were
compared in the presence of ifenprodil, demonstrating a significant reduction in Mg2+ block
associated with GluN2BN615I (ins)(t(16.0) = 5.9, pcorr = 0.00022).
See Table 3.3 for samples sizes and summary values.
Figure 3.18 and Table 3.3 show current density. All groups show lower currents in the
presence of ifenprodil. The comparisons of interest are between wild type GluN2B and
GluN2BN615I in the absence of ifenprodil, highlighting a reduction in current density, and also
between GluN2B(ins) and GluN2BN615I (ins) in the presence of ifenprodil, where there is also a
















































*** *** *** *** *** **
n.s. n.s. * *
No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.18: Current density is reduced in neurons transfected with GluN2BN615I and
ifenprodil insensitive GluN2BN615I
The plot shows current density before and after ifenprodil (3 µM) application for untransfected
neurons and neurons transfected with an inert control (β globin), 2B, 2B(ins), 2BN615I or
2BN615I (ins) NMDAR subunits. A two-way repeated measures ANOVA showed main effects of
transfected construct (F(5,71) = 2.3, p = 0.0496) and ifenprodil (F(1,71) = 371, p < 2e–16) with
a significant interaction (F(5, 71) = 9.5, p= 6.1e–7). Planned post-hoc paired t–tests (Bonferroni
corrected) showed that ifenprodil was associated with a significant reduction in current density
in all groups: untransfected neurons (t(10) = 13.0, pcorr = 1.4e–6), β globin (t(10) = 8.9, pcorr =
4.6e–5), 2B (t(10) = 7.9, pcorr = 0.00013), 2BN615I (t(10) = 7.6, pcorr = 0.000019), 2B(ins) (t(20) =
9.8, pcorr = 4.6e–8) and 2BN615I (ins) (t(11) = 5.0, pcorr = 0.0038). Further post-hoc independent t–
tests were used to compare transfected constructs in the absence of ifenprodil; these showed no
significant difference in current density between untransfected neurons and neurons transfected
with β globin or 2B, but a significant reduction in current density in neurons transfected with
2BN615I (t(16.0) = 3.4, pcorr = 0.039). Next, 2B(ins) and 2BN615I (ins) were compared in the
presence of ifenprodil, demsontrating a significant reduction in current density associated with
2BN615I (ins) (t(27.3) = 3.2, pcorr = 0.035).
See Table 3.3 for samples sizes and summary values.
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3.4.4 The GluN2BV618G mutation reduces Mg2+ block and current density
The final mutation to be examined was GluN2BV618G. The same experiments were performed
















Figure 3.19: Representative traces from neurons transfected with wild type GluN2B or
GluN2BV618G, wild type and ifenprodil insensitive forms
(A) Representative whole-cell voltage-clamp recording from DIV 9 neuron transfected with
2BV618G, showing inhibition by Mg2+ (1 mM) before and after one minute of ifenprodil (3 µM)
application. Holding potential –65 mV. Responses are normalised to the peak amplitude.
(B) As for (A) but neurons transfected with 2BV618G (ins).
Figure 3.20 and Table 3.3 show ifenprodil sensitivity. As expected, ifenprodil sensitivity of
GluN2B(ins) was lower than that of wild type GluN2B. However, unexpectedly the ifenprodil
sensitivity of cells transfected with GluN2BV618G (ins) was not different to that of neurons
transfected with GluN2BV618G. Potentially this reflects poor transfection or expression of the
GluN2BV618G (ins) subunits. The difference in ifenprodil sensitivity between GluN2B(ins) and
GluN2BV618G (ins) is therefore of uncertain significance. Also unexpected is that the ifenprodil
sensitivity of GluN2BV618G subunits was lower than that of wild type GluN2B. This is hard to
account for given that there is no theoretical reason the GluN2BV618G mutation should affect
ifenprodil sensitivity.
Figure 3.21 and Table 3.3 show Mg2+ block. The finding of most interest is the lower
Mg2+ block in cells transfected with GluN2BV618G versus wild type GluN2B, in the absence
of ifenprodil. There was no difference between wild type and mutant ifenprodil insensitive
forms, but this may reflect poor expression of the mutant subunit as suggested above. There
was also an increase in Mg2+ block in wild type GluN2B in the presence of ifenprodil, which
is again likely to reflect a technical issue with incomplete NMDA wash out.
Figure 3.22 and Table 3.3 show current density. As with all previous mutations, there is
a striking reduction in current density in the presence of ifenprodil in all groups, reflecting



















































Figure 3.20: Ifenprodil inhibition is reduced in neurons transfected with GluN2BV618G but
not with ifenprodil insensitive GluN2BV618G
The bar chart shows % inhibition by ifenprodil (3 µM) for untransfected neurons and neurons
transfected with an inert control (β globin), 2B, 2B(ins), 2BV618G or 2BV618G (ins) NMDAR subunits.
A one-way ANOVA showed a significant main effect of transfected subunit (F(5,74) = 28.2, p <
7.3e–16). Planned post-hoc independent t–tests showed no significant difference in ifenprodil
sensitivity between untransfected neurons and neurons transfected with β globin or 2B. There
was a highly significant reduction in ifenprodil sensitivity in neurons transfected with 2B(ins)
vs 2B (t(27.6) = 9.3, pcorr = 3.3e–9) although no significant difference between 2BV618G and
2BV618G (ins). Interestingly, 2BV618G showed lower sensitivity than 2B (t(18.5) = 3.2, pcorr = 0.035)
and 2BV618G (ins) showed greater ifenprodil sensitivity than 2B(ins) (t(31.0) = 4.9, pcorr = 0.00016).
and GluN2BV618G, where a reduction in current density is seen in the absence of ifenprodil.
A similar pattern is seen with the ifenprodil insensitive forms in the presence of ifenprodil,
although this finding is of uncertain significance as it may merely reflect the endogenous











































n.s. n.s. ** n.s. n.s. n.s.
n.s. n.s. * n.s.
No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.21: Mg2+ block is reduced in neurons transfected with GluN2BV618G
The plot shows % inhibition by Mg2+ (1 mM) before and after ifenprodil (3 µM) application
for untransfected neurons and neurons transfected with an inert control (β globin), 2B, 2B(ins),
2BV618G or 2BV618G (ins) NMDAR subunits. A two-way repeated measures ANOVA showed main
effects of transfected construct (F(5,74) = 10.3, p = 1.6e–7) and ifenprodil (F(1,74) = 28.4, p
= 1e–6) with a significant interaction (F(5, 74) = 4.6, p = 0.0011). Planned post-hoc paired
t–tests (Bonferroni corrected) showed that ifenprodil was associated with a small but significant
increase in Mg2+ block in 2B neurons (t(11) = 4.5, pcorr = 0.0086), but no difference in Mg2+
block before and after ifenprodil application in any other groups. Further post-hoc independent
t–tests were used to compare transfected constructs in the absence of ifenprodil; these showed
no significant difference in Mg2+ block between untransfected neurons and neurons transfected
with β globin or 2B, but a significant reduction in Mg2+ block in cells transfected with 2BV618G
compared with 2B (t(15.4) = 3.4, pcorr = 0.040). Finally, 2B(ins) and 2BV618G (ins) were compared
in the presence of ifenprodil, with no significant difference in Mg2+ block seen after correction
for multiple comparison.
















































*** *** *** *** *** ***
n.s. n.s. * *
No ifenprodil With ifenprodil No ifenprodil (mean) With ifenprodil (mean)
Figure 3.22: Current density is reduced in neurons transfected with GluN2BV618G and
ifenprodil insensitive GluN2BV618G
The plot shows current density before and after ifenprodil (3 µM) application for untransfected
neurons and neurons transfected with an inert control (β globin), 2B, 2B(ins), 2BV618G or
2BV618G (ins) NMDAR subunits. A two-way repeated measures ANOVA showed main effects of
transfected construct (F(5,74) = 3.3, p = 0.0090) and ifenprodil (F(1,74) = 475, p < 2e–16) with a
significant interaction (F(5, 74) = 11.5, p = 3.1e–8). Planned post-hoc paired t–tests (Bonferroni
corrected) showed that ifenprodil was associated with a significant reduction in current density
in all groups: untransfected neurons (t(11) = 17.2, pcorr = 2.8e–8), β globin (t(11) = 11.9,
pcorr = 1.2e–6), 2B (t(11) = 7.5, pcorr = 0.00012), 2BV618G (t(10) = 8.0, pcorr = 0.000012), 2B(ins)
(t(20) = 9.8, pcorr = 4.6e–8) and 2BV618G (ins) (t(11) = 6.7, pcorr = 0.00039). Further post-hoc
independent t–tests were used to compare transfected constructs in the absence of ifenprodil;
these showed no significant difference in current density between untransfected neurons and
neurons transfected with β globin or 2B , but a significant reduction in current density in neurons
transfected with 2BV618G (t(16.3) = 3.8, pcorr = 0.015). Next, 2B(ins) and 2BV618G (ins) were
compared in the presence of ifenprodil, demsontrating a significant reduction in current density
associated with 2BV618G (ins) (t(28.0) = 3.5, pcorr = 0.018).
See Table 3.3 for samples sizes and summary values.
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3.5 Single channel properties of mutant diheteromers
In the previous section, three of the four mutant subunits investigated were found to
be associated with reduced current density when expressed in cultured neurons. This is
an interesting finding which could be due to reduced membrane trafficking of receptors
containing mutant subunits (suppressing endogenous subunits also) or to an alteration of
NMDAR properties such that less current was able to flow when a receptor was activated. The
location of the mutations inside the receptor pore suggested that ion conductance may well be
altered. To test this possibility, single channel recordings were made and channel conductance
directly measured.
An initial small data set was collected in outside-out patches pulled from oocytes
expressing GluN2AN615K and GluN2AR586K-containing NMDARs. However, as oocytes are
seasonally unavailable, HEK293 cells were used to generate a further, larger data set from
GluN2AN615K and GluN2BN615I containing NMDARs. Unfortunately, low expression rates
were achieved in HEK293 cells, with many silent patches. In order to maximise throughput,
recordings were made from cell-attached patches rather than the gold standard of outside-out
patches (which allow control of absolute holding potential, and offer more strategies to reduce
noise).
3.5.1 The GluN2AN615K mutation reduces conductance when expressed in oocytes
Figure 3.23 shows representative recordings of wild type and GluN2AN615K-containing
NMDARs expressed in oocytes. These are held at the same holding potential and plotted
to the same scale, and it is immediately apparent that the current flowing during openings
of GluN2AN615K NMDARs is of much smaller amplitude than that flowing during wild type
GluN2A openings. This four-fold reduction in conductance is quantified in Figure 3.23C and
Table 3.4.
Table 3.4: Summary values for outside-out single channel recordings in oocytes
GluN2A GluN2AN615K GluN2AR586K
Conductance (pS) 58 ± 3 15 ± 1 61 ± 2
Mean open time (ms) 4.1 ± 0.3 11.4 ± 2.6 3.2 ± 0.3
τ1 (ms) 4.0 ± 0.3 12.1 ± 3.1 3.5 ± 0.2
Number of openings 2555 774 1139




































Figure 3.23: GluN2AN615K reduces single channel conductance in oocytes
(A) Representative voltage-clamp recordings from outside-out patched pulled from oocytes
expressing 2A wild type containing NMDARs. Holding potential –60 mV.
(B) As for (A) but oocytes expressing 2AN615K containing NMDARs.
(C) The bar chart shows conductance. A t–test showed that conductance in NMDARs containing
2AN615K was signficantly lower than in NMDARs containing wild type 2A subunits (t(3.4) = 14.6,
p = 0.00036). See Table 3.4 for samples sizes and summary values.
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Figure 3.24 shows the dwell time analysis performed. As some of the patches had
multiple channels present, analysis of closed time and open probability was difficult. Analysis
was therefore restricted to open times only, with any events consisting of multiple channel
openings discarded. There was a trend towards longer openings in GluN2AN615K containing
NMDARs, but this did not achieve significance. The small number of recordings made in































   













Figure 3.24: GluN2AN615K does not influence NMDAR open times in oocytes
(A) Representative histogram showing frequency of wild type 2A single channel open times,
fitted with an exponential decay curve.
(B) As for (A) but oocytes expressing 2AN615K containing NMDARs.
(C) The bar chart shows the time constants (tau) fitted to single channel open time frequency
distributions. A single exponential was fitted in each case. A t–test showed no significant
difference between wild type 2A and 2AN615K containing NMDARs.
(D) The bar chart shows mean single channel open times. A t–test showed no significant
difference between wild type 2A and 2AN615K containing NMDARs.
See Table 3.4 for samples sizes, event numbers, and summary values.
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3.5.2 The GluN2AR586K mutation does not affect single channel properties when
expressed in oocytes
Figure 3.25 shows representative recordings of wild type and GluN2AR586K containing
NMDARs expressed in outside-out patches pulled from oocytes. These traces give an
impression of similar amplitudes and open durations, and indeed there were no differences
identified in conductance or open times when comparing GluN2AR586K and wild type GluN2A




































Figure 3.25: GluN2AR586K does not influence single channel conductance in oocytes
(A) Representative voltage-clamp recordings from outside-out patches pulled from oocytes
expressing 2A wild type NMDARs. Holding potential –60 mV.
(B) As for (A) but oocytes expressing 2AR586K containing NMDARs.
(C) The bar charts show conductance. A t–test showed no significant difference between wild
type 2A and 2AR586K containing NMDARs.



















































Figure 3.26: GluN2AR586K does not influence NMDAR open times in oocytes
(A) Representative histogram showing frequency of wild type 2A single channel open times,
fitted with an exponential decay curve.
(B) As for (A) but oocytes expressing 2AR586K containing NMDARs.
(C) The bar chart shows the time constants (tau) fitted to single channel open time frequency
distributions. A single exponential was fitted in each case. A t–test showed no significant
difference between wild type 2A and 2AR586K containing NMDARs.
(D) The bar chart shows mean single channel open times. A t–test showed no significant
difference between wild type 2A and 2AR586K containing NMDARs.
See Table 3.4 for samples sizes, event numbers, and summary values.
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3.5.3 The GluN2AN615K mutation reduces conductance and increases open times
when expressed in HEK293 cells
GluN2AR586K subunits were not explored further as the data in oocytes excluded any major
efffect upon single channel properties. However, GluN2AN615K subunits were expressed in
HEK293 cells and again found to have a marked impact on single channel properties.
Figure 3.27 shows representative traces from cell-attached patches formed with HEK293
cells expressing wild type and mutant NMDARs. The channel openings now appear as
positive deflections from baseline because the NMDAR-mediated cation current is flowing
away from the patch electrode, rather than towards it (as with outside-out patches or whole-
cell configurations). The traces are plotted to the same scale and patches held at the same
holding potential, although as the membrane potential of the HEK293 cells was unknown,
the patch potential (holding potential minus membrane potential) and hence the driving force
for current flow may be different. There are also two channels present in the GluN2AN615K
trace, with a few double amplitude openings evident. Even with these complications, a
marked difference in current amplitude can be seen between the two subunit types. The
conductance was quantified by measuring the current amplitude at a range of holding
potentials, and calculating the slope of the line: this gives the conductance (Figure 3.27C).
The lower conductance seen in GluN2AWT diheteromers expressed in HEK293 cells (43 pS)
compared to oocytes (58 pS) is likely to reflect the higher Ca2+ concentration used for external
solutions in recordings in HEK293 cells (2 mM) than in oocytes (0.85 mM) as higher Ca2+
decreases NMDAR conductance (Gibb and Colquhoun, 1992). The slopes of the GluN2AN615K
containing NMDARs are about a third that of the wild type NMDARs (Figure 3.27E, Table
3.5). Figure 3.27D shows the same data with lines constrained to pass through the origin
(as no driving force results in no current) to allow an approximation of patch potential to be
obtained and the groups more clearly compared.
Table 3.5: Summary values for cell-attached single channel recordings in HEK293 cells
GluN2A GluN2AN615K GluN2B GluN2BN615I
Conductance (pS) 43 ± 3 16 ± 1 54 ± 2 14 ± 2
Mean open time (ms) 0.85 ± 0.05 1.28 ± 0.09 0.69 ± 0.07 0.51 ± 0.04
τ1 (ms) 0.74 ± 0.05 0.51 ± 0.07 0.59 ± 0.08 0.45 ± 0.05
τ2 (ms) not fitted 1.87 ± 0.11 not fitted not fitted
%τ1 – 51 ± 5 – –
τweighted (ms) 0.74 ± 0.05 1.13 ± 0.09 0.59 ± 0.08 0.45 ± 0.05
Number of openings 6748 3635 3106 7371





































































Figure 3.27: GluN2AN615K reduces single channel conductance in HEK293 cells
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Figure 3.27: GluN2AN615K reduces single channel conductance in HEK293 cells
(A) Representative voltage-clamp recordings from cell-attached patches in HEK293 cells expressing 2A
wild type NMDARs. Holding potential –100 mV.
(B) As for (A) but HEK293 cells expressing 2AN615K containing NMDARs. There are two channels in this
patch.
(C) Single-channel unitary amplitude plotted against holding potential (membrane potential unknown)
and fitted with linear regression. The slope of the regression line is the conductance. The estimated
membrane potentials may be higher than expected (approximately –40 mV) as the cells are depolarised
in the presence of glutamate released from nearby dying cells.
(D) Single-channel unitary amplitude plotted against patch potential by setting intercept to zero.
(E) The bar chart shows conductance. A t–test showed that conductance in NMDARs containing 2AN615K
was signficantly lower than in NMDARs containing 2A subunits (t(9.0) = 10.3, p < 3e–6). See Table 3.5
for samples sizes and summary values.
Figure 3.28 shows the dwell time analysis performed. As the majority of the patches had multiple
channels present, dwell time analysis was again restricted to open times only, with any events consisting
of multiple channel openings discarded. The mean open times in GluN2AN615K containing NMDARs
were found to be longer than those in wild type NMDARs, and required a second, longer, time constant
to provide a good fit to the open time distribution (see Table 3.5 for values), giving a longer weighted time
constant. These findings are similar to what was found in the smaller data set in oocytes (section 3.5.1).



















































Figure 3.28: GluN2AN615K increases NMDAR open times in HEK293 cells
(A) Representative histogram showing frequency of wild type 2A single channel open times,
fitted with an exponential decay curve.
(B) As for (A) but cells expressing 2AN615K containing NMDARs.
(C) The bar chart shows the weighted time constants fitted to single channel open time
frequency distributions. A t–test showed that NMDARs containing 2AN615K had significantly
longer time constants than wild type 2A NMDARs (t(16.1) = 4.0, p = 0.00097).
(D) The bar chart shows mean single channel open times. A t–test showed that NMDARs
containing 2AN615K had significantly longer time constants than wild type 2A NMDARs (t(16.0)
= 4.3, p = 0.00055).
See Table 3.5 for samples sizes, event numbers, and summary values.
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3.5.4 The GluN2BN615I mutation reduces conductance
One of the GluN2B pore mutants was investigated next: GluN2BN615I. Figure 3.29 shows representative
traces from cell-attached patches formed with HEK293 cells expressing wild type and mutant NMDAR.
As with GluN2AN615K, the conductance slopes for the mutant subunit are well separated from the wild
type NMDAR, whether plotted against holding potential (Figure 3.29C) or patch potential (Figure 3.29D).





































































Figure 3.29: GluN2BN615I reduces single channel conductance in HEK293 cells
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Figure 3.29: GluN2AN615K reduces single channel conductance in HEK293 cells
(A) Representative voltage-clamp recordings from cell-attached patches in HEK293 cells expressing 2B
wild type NMDARs. Holding potential –100 mV.
(B) As for (A) but HEK293 cells expressing 2BN615I containing NMDARs. There are two channels in this
patch.
(C) Single-channel unitary amplitude plotted against holding potential (membrane potential unknown)
and fitted with linear regression. The slope of the regression line is the conductance.
(D) Single-channel unitary amplitude plotted against patch potential by setting intercept to zero.
(E) The bar chart shows conductance. A t–test showed that conductance in NMDARs containing 2BN615I
was signficantly lower than in NMDARs containing 2B subunits (t(6.1) = 13.7, p < 8e–6). See Table 3.5
for samples sizes and summary values.
Figure 3.30 shows the open times of wild type GluN2B and GluN2BN615I containing NMDARs, which
















































Figure 3.30: GluN2BN615I does not influence NMDAR open times in HEK293 cells
(A) Representative histogram showing frequency of wild type 2B single channel open times,
fitted with an exponential decay curve.
(B) As for (A) but HEK293 cells expressing 2BN615I containing NMDARs.
(C) The bar chart shows the time constants fitted to single channel open time frequency
distributions. A single exponential was fitted in each case. A t–test showed no significant
difference between wild type 2B and 2BN615I containing NMDARs.
(D) The bar chart shows mean single channel open times. A t–test showed no significant
difference between wild type 2B and 2BN615I NMDARs.
See Table 3.5 for samples sizes, event numbers, and summary values.
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3.6 Discussion
3.6.1 Summary of findings
This chapter assessed the impact of four NMDAR subunit disease-associated mutations on a range of
basic receptor properties in three heterologous systems. The principal finding is that three of the four
mutations studied result in substantial alterations in key receptor properties: GluN2AN615K , GluN2BN615I
and GluN2BV618G all cause reduced Mg2+ block and current density, GluN2AN615K and GluN2BN615I
cause reduced single channel conductance and GluN2AN615K also increases channel open times. These
effects support the mutations’ role in disease causation. The GluN2AR586K mutation was not found to
have any effect on any of the parameters assessed, suggesting this mutation may not be relevant to the
carrier’s disorder.
3.6.2 GluN2A and GluN2B pore mutations reduce Mg2+ block
The GluN2AN615K mutation was found to cause negligible Mg2+ block when expressed as diheteromers
in oocytes, replicating previous work (Endele et al., 2010). This mutation and the two GluN2B pore
mutations were also found to significantly reduce Mg2+ block when expressed in cultured neurons
(although the evidence is weaker for GluN2BV618G, as the ifenprodil insensitive versions did not show
a significant difference). GluN2AN615K caused the biggest reduction (approximately halving Mg2+ block
on average), with a lesser reduction seen with GluN2BN615I (an average drop of around a quarter) and
GluN2BV618G (an average drop of around 10%).
The difference in effect between the mutations will relate both to the different residues they encode
and to their slightly different positions in the pore. The GluN2AN615K mutation is likely to have the largest
effect because it modifies the residue previously found to be the strongest determinant of Mg2+ block
(the “N+1” site asparagine) (Wollmuth et al., 1998), whereas the GluN2BN615I mutation modifies the next
most important site (the “N” site asparagine) and the GluN2BV618G mutation influences a nearby residue
which has not previously been identified as important in Mg2+ block.
The properties of the replacement residues are also likely to impact on Mg2+ block and ion
permeation. Figure 3.31 shows amino acids clustered by their biochemical properties in a Venn diagram.
Asparagine is a hydrophilic (polar), uncharged amino acid. In the case of GluN2AN615K, asparagine is
replaced with lysine, which is positively charged. This positive charge would be expected to repel rather
than interact with Mg2+ ions and other cations. In the case of GluN2BN615I, asparagine is replaced with
isoleucine, which is also uncharged but hydrophobic. As transmembrane ion pores require a lining of
hydrophilic residues, the presence of a hydrophobic residue is likely to be quite structurally disruptive,
even if the residue does not directly repel positively charged ions. In the case of GluN2BV618G, a relatively
large, hydrophobic valine is replaced by a very small glycine. As glycine is so small, this alteration may
be easier to accommodate than the other mutations.
The reduction in Mg2+ block seen with the three mutations in neurons was much more variable
and of lower magnitude than that seen in oocytes, within this study and by others (Endele et al., 2010;
Lemke et al., 2014). This is due to the presence of endogenous GluN2B subunits within neurons, and
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Figure 3.31: Biochemical properties of amino acids
This figure shows the 20 naturally arising amino acids plotted on a Venn diagram to emphasise
shared and contrasting properties. Taken from Esquivel et al. (2013).
arises from either cell to cell variability in the proportion of wild type versus mutant NMDAR diheteromers,
and/or incorporation of mutant subunits into triheteromers with wild type GluN2B. The fact that reductions
in Mg2+ block are seen despite the presence of wild type NMDAR subunits demonstrates that the mutant
subunits are being expressed at the cell surface. It also supports the idea that these heterozygously
carried mutations could have an impact in an individual who also has wild type receptors.
Any reduction in Mg2+ block is of high physiological relevance as voltage dependent block by Mg2+ is
crucial to the NMDAR’s role as a molecular coincidence detector (Bliss and Collingridge, 1993), whereby
opening of NMDARs requires both the presence of glutamate and depolarisation of the postsynaptic
membrane (Mayer et al., 1984; Nowak et al., 1984). If block by Mg2+ is removed or reduced, it is possible
that synaptic plasticity would become partially uncoupled from the inputs received at the synapse,
leading to dysregulation of learning and memory, and potentially leading to the associated phenotype
of intellectual disability.
3.6.3 GluN2AN615K alters potency of channel blockers
GluN2AN615K was also found to alter the potency of small molecule channel blockers, with the potency
of memantine and amantadine markedly reduced, ketamine somewhat reduced and dextromethorphan
enhanced. These findings are consistent with subsequently published work (Pierson et al., 2014). The
variation in the mutation’s effect on different channel blockers likely relates to the variation in residues
that are of primary importance for interaction with the blockers.
Considering memantine and amantadine (which is structurally very similar to memantine), studies
employing site directed mutagenesis have shown that memantine interacts with the same residues as
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Mg2+, with the “N” and “N+1” site contributing in the case of GluN2B (Kashiwagi et al., 2002) and GluN2A
(Chen and Lipton, 2005). However, the GluN1 “N” site is the dominant site for interaction with memantine,
and other residues also impact on memantine binding (reviewed in (Johnson and Kotermanski, 2006)
and see Figure 3.32. This is probably why the effect of the GluN2AN615K mutation on memantine and
amantadine block is less marked than its effect on Mg2+ block.
Figure 3.32: Sites important for binding of memantine
This figure shows the location of residues identified as important in binding of memantine as
black circles. The “N” sites in GluN1 (“NR1”) and GluN2A/B (“NR2”) are marked with white
asterisks within black circles. The “N+1” site in GluN2A/B is the neighbouring black circle.
Figure taken from Johnson and Kotermanski (2006).
Ketamine also interacts with residues involved in Mg2+ block, with the GluN1 “N” site identified as
key, and the GluN2B “N” site as also important (Yamakura et al., 1993). The role of the “N+1” site in either
subunit, or the GluN2A “N” site, does not appear to have been directly tested. The data presented here
suggest that the GluN2A “N+1” site is less important for interacting with ketamine than for memantine or
amantadine.
In contrast to the channel blockers discussed so far, dextromethorphan’s primary metabolite
dextrorphan interacts with residues in the more extracellular portion of the pore vestibule (LePage et al.,
2005). Dextrorphan’s binding is not influenced by mutations in the GluN1 “N” site (LePage et al., 2005)
but no previous work has assessed the impact of mutating the GluN2A “N+1” site. The results of this
study and others (Pierson et al., 2014) suggest that the GluN2A “N+1” site does somehow modulate the
binding of dextromethorphan, potentially via a conformational change in the more extracellular region of
the pore.
The increased potency conferred by the GluN2AN615K mutation suggests that dextromethorphan (a
common ingredient in cough medicines) may be of therapeutic benefit to the carrier of the GluN2AN615K
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mutation or similar pore mutations. However, if the primary problem is insufficient current flow, rather than
inappropriate current flow (see next section), dextromethorphan could potentially exacerbate symptoms.
3.6.4 GluN2A and GluN2B pore mutations reduce current density and GluN2AN615K
and GluN2BN615I reduce conductance
All three pore mutations were found to significantly reduce NMDAR current density when expressed in
neurons, with GluN2BN615I associated with a reduction to about half, and GluN2AN615K and GluN2BV618G
a reduction of about a third (although the evidence is weaker for GluN2BV618G, as the ifenprodil
insensitive versions did not show a significant difference). Although this could reflect reduced expression
of the mutant subunits, the fact that the change in current density was associated with a reduction
in Mg2+ block argues that the mutant subunits are being expressed and are reducing conductance.
When conductance was directly evaluated via single channel recordings, a substantial three to four-fold
reduction in conductance was indeed found with GluN2AN615K and GluN2BN615I.
Because the residues that interact with Mg2+ also comprise one of the narrowest parts of the ion
permeation pathway, it makes sense that mutations that affect Mg2+ block also affect conductance.
Mutations of the “N” site have been found to influence conductance previously in GluN1 (Behe et al.,
1995; Schneggenburger and Ascher, 1997) and GluN2B (Premkumar et al., 1997). As with Mg2+ block,
different amino acid class alterations at slightly different parts of the pore could explain the differences in
extent of reduction in current density seen with the different mutations.
A reduction in conductance could be detrimental to normal neuronal function as a given NMDAR
activation would allow smaller currents through, contributing less to overall charge transfer and potentially
altering Ca2+ signalling. The impact on Ca2+ signalling is hard to predict, as previous work has found the
mutations to also influence Ca2+ permeability: GluN2AN615K reduces it (Endele et al., 2010) and the two
GluN2B mutations increase it (Lemke et al., 2014). Thus a diheteromeric GluN2AN615K NMDAR would
allow smaller currents of all cations to pass when activated, but a diheteromeric GluN2BN615I might allow
smaller sodium currents but equal or even elevated Ca2+ currents.
In contrast to the “gain of function” reduction in Mg2+ block observed, the reduction in conductance is
a “loss of function”. This makes it hard to predict whether blocking or potentiating mutant subunit function
would be of benefit.
3.6.5 GluN2AN615K increases channel open time duration
An interesting and unpredicted finding was that the GluN2AN615K mutation increases channel open times
by about 50%. This may be a false result, as the lower conductance of the mutant makes brief closures
harder to detect than in wild type NMDARs. Indeed, the finding in the next chapter that deactivation
rates are unaffected by the GluN2AN615K mutation (see Section 4.3.2) is not consistent with a prolonged
channel opening time, unless the burst pattern is also altered.
However, if the finding of prolonged openings is true, this implies the mutation is having some
impact on channel gating. Gating is classically thought of as dependent primarily on agonist binding
and dissociation, coupled to a conformational change in the channel: opening of the “activation gate”. In
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NMDARs, the activation gate is known to be formed by the SYTANLAAF motif in the M3 region (reviewed
in Traynelis et al. (2010)). However, gating can also be affected by the permeation pathway if the channel
is unable to shut while a permeant ion is within. Previous work mutating the GluN1 “N” site supports this
idea (Schneggenburger and Ascher, 1997). Thus, mutations affecting conductance, perhaps by slowing
the speed of ion travel through the pore, could potentially increase open times. An increase in mean open
time is of physiological relevance as this could increase the charge transfer during a given exposure to
agonist, influencing excitability and Ca2+ entry. However, the consequences are hard to predict in the
case of the GluN2AN615K mutation, which has the opposing effects of both reducing conductance and
prolonging opening.
3.6.6 GluN2AR586K has no effect on Mg2+ block or conductance
The GluN2AR586K mutation was not found to influence Mg2+ block, current density or conductance despite
its relatively close proximity to the location of the other mutations studied here (the pore mutations are
in the membrane re-entrant loop (M2) and the GluN2AR586K mutation is in in the M1-M2 linker region, a
cytosolic loop between the first transmembrane domain (M1) and M2). It is hard to hypothesise about
the likely impact of the GluN2AR586K mutation as little work has been done on the functional role of the
M1-M2 linker region, and it was not possible to resolve it in a recent crystal structure of the NMDAR
transmembrane regions (Lee et al., 2014). It is possible the GluN2AR586K mutation leads to alterations
in function that have not been investigated in this study. It is also possible that the mutation does not
alter NMDAR function, and that its presence in an individual with a neurodevelopmental disorder was
coincidental. This is particularly likely as the mutation was inherited. Unfortunately no information was
provided on the phenotype of the parent who also carried the mutation.
3.6.7 Limitations
The major limitation of work done in this chapter is that the mutant NMDAR expressed in oocytes
and HEK293 cells were all diheteromeric, whereas a substantial proportion of NMDAR expressed
physiologically are triheteromeric (see Chapter 4). It is very hard to predict what impact, if any, a mutant
subunit would have in partnership with a wild type GluN2 subunit. Some of the NMDAR expressed in
cultured neurons may well have been triheteromers containing mutant subunits but this would have been
as part of a mixed population and there was no way of isolating out their properties. A further limitation
is the poor approximation of heterozygosity in neurons: the mutant subunits were overexpressed and
may conceivably not be incorporated into functional receptors to the same extent in vivo. Further, the
developmental impact of the mutations could not be assessed as they were only transiently transfected
in neurons, in the case of GluN2B mutants much later than their expression would normally begin, and
in the case of GluN2A mutants, much earlier.
3.6.8 Conclusion
This chapter has provided evidence that the GluN2AN615K, GluN2BN615I and GluN2BV618G mutations are
able to influence important receptor properties in ways which could potentially alter synaptic plasticity
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and influence risk for the neurodevelopmental disorders experienced by their carriers. It has not found




One missense mutation has a
dominant negative effect in
triheteromeric NMDARs
107
4.1 Chapter summary and key findings
1. Triheteromeric NMDARs containing one wild type subunit and one GluN2AN615K subunit were
generated. This was confirmed using glutatamate deactivation rates.
2. Glutamate deactivation rates are not influenced by any of the pore mutations (GluN2AN615K,
GluN2BN615I or GluN2BV618G).
3. Triheteromers consisting of a wild type subunit and GluN2AN615K subunit show a reduction in Mg2+
block and a slowing in Mg2+ on and off rates.
4. The identity of the wild type partnering subunit matters: Mg2+ block in triheteromers containing wild
type GluN2A subunits is less influenced by the presence of the mutant GluN2AN615K subunit than in
triheteromers containing wild type GluN2B.
5. Diheteromers consisting of two GluN2BN615I or two GluN2BV618G subunits show a potentiation of
current in the presence of Mg2+.
6. The dominant negative influence of the GluN2AN615K subunit when partnered with wild type subunits
supports a role in disease causation.
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4.2 Introduction
NMDARs are heterotetramers comprised of four subunits, two type one and two others, of which GluN2A
and GluN2B are the commonest in the rodent forebrain (Monyer et al., 1994). The identity of the subunits
partnering GluN1 impacts on NMDAR properties important in synaptic plasticity (reviewed in (Wyllie et al.,
2013)). For example, GluN2B has a slower deactivation timecourse than GluN2A (Vicini et al., 1998),
prolonging the duration of activity following a brief exposure to glutamate and thus influencing charge
transfer and potentially synaptic plasticity (Erreger et al., 2005).
When both partnering subunits are the same, NMDARs are termed diheteromers. However, when
two different subunits are paired with GluN1, NMDARs are termed triheteromers. Evidence from co-
immunoprecipitation studies (Al-Hallaq et al., 2007; Dunah and Standaert, 2003; Luo et al., 1997; Sheng
et al., 1994) and electrophysiology (Gray et al., 2011; Rauner and Kohr, 2011; Tovar et al., 2013)
suggest that a substantial proportion of NMDARs in the forebrain of adult rodents are GluN2A/GluN2B
triheteromers, although one co-immunoprecipitation studies found the proportion to be low, at 6% (Chazot
and Stephenson, 1997).
The work in Chapter 3 referred to the impact of NMDAR pore mutations in diheteromers. However,
these mutations have only been found heterozygously, and it is probable that they will predominantly
be expressed alongside wild type subunits in triheteromers. In order to better model the impact of a
mutation on NMDAR properties in humans it is therefore necessary to express the mutant subunit as
part of a triheteromer.
Expressing triheteromeric NMDARs is a significant technical challenge. It was first achieved by
Hatton and Paoletti, who demonstrated that sensitivity to subunit-specific allosteric modulators (zinc and
ifenprodil) was intermediate in triheteromers (Hatton and Paoletti, 2005). However, this approach was
limited by the requirement for one subunit within each triheteromer to carry mutations removing Mg2+
block and greatly reducing glutamate potency. Recently, two groups independently developed related
methodologies to dictate NMDAR subunit composition by modifying NMDAR subunit C termini to include
ectopic endoplasmic reticulum retention signals (Hansen et al., 2014; Stroebel et al., 2014). Both rely
on fusing peptide tags to NMDAR C termini which will only allow escape from the endoplasmic reticulum
when partnered with the appropriate tag. Table 4.1 compares the two approaches and Figure 4.1 shows
a schematic of the method used by Hansen et al.
Table 4.1: Comparison of two related methodologies for generating triheteromeric NMDARs
Hansen 2014 Stroebel 2014
Control of expression Fusion of peptide tags to C termini
C termini Largely intact but 2B replaced by 2A Almost absent
GluN1 Wild type GluN1-1a Mutated GluN1-1a
Expression Well expressed, care needed to avoid leak Less expression, minimal leak
Cell types Oocytes and HEK293 cells Oocytes only
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Figure 4.1: Generation of obligate triheteromeric NMDAR.
Taken from Hansen et al. (2014). (A) Schematic of wild type and modified GluN2 subunits.
“CX” denotes the C1 or C2 peptide tags modifying endoplasmic reticulum retention, fused to
the end of the GluN2A C terminus. In the case of GluN2B modified subunits, the C terminus
has been replaced with that of GluN2A. (B) Depicts the outcome of different pairings of subunits
with modified C termini: subunit pairings which both have C1 or both have C2 will have exposed
retention signals and be retained in the endoplasmic reticulum. Subunits which have partnering
modifications will have their retention signals masked and achieve surface expression.
Both approaches suffer to some extent from leak currents, whereby non-desired subunit
combinations are able to escape retention and achieve surface expression. As this seems to result
from the endoplasmic reticulum retention pathways being overwhelmed, leak currrents can be minimised
by limiting GluN1 expression and avoiding cells with large magnitude currents (Hansen et al., 2014).
Despite their differences, the two approaches made very similar observations about GluN2A/GluN2B
triheteromeric properties. Firstly, where properties differ between GluN2A and GluN2B, the majority of
triheteromer properties are intermediate, but dominated by GluN2A. The open probability, glutamate
potency, glutamate deactivation rate, zinc sensitivity and ifenprodil sensitivity of GluN2A/GluN2B
triheteromers are closer to that of GluN2A diheteromers than GluN2B diheteromers (Hansen et al., 2014;
Stroebel et al., 2014). The exceptions are triheteromeric glycine potency, which is closer to that seen in
GluN2B diheteromers (Stroebel et al., 2014), and spermine potentiation, which is almost identical to that
seen in GluN2A diheteromers (Stroebel et al., 2014). This means spermine potentiation could potentially
be more sensitive in detecting the onset of GluN2A expression than the more commonly used ifenprodil
inhibition, because the expression of triheteromers will shift the spermine response to that of GluN2A,
rather than to an intermediate value as in the case of ifenprodil. This observation is used in Chapter 5.
This chapter describes the application of the technique developed by Hansen et al. to express
triheteromeric receptors containing one wild type subunit and one mutant subunit in HEK293T cells.
HEK293T cells were chosen over oocytes because of their year-round availability and relative ease
of making electrophysiological recordings, in particular the ability to assess glutamate deactivation
rates. The expression of mutant subunits as triheteromers with wild type partner subunits allows better
modelling of the impact of the mutant subunit in its heterozygous human carrier, who is likely to have a
mixed population of wild type and mutant diheteromers and triheteromers.
The overarching finding of this chapter is that the GluN2AN615K mutation has a dominant negative
effect on NMDARs containing wild type subunits. This strengthens the evidence in support of the
hypothesis that this mutation is responsible for the severe neurodevelopmental disorder experienced by
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its carrier. The key property investigated was Mg2+ block, which was found to be reduced in GluN2AN615K
containing triheteromeric NMDARs.
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4.3 Glutamate deactivation rates
4.3.1 Glutamate deactivation rates allow triheteromers to be distinguished from
diheteromers
Previous work identified that the glutamate deactivation rates of GluN2A/GluN2B triheteromers were
intermediate to those of GluN2A and GluN2B diheteromers (Hansen et al., 2014; Stroebel et al., 2014).
To replicate this finding, HEK293T cells were transfected to express either diheteromers with unmodified
C termini (e.g. wild type 2A/2A), diheteromers with modified C termini (e.g. 2AC1/2AC2) or triheteromers
with modified C termini (e.g. 2AC1/2BC2). Whole-cell voltage-clamp recordings were then made while
cells underwent precisely controlled glutamate exposure (5 ms or 2 s). This allowed the assessment
of glutamate deactivation rates: the rate of decline of current following the removal of glutamate.
Example traces showing glutamate deactivation currents following a 5 ms exposure are in Figure 4.2A
and following a 2 s exposure in Figure 4.3A. These currents can be well approximated by one or two
component exponential decay functions. The weighted time constants fitted to the deactivation curves
after a 5 ms exposure are shown in Figure 4.2B and C and after a 2 s exposure in Figure 4.3B and
C. Summary values for fast, slow, and weighted time constants are provided in Table 4.3 and 4.4. The
nomenclature used in this chapter is quite complex, so please see Table 4.2 for a guide.
Table 4.2: Nomenclature used to describe wild type and mutant triheteromeric constructs
Full name Short name Group name
(used in tables and figures) (for pooled data)
Wild type constructs
GluN2A wild type 2A 2A WT
GluN2AC1/ GluN2AC2 2AC1C2
GluN2B wild type 2B 2B WT
GluN2BAC1/ GluN2BAC2 2BC1C2
GluN2AC1/ GluN2BAC2 2A/2B 2A/2B WT
GluN2BAC1/ GluN2AC2 2B/2A
Mutant constructs: GluN2AN615K as example
GluN2AN615K 2AN615K 2A N615K
GluN2AC1N615K/GluN2AC2N615K 2AN615KC1C2
GluN2AC1N615K/GluN2AC2WT 2AN615K/2A 2A N615K / 2A WT
GluN2AC1WT/GluN2AC2N615K 2A/2AN615K
GluN2AC1N615K/GluN2BAC2WT 2AN615K/2B 2A N615K / 2B WT
GluN2BAC1WT/GluN2AC2N615K 2B/2AN615K
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The data in Figures 4.2, 4.3, and Tables 4.3, 4.4 demonstrate three important points. Firstly, the
modified C termini do not influence glutamate deactivation rate: the time constants for diheteromers
with wild type and modified C termini are the same, following either a 5 ms or 2 s agonist exposure.
Wild type and modified C termini data were therefore pooled for subsequent analyses. Secondly, the
pairing of a given subunit with a given modified C terminus does not influence the likelihood of assembly:
2A/2B triheteromers have the same glutamate deactivation rates as 2B/2A triheteromers. (If a particular
modified subunit was more likely to assemble with itself (“escape”) this would have led to diheteromeric
outliers.) These data were therefore pooled for subsequent analyses. Finally, and importantly, the
glutamate deactivation rates for triheteromers are significantly different to those for either diheteromer,
showing an intermediate value closest to that of GluN2A diheteromers.
Table 4.3: Glutamate deactivation time constants (1 mM, 5 ms exposure) for wild type NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2A 47 ± 4 227 ± 60 94 ± 3 55 ± 2 6
2AC1C2 41 ± 3 113 ± 14 93 ± 4 45 ± 4 7
2A WT 44 ± 3 178 ± 40 93 ± 3 50 ± 3 13
2B 255 ± 16 959 ± 54 57 ± 2 555 ± 35 7
2BC1C2 256 ± 36 1000 ± 188 68 ± 4 454 ± 42 8
2B WT 255 ± 20 981 ± 100 63 ± 3 501 ± 30 15
2A/2B 68 ± 6 218 ± 40 92 ± 4 79 ± 3 8
2B/2A 53 ± 4 336 ± 97 89 ± 3 75 ± 7 7
2A/2B WT 61 ± 4 289 ± 61 91 ± 2 77 ± 4 15
Table 4.4: Glutamate deactivation time constants (1 mM, 2 s exposure) for wild type NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2A 64 ± 8 233 ± 21 95 ± 2 73 ± 5 6
2AC1C2 62 ± 5 not fitted 100 4 62 ± 5 7
2A WT 63 ± 4 233 ± 21 98 ± 1 67 ± 4 13
2B 356 ± 58 923 ± 157 60 ± 8.5 676 ± 40 7
2BC1C2 385 ± 60 1134 ± 111 78 ± 5 558 ± 45 8
2B WT 372 ± 41 1020 ± 100 70 ± 5 613 ± 33 15
2A/2B 93 ± 9 248 98 ± 2 96 ± 8 8
2B/2A 75 ± 5 529 ± 83 95 ± 1 95 ± 9 7










































































Figure 4.2: Glutamate deactivation rates following 5 ms exposure are unaffected by
modification of C termini
(A) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing wild
type 2A and 2B diheteromers, and 2A/2B triheteromers, activated by brief exposure to glutamate
(1 mM, 5 ms). Responses are normalised to the peak amplitude.
(B) The bar graph shows glutamate deactivation weighted time constants for wild type construct
pairs with and without modified C termini. t–tests (Bonferroni corrected) showed no significant
differences between construct pairs.
(C) The bar graph shows glutamate deactivation weighted time constants with construct pairs
pooled. A one-way ANOVA showed a significant effect of subunit (F(2,40)= 194, p < 2e–16),
with post hoc t–tests (Bonferroni corrected) demonstrating significant differences between 2A
and 2B (t(14.2) = 15.0, pcorr =1.2e–09), and with triheteromers exhibiting an intermediate value
significantly different to both 2A (t(24.5) = 6.0, pcorr = 6.9e–06) and 2B (t(14.4) = 14.1, pcorr =
2.5e–09).











































































Figure 4.3: Glutamate deactivation rates following 2 s exposure are unaffected by
modification of C termini
(A) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing wild
type 2A and 2B diheteromers, and 2A/2B triheteromers, activated by prolonged exposure to
glutamate (1 mM, 2 s). Responses are normalised to the peak amplitude.
(B) The bar graph shows glutamate deactivation weighted time constants for wild type construct
pairs with and without modified C termini. t–tests (Bonferroni corrected) showed no significant
differences between construct pairs.
(C) The bar graph shows glutamate deactivation weighted time constants with construct pairs
pooled. A one-way ANOVA showed a significant effect of subunit (F(2,40)= 231, p < 2e–16),
with post hoc t–tests (Bonferroni corrected) demonstrating significant differences between 2A
and 2B (t(14.4) = 16.4, pcorr =3.2e-10), and with trihetomers exhibiting an intermediate value
significantly different to both 2A (t(23.7) = 4.3, pcorr = 0.0008) and 2B (t(14.8) = 15.4, pcorr =
4.8e-10).
See Table 4.2 for how pairs were pooled and see Table 4.4 for summary values and sample
sizes.
115
4.3.2 The GluN2AN615K mutation does not influence glutamate deactivation rates
Glutamate deactivation rates for diheteromers containing the GluN2AN615K pore mutation were examined
next (Figure 4.4 and Tables 4.5 and 4.6). The first finding is that, as for the wild type subunits, the modified
C termini do not influence glutamate deactivation rates in GluN2AN615K subunits. These data were pooled
for subsequent analyses. The second finding is that the glutatamate deactivation rates for GluN2AN615K
are the same as those for GluN2A wild type.
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Figure 4.4: GluN2AN615K does not alter glutamate deactivation rates
(A) The bar graph shows glutamate deactivation (1 mM, 5 ms exposure) weighted time
constants for 2AN615K construct pairs with and without modified C termini. A t–test showed
no significant difference between the construct pairs.
(B) The bar graph shows glutamate deactivation (1 mM, 5 ms exposure) weighted time
constants with construct pairs pooled. A t–test showed no significant difference between 2A
and 2AN615K glutamate deactivation rates.
(C) The bar graph shows glutamate deactivation (1 mM, 2 s exposure) weighted time constants
for 2AN615K construct pairs with and without modified C termini. A t–test showed no significant
difference between the construct pairs.
(D) The bar graph shows glutamate deactivation (1 mM, 2 s exposure) weighted time constants
for 2AN615K construct pairs with construct pairs pooled. A t–test showed no significant difference
between 2A and 2AN615K glutamate deactivation rates.
See Table 4.2 for how pairs were pooled and see Tables 4.5 and 4.6 for summary values and
sample sizes.
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Next, subunit pairings designed to produce triheteromers containing one mutant GluN2AN615K
subunit were investigated (Figure 4.5 and Tables 4.5 and 4.6). As seen with wild type subunits, the
partnering of a particular C termini modification with a particular subunit did not influence glutamate
deactivation rates. These data were therefore pooled for subsequent analyses. As would be expected,
triheteromers containing two GluN2A subunits (one mutant, one wild type ) exhibited deactivation rates
indistinguishable from wild type or mutant GluN2A diheteromers. Similarly, triheteromers containing one
GluN2B subunit and one GluN2AN615K mutant subunit displayed deactivation rates indistinguishable from
those seen in wild type triheteromers. This is an important finding as it confirmed that subunit pairings
containing GluN2AN615K mutant subunits were able to assemble as triheteromers.
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Table 4.5: Glutamate deactivation time constants (1 mM, 5 ms exposure) for GluN2AN615K
containing NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2AN615K 35 ± 1 223 ± 55 96 ± 2 44 ± 6 6
2AN615KC1C2 40 ± 3 186 99 ± 1 41 ± 3 7
2A N615K 38 ± 2 214 ± 40 98 ± 1 43 ± 3 13
2AN615K/2A 43 ± 3 175 ± 24 97 ± 1 47 ± 2 10
2A/2AN615K 51 ± 2 470 100 ± 0 52 ± 2 10
2A N615K / 2A WT 47 ± 2 234 ± 62 98 ± 1 49 ± 2 20
2AN615K/2B 54 ± 5 318 ± 80 89 ± 3 73 ± 5 10
2B/2AN615K 63 ± 5 343 ± 73 93 ± 3 85 ± 11 10
2A N615K / 2B WT 59 ± 4 328 ± 55 91 ± 2 79 ± 6 20
Table 4.6: Glutamate deactivation time constants (1 mM, 2 s exposure) for GluN2AN615K
containing NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2AN615K 56 ± 5 not fitted 100 56 ± 5 5
2AN615KC1C2 57 ± 4 289 99 ± 1 59 ± 2 7
2A N615K 57 ± 3 289 100 ± 0 58 ± 2 12
2AN615K/2A 64 ± 5 237 99 ± 1 66 ± 5 10
2A/2AN615K 77± 6 not fitted 100 ± 0 77 ± 6 10
2A N615K / 2A WT 70 ± 4 237 100 ± 0 71 ± 4 20
2AN615K/2B 81± 7 412 ± 145 96 ± 2 91 ± 4 10
2B/2AN615K 121± 29 253 ± 104 81 ± 11 103 ± 7 10
2A N615K / 2B WT 101 ± 15 321 ± 85 89 ± 6 97 ± 4 20
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Figure 4.5: GluN2AN615K subunits can form triheteromers with wild type GluN2 subunits
(A) The bar graph shows glutamate deactivation (1 mM, 5 ms exposure) weighted time
constants for 2AN615K triheteromeric subunit pairs with alternate pairings of subunit and modified
C terminus. t–tests showed no significant differences between the construct pairs.
(B) The bar graph shows glutamate deactivation (1 mM, 5 ms exposure) weighted time
constants for 2AN615K triheteromeric subunit pairs with construct pairs pooled. t–tests showed
no significant differences between the subunit pairs.
(C) The bar graph shows glutamate deactivation (1 mM, 2 s exposure) weighted time constants
for 2AN615K triheteromeric subunit pairs with alternate pairings of subunit and modified C
terminus. t–tests showed no significant differences between the subunit pairs.
(D) The bar graph shows glutamate deactivation (1 mM, 2 s exposure) weighted time
constants for wild type and 2AN615K triheteromeric subunit pairs with construct pairs pooled. t–
tests showed no significant difference between wild type and 2AN615K containing triheteromers’
glutamate deactivation rates.
See Table 4.2 for how pairs were pooled and see Tables 4.5 and 4.6 for summary values and
sample sizes.
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4.3.3 The GluN2BN615I and GluN2BV618G mutations do not influence glutamate
deactivation rates
The effect of pore mutations in the GluN2B subunit on glutamate deactivation rates were assessed next
(Figure 4.6 and Tables 4.7 and 4.8). The modified C termini were associated with a faster deactivation
rate in GluN2BN615I diheteromers. Therefore, only GluN2B pore mutant subunits with wild type C
termini were used for comparison with wild type GluN2B. This demonstrated that the GluN2BN615I and
GluN2BV618G mutations do not influence glutamate deactivation rates.
Table 4.7: Glutamate deactivation time constants (1 mM, 5 ms exposure) for GluN2BN615I and
GluN2BV618G containing NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2BN615I 248 ± 10 856 ± 35 58 ± 3 502 ± 17 6
2BN615IC1C2 230 ± 22 754 ± 64 70 ± 6 384 ± 15 7
2BN615I/2A 55 ± 4 159 ± 88 85 ± 13 60 ± 3 5
2BN615I/2B 220 ± 13 744 ± 61 57 ± 7 397 ± 23 6
2BV618G 157 ± 19 1006 ± 93 40 ± 1 666 ± 57 4
2BV618GC1C2 79 976 52 509 1
2BV618G/2A 40 ± 4 127 ± 64 87 ± 12 46 ± 4 5
2BV618G/2B 249 ± 14 833 ± 80 57 ± 5 497 ± 19 3
Table 4.8: Glutamate deactivation time constants (1 mM, 2 s exposure) for GluN2BN615I and
GluN2BV618G containing NMDARs
GluN2 subunits τ fast (ms) τslow (ms) % fast τweighted (ms) n
2BN615I 345 ± 15 1055 ± 53 59 ± 2 632 ± 30 6
2BN615IC1C2 314 ± 12 1110 72 ± 4 502 ± 14 7
2BN615I/2A 76 ± 5 not fitted 100 ± 0 77 ± 5 5
2BN615I/2B 303 ± 10 1358 ± 368 65 ± 8 559 ± 47 6
2BV618G 461 ± 70 2053 ± 800 53 ± 9 1064 ± 216 4
2BV618GC1C2 108 1102 43 673 1
2BV618G/2A 55 ± 8 290 98 ± 2 59 ± 5 5
2BV618G/2B 343 ± 24 1214 ± 134 64 ± 5 649 ± 17 3
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Figure 4.6: GluN2B pore mutations do not alter glutamate deactivation rates
(A) The bar graph shows glutamate deactivation (1 mM, 5 ms exposure) weighted time
constants for 2B, 2BN615I and 2BV618G diiheteromeric construct pairs with and without modified
C termini. A t-test showed a signifcant difference between 2BN615I with and without modified
C termini (t(10.5) = 5.1, p = 0.0004). Statistical comparisons were not possible with 2BV618G
C1C2 as only one cell with modified C termini was obtained. Subunit pairs were therefore not
pooled. Instead, wild type and mutant subunits without modified C termini were compared. t–
tests showed no significant differences.
(B) The bar graph shows glutamate deactivation (1 mM, 2 s exposure) weighted time constants
for 2B, 2BN615I and 2BV618G diiheteromeric subunit pairs with and without modified C termini. A
t–test showed a signifcant difference between 2BN615I with and without modified C termini (t(7.1)
= 34.0, p = 0.0053). Statistical comparisons were not possible with 2BV618G C1C2 as only one
cell with modified C termini was obtained. Subunit pairs were therefore not pooled. Instead,
wild type and mutant subunits without modified C termini were compared. t–tests showed no
significant differences.
See Tables 4.7 and 4.8 for summary values and sample sizes.
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Subunit pairings designed to produce triheteromers containing one mutant GluN2B subunit produced
a complex set of results (Figure 4.7 and Tables 4.7 and 4.8). These data show that cells transfected with
subunits designed to produce triheteromers containing two GluN2B subunits, one mutant and one wild
type, mainly show deactivation rates indistinguishable from GluN2B diheteromers containing two wild
type or two mutant subunits (with the exception of GluN2BN615I following brief glutamate exposure).
However, cells transfected with subunits designed to produce triheteromers containing one GluN2A
subunit and one mutant GluN2B subunit showed deactivation rates that were closer to GluN2A than
expected, and were in fact faster than those seen in wild type triheteromers. This was seen with both
GluN2B pore mutants and at either duration of agonist exposure. This suggests that some GluN2A
diheteromers had been able to escape the endoplasmic reticulum retention system, achieve surface
expression, and contribute to the glutamate deactivation time course. Because it was not possible to be
confident that triheteromers containing one copy of either GluN2B mutant subunit were being generated,
the remainder of this chapter discusses only findings related to GluN2B pore mutant diheteromers.
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Figure 4.7: Glutamate deactivation rates in construct pairings designed to produce
GluN2BN615I and GluN2BV618G containing triheteromers suggest GluN2A diheteromeric
escape current
(A) Glutamate deactivation (1 mM, 5 ms exposure) weighted time constants for wild type and
2BN615I triheteromeric subunit pairs. t–tests showed significant reductions in deactivation rates
in pairs containing 2BN615I with modified C termini compared with 2B diheteromers (t(17.8) =
2.8, pcorr = 0.026) and 2A/2B triheteromers (t(13.1) = 3.45, pcorr = 0.008).
(B) Glutamate deactivation (1 mM, 5 ms exposure) weighted time constants for wild type and
2BV618G triheteromeric subunit pairs. t–tests showed a significant reduction in deactivation rates
in pairs containing 2BN615I with modified C termini compared with 2A/2B triheteromers (t(11.8)
= 6.0, pcorr = 1.2e-4) but not with GluN2B diheteromers.
(C) Glutamate deactivation (1 mM, 2 s exposure) weighted time constants for wild type and
2BN615I triheteromeric construct pairs. t–tests showed no significant differences between the
construct pairs.
(D) Glutamate deactivation (1 mM, 2 s exposure) weighted time constants for wild type and
2BV618G triheteromeric construct pairs. t–tests showed a significant reduction in deactivation
rates in pairs containing 2BN615I with modified C termini compared with 2A/2B triheteromers
(t(14.3) = 4.9, pcorr = 0.0004) but not with 2B diheteromers.
See Tables 4.7 and 4.8 for summary values and sample sizes.
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4.4 Mg2+ block in diheteromeric and triheteromeric NMDARs containing
GluN2AN615K subunits
4.4.1 Mg2+ percentage inhibition
GluN2AN615K mutant subunits expressed as diheteromers have been previously shown to reduce Mg2+
block in this study (Chapter 3) and by others (Endele et al., 2010). However, the mutation’s impact
on Mg2+ block in triheteromers remained unexplored, despite this subunit configuration being more
physiologically relevant. Having generated GluN2AN615K containing triheteromers, Mg2+ block was
therefore a priority for investigation.
First, the extent of Mg2+ block was investigated. Transfected cells were first exposed to glutamate,
to establish a baseline response, and then underwent precisely timed exposure to glutamate co-applied
with Mg2+, before being returned to glutamate alone (in the continuous presence of glycine). This allowed
the percentage reduction in glutamate-evoked current in the presence of Mg2+ to be calculated, and the
precisely controlled timing of exposure also allowed Mg2+ block on and off rates to be evaluated (see
Section 4.5.2).
Representative traces are shown in Figure 4.8. It was first confirmed that the C terminus
modifications did not themselves influence Mg2+ block (Figure 4.9). The extent of Mg2+ block in subunit
pairings with and without modified C termini was not different for either wild type or GluN2AN615K subunits.
This meant data from wild type and modified subunits could be pooled for subsequent analyses, and also




























Figure 4.8: Representative traces showing Mg2+ block in wild type and GluN2AN615K
mutant diheteromers and triheteromers
(A–F) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing the
subunits indicated during exposure to glutamate (1 mM) and Mg2+ (1 mM) while held at –60 mV.









































Figure 4.9: Mg2+ block is not altered by modified C termini
The bar graph shows Mg2+ block (1 mM) in NMDARs with and without modified C termini at
a holding potential of –60 mV. t–tests (Bonferroni corrected) showed no signficant differences
between wild type and modified subunits.
Data comparing percentage Mg2+ block in cells expressing wild type, wild type triheteromeric,
GluN2AN615K mutant diheteromeric and GluN2AN615K mutant triheteromeric NMDARs are presented in
Figures 4.10 and 4.11, and Tables 4.9 and 4.10. These data demonstrate four main findings. Firstly,
they show that wild type triheteromers show the same extent of Mg2+ inhibition as wild type GluN2A
and GluN2B diheteromers: a near complete block at approximately physiological Mg2+ concentration
(1 mM) and holding potential (–60 mV). Secondly, they replicate previous work showing a highly
significant reduction in Mg2+ block in GluN2AN615K diheteromers, with block at negligible levels under
near physiological conditions. Thirdly, they show that triheteromers containing one mutant GluN2AN615K
subunit exhibit Mg2+ block intermediate to diheteromers comprised of wild type and GluN2AN615K
subunits. This is important because it demonstrates a dominant negative effect of the GluN2AN615K
subunit: one alone, paired with a wild type subunit, is sufficient to significantly reduce NMDAR Mg2+
block. Finally, they show that the identity of the wild type partner subunit in mutant triheteromers matters:
the extent of Mg2+ block seen with a wild type GluN2A subunit partner is signficantly higher than that
seen with a wild type GluN2B subunit partner.
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2A N615K / 2A
2A N615K / 2B
2A N615K
Figure 4.10: Mg2+ block is reduced in GluN2AN615K mutant diheteromers and triheteromers
(A) Summary data showing 1 mM Mg2+ block at three holding potentials for wild type and 2AN615K
containing diheteromers and triheteromers. Stars indicate significance level of comparison of means
of mutant NMDARs with relevant wild type control (see text below). A two-way repeated measures
ANOVA showed a significant main effect of subunit (F(5, 80) = 538, p < 2e–16) and of holding potential
(F(2, 160) = 701, p < 2e–16). There was also a significant interaction (F(10,160) = 44, p < 2e–16),
however, as the key contrasts of interest were between subunits, the interaction of subunit with holding
potential in determining Mg2+ block was not explored. Post hoc t–tests (Bonferroni corrected) showed no
significant differences between Mg2+ block in wild type subunits. However, Mg2+ block was significantly
reduced in GluN2AN615K compared to 2A (t(13.9) = 70.3, pcorr < 2e–15) and between 2AN615K/2A and
2A (t(26) = 19.4, pcorr < 2e–15). 2A/2B and 2AN615K/2B also showed significantly different Mg2+ block
(t(29) = 35.1, pcorr < 2e–15). Further key contrasts (not marked on the figure) showed that 2AN615K
diheteromers showed significantly lower Mg2+ block than 2AN615K/2A (t(20) = 19.1, pcorr < 2e–13) and
2AN615K/2B (t(21.4) = 18.5, pcorr < 1e–13). Finally, 2AN615K/2A showed significantly higher Mg2+ block
than 2AN615K/2B (t(30.6) = 5.8, pcorr < 2e–5)). Post hoc paired t–tests comparing holding potentials
showed that Mg2+ block at –40 mV was significanty less than at –60 mV (t(85) = 12.2, pcorr < 3e–15),
which was significantly less than at –80 mV (t(85) = 12.8, pcorr < 3e–15).
(B) Summary data showing 100 µM Mg2+ block at three holding potentials for wild type and GluN2AN615K
containing diheteromers and triheteromers. Stars indicate significance level of comparison of means of
mutant NMDARs with relevant wild type control (see text below). A two-way repeated measures ANOVA
showed a significant main effect of subunit (F(5, 28) = 255, p < 2e–16) and of holding potential (F(2,
56) = 115, p < 2e–16). There was also a significant interaction (F(10,56) = 5.6, p < 1.1e–5), however,
as the key contrasts of interest were between subunits, the interaction of subunit with holding potential in
determining Mg2+ block was not explored. Post hoc t–tests (Bonferroni corrected) showed no significant
differences between Mg2+ block in wild type subunits. Similarly to the 1 mM Mg2+ concentration,
there was a significant difference in Mg2+ block between 2A and 2AN615K (t(4.6) = 51, pcorr < 1.2e–
6) and between 2A and 2AN615K/2A (t(6) = 13.2, pcorr < 9.5e–5). 2A/2B and 2AN615K/2B also showed
significantly different Mg2+ block (t(7) = 30.6, pcorr < 7.6e–8). Further key contrasts (not marked on the
figure) showed that 2AN615K diheteromers showed significantly lower Mg2+ block than 2AN615K/2A (t(5.3)
= 4.6, pcorr < 0.04) and 2AN615K/2B (t(10.3) = 6.9, pcorr < 0.0003). 2AN615K/2A did not show significantly
higher Mg2+ block than 2AN615K/2B at this concentration. Post hoc paired t–tests comparing holding
potentials showed that Mg2+ block at –40 mV was significanty less than at –60 mV (t(33) = 7.3, pcorr <
3e–7), which was significantly less than at – 80 mV (t(33) = 5.6, pcorr < 4e–5).
See Tables 4.9 and 4.10 for samples sizes and summary values.
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Table 4.9: 1 mM Mg2+ block in wild type and GluN2AN615K containing diheteromers and
triheteromers
Holding potential
GluN2 subunits –80 mV –60 mV –40 mV n
2A WT 105 ± 2 102 ± 1 97 ± 1 11
2A/2B 108 ± 2 102 ± 1 97 ± 1 13
2B WT 111 ± 2 104 ± 1 97 ± 2 13
2AN615K/2A 69 ± 2 53 ± 2 37 ± 3 19
2AN615K/2B 55 ± 2 36 ± 1 23 ± 1 18
2AN615K 14 ± 1 8 ± 1 7 ± 1 12
Table 4.10: 100 µM Mg2+ block in wild type and GluN2AN615K containing diheteromers and
triheteromers
Holding potential
GluN2 subunits –80 mV –60 mV –40 mV n
2A WT 97 ± 1 89 ± 1 64 ± 3 4
2A/2B 104 ± 2 95 ± 4 70 ± 1 5
2B WT 97 ± 4 89 ± 5 71 ± 4 6
2AN615K/2A 38 ± 4 26 ± 5 13 ± 4 6
2AN615K/2B 24 ± 1 15 ± 2 10 ± 3 8
































































Figure 4.11: Mg2+ block is reduced in GluN2AN615K mutant diheteromers and
triheteromers: current–voltage curves
(A-F) Current-voltage plots showing a similar extent of Mg2+ block for diheteromeric and
triheteromeric wild type subunits (2A (n = 6), 2A/2B (n = 6), 2B (n = 4)), but a reduction in
block for 2AN615K/2A triheteromers (n = 15), a further reduction with 2AN615K/2B triheteromers (n
= 13) and almost negligible block with 2AN615K diheteromers (n = 6).
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4.4.2 Mg2+ block kinetics
The kinetics of Mg2+ block were measured using the experimental set up described in Section 4.5.1 and
analysed as described in the Methods chapter (Section 2.3.3). Only recordings made in the presence of
1 mM Mg2+ at –80 mV were analysed, as larger amplitude responses can be fitted most accurately.
4.4.2.1 Mg2+ block on rates
Data showing Mg2+ block on rates are presented in Figure 4.12 and Table 4.11. These data are
highly variable, reflecting the technical difficulty of achieving exactly timed solution exchange across
cells of different size and slightly different position relative to the solution interface. Variability may also
be introduced by the difficulty in fitting the low amplitude, slow onset of Mg2+ block in GluN2AN615K
diheteromers. These issues mattered less for the glutamate deactivation rates reported earlier in the
chapter as their time courses are much longer, and amplitudes larger. However, the detection of between
group differences for the rapid on/off rates of Mg2+ ideally requires a larger number of cells, and this
experiment lacked power to identify all possible differences. With the awareness that there may be
some type II errors, some conclusions can be drawn from these data. The first finding is that there
is no difference in Mg2+ block on rates between wild type subunits: all block rapidly. Secondly, there
is no difference between GluN2AN615K mutant triheteromers containing a GluN2A or GluN2B wild type
partner. Data for receptors with “0” mutant subunits (wild type ) was therefore pooled, as was that for
NMDARs with one mutant subunit, presented in Figure 4.12C. This led to the third finding: triheteromers
containing one mutant GluN2AN615K subunit show a slower Mg2+ on rate than wild type diheteromers.
This is an interesting finding both because it provides further evidence of the dominant negative effect
of the GluN2AN615K mutation, and also because it strengthens the evidence that mutant triheteromers
are being generated rather than a mixed population of wild type and mutant diheteromers. If a mixed
population was present, nearly all of the Mg2+ block seen would be due to wild type diheteromers, and
their larger amplitude, more rapid component would be expected to dominate the fit parameters.
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Table 4.11: Mg2+ (1 mM) on rates in wild type and GluN2AN615K containing diheteromers and
triheteromers in the continuous presence of glutamate (1 mM)
GluN2 subunits Tau fast (ms) Tau slow (ms) % fast Tau weighted (ms) n
2A WT 1.9 ± 0.1 314 ± 32 96 ± 1 12.5 ± 3.6 11
2A/2B 2.1 ± 0.2 325 ± 62 96 ± 1 17.3 ± 5.6 13
2B WT 2.4 ± 0.3 211 ± 34 95 ± 1 12.0 ± 2.3 14
No mutant subunits 2.2 ± 0.1 280 ± 27 96 ± 1 14.0 ± 2.3 38
2AN615K/2A 3.7 ± 0.3 273 ± 23 75 ± 3 69.2 ± 10.5 19
2AN615K/2B 3.4 ± 0.3 265 ± 26 77 ± 4 62.6 ± 11.3 17
1 mutant subunit 3.6 ± 0.2 269 ± 17 76 ± 3 66.1 ± 7.6 36




















































































Figure 4.12: Triheteromers containing GluN2AN615K have slower Mg2+ on rates
(A) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing wild
type 2A diheteromers, 2AN615K/2A triheteromers and 2AN615K diheteromers, showing inhibition
by Mg2+. Responses are normalised to the peak amplitude.
(B) The bar graph shows Mg2+ on rate weighted time constants for wild type and 2AN615K
containing NMDARs. t–tests showed no significant differences between wild type subunits, or
between triheteromers containing one 2AN615K subunit. These NMDARs were therefore pooled
for subsequent analysis.
(C) The bar graph shows glutamate deactivation weighted time constants with pooling of
NMDARs carrying zero, one or two mutant subunits. A one-way ANOVA showed a significant
effect of mutation number (F(2,84) = 12.6, p < 2e–5), with post hoc t–tests (Bonferroni
corrected) demonstrating a significant difference between NMDARs containing no mutations
and triheteromers containing one mutation (t(41.5) = 6.6, pcorr = 2e–7).
See Table 4.11 for summary values and sample sizes.
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4.4.2.2 Mg2+ block off rates
Data showing Mg2+ block off rates are presented in Figure 4.13 and Table 4.12. Comparing off rates
between subunits shows a very similar pattern to what was found for on rates. All the wild type subunits
show the same off rate. Triheteromers with one mutant GluN2AN615K show the same off rate whether
partnered with wild type GluN2A or GluN2B. When data is pooled by number of mutant subunits, it can
be seen that triheteromers containing only one mutant GluN2AN615K subunit show an off rate which is
intermediate between wild type and mutant diheteromers, and significantly slower than that seen in wild
type diheteromers.
Table 4.12: Mg2+ (1 mM) off rates in wild type and GluN2AN615K containing diheteromers and
triheteromers in the continuous presence of glutamate (1 mM)
GluN2 subunits Tau fast (ms) Tau slow (ms) % fast Tau weighted (ms) n
2A WT 24 ± 2 183 ± 58 92 ± 5 30 ± 3 11
2A/2B 22 ± 3 180 ± 42 89 ± 6 34 ± 6 13
2B WT 22 ± 4 213 ± 69 85 ± 3 40 ± 5 14
No mutant subunits 22 ± 2 198 ± 38 89 ± 3 35 ± 3 37
2AN615K/2A 23 ± 5 285 ± 31 84 ± 3 62 ± 6 19
2AN615K/2B 17 ± 2 204 ± 19 84 ± 2 46 ± 4 17
1 mutant subunit 20 ± 3 246 ± 20 84 ± 2 54 ± 4 36

















































































Figure 4.13: Triheteromers containing GluN2AN615K have slower Mg2+ off rates
(A) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing wild
type 2A diheteromers, 2AN615K/2A triheteromers and 2AN615K diheteromers, showing inhibition
by Mg2+. Responses are normalised to the peak amplitude.
(B)The bar graph shows Mg2+ off rate weighted time constants for wild type and 2AN615K
containing NMDARs. t–tests showed no significant differences between wild type subunits, or
between triheteromers containing one 2AN615K subunit. These NMDARs were therefore pooled
for subsequent analysis.
(C) The bar graph shows glutamate deactivation weighted time constants with pooling of
NMDARs carrying zero, one or two mutant subunits. A one way ANOVA showed a significant
effect of mutation number (F(2,83) = 8.8, p < 0.0004), with post hoc t–tests (Bonferroni
corrected) demonstrating a significant difference between NMDARs containing no mutations
and triheteromers containing one mutation (t(65.5) = 4.0, pcorr < 0.0005).
See Table 4.12 for summary values and sample sizes.
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4.5 Mg2+ block in diheteromeric NMDARs containing GluN2BN615I or
GluN2BV618G subunits
The generation of triheteromers containing one mutant GluN2B subunit (either GluN2BN615I or
GluN2BV618G) was more vulnerable to diheteromeric escape current than that of triheteromers containing
the mutant GluN2AN615K subunit (see Section 4.3.3). Triheteromers containing either GluN2B mutant are
therefore not considered further here. However, there were no difficulties in generating diheteromeric
GluN2B mutant NMDARs, whose properties are described further below.
4.5.1 Mg2+ percentage inhibition
GluN2BN615I and GluN2BV618G diheteromers have been shown to alter Mg2+ block in this study (Chapter
3) and by others (Lemke et al., 2014). However, work done in the previous chapter was in transfected
neurons and thus represented a mixed population of wild type and mutant subunit containing NMDARs.
The brief functional characterisation performed by Lemke et al., used Xenopus laevis oocytes as an
expression system, with a small sample size, and did not report kinetics. It was therefore of interest to
investigate the properties of the GluN2B pore mutant diheteromers in the alternative expression system
of HEK293T cells.
The extent of Mg2+ block was investigated as described in Section 4.5.1. Representative traces are
shown in Figure 4.14. Data showing percentage Mg2+ block in cells expressing wild type, GluN2BN615I
and GluN2BV618G diheteromeric NMDARs are presented in Figures 4.15 and 4.16. The most startling
aspect of these data is the significant potentiation of current elicited by Mg2+ in both mutant subunits. This














Figure 4.14: Mg2+ potentiates current in 2B mutant diheteromers: representative traces
(A–C) Representative whole-cell voltage-clamp recordings from HEK293T cells expressing the
subunits indicated during exposure to glutamate (1 mM) and Mg2+ (1 mM) while held at –60 mV.











































Figure 4.15: Mg2+ potentiates current in 2B mutant diheteromers
(A) Summary data showing 1 mM Mg2+ block at three holding potentials for wild type NMDARs
and 2BN615I containing diheteromers (with wild type C termini). Stars indicate significance level
of comparison of means of 2BN615I diheteromers with 2B wild type diheteromers. A two-way
repeated measures ANOVA showed a significant main effect of subunit (F(3, 39) = 538, p <
2e–16) and of holding potential (F(2, 78) = 81.8, p = 0.001). There was also a significant
interaction (F(2, 78) = 4, p = 0.001), however, as the key contrasts of interest were between
subunits, the interaction of subunit with holding potential in determining Mg2+ block was not
explored. Post hoc t–tests (Bonferroni corrected) showed no significant differences between
Mg2+ block in wild type subunits. However, Mg2+ block was significantly reduced (t(6.9) = 47,
pcorr < 3e-9) in 2BN615I (-37 ± 4, n = 6) compared to 2B (104 ± 3, n = 13). Post hoc paired
t–tests comparing holding potentials showed that Mg2+ block at –40 mV was significanty less
than at –60 mV (t(42) = 8.5, pcorr < 6e–10), which was significantly less than at – 80 mV (t(42)
= 3.9, pcorr < 0.002).
(B) Summary data showing 1 mM Mg2+ block at three holding potentials for wild type NMDARs
and 2BV618G containing diheteromers (with wild type C termini). A two-way repeated measures
ANOVA showed a significant main effect of subunit (F(3, 34) = 249, p < 2e–16) and of
holding potential (F(2, 68) = 96.1, < 2e–16). Post hoc t–tests (Bonferroni corrected) showed
no significant differences between Mg2+ block in wild type subunits. As only one cell expressing
2BV618G was recorded from, statistical tests could not be performed. However, the same
potentiation effect was apparent as seen with 2BN615I (Mg2+ block in 2BV618G (-33, n = 1)).
Post hoc paired t–tests comparing holding potentials showed that Mg2+ block at –40 mV was
significanty less than at –60 mV (t(37) = 8.6, pcorr < 2e–9), which was significantly less than at


































Figure 4.16: Mg2+ potentiates current in 2B mutant diheteromers: current–voltage curves
(A-C) Current-voltage plots showing a potentiation of current in the presence of Mg2+ at all
negative holding potentials with diheteromeric 2BN615I (n=6) and 2BV618G (n=3) but not wild type
2B (n=4).
Some preliminary experiments were performed to consider some potential mechanisms by which
this potentiation may arise. Firstly, current-voltage curves were repeated in a higher concentration of
external Ca2+ (2 mM vs. 0.5 mM) (see Figure 4.17). If the increased current were due to an increased
Ca2+ conductance, the current potentiation would be predicted to be higher in the presence of high Ca2+
than low Ca2+, and the reversal potential to have shifted more positively (towards that of Ca2+). The data
































Figure 4.17: Potentiation of current by Mg2+ in 2B mutant diheteromers is unlikely to be
due to increased Ca2+ conductance
(A-C) Current-voltage plots showing no influence of increasing Ca2+ concentration on
potentiation of current by Mg2+ in diheteromeric wild type 2A (n=3), 2BN615I (cell not recorded
from below –50 mV) and 2BV618G. Low Ca2+ = 0.5 mM, high Ca2+ = 2 mM.
Secondly, current-voltage curves were repeated with a higher concentration of external Mg2+ (10
mM vs 1 mM) (Figure 4.18). If the increased current were due to a new Mg2+ conductance, the current
potentiation would be predicted to be higher in the presence of high Mg2+ than low Mg2+, and the reversal
potential to have shifted more positively (towards that of Mg2+). Alternatively, if Mg2+ was increasing
open probability, or an existing conductance (e.g. Na+), current potentiation would be seen without an
alteration in reversal potential. The latter pattern is what the preliminary data in Figure 4.18 suggest.
GluN2BV618G diheteromers exhibit an approximately 1.5–fold increase in current in the presence of 1
mM Mg2+ and an approximately four-fold increase in current in the presence of 10 mM Mg2+, without
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a notable shift in reversal potential. Further, the effect does not appear to be voltage-dependent. In
summary, the potentiation of current by Mg2+ in GluN2B mutant diheteromers is dose-dependent and












































Figure 4.18: Increasing Mg2+ concentration increases Mg2+ potentiation in GluN2BV618G
mutant diheteromers
(A) The current-voltage plot shows that increasing Mg2+ concentration from low (1 mM) to high
(10 mM) is associated with a large increase in potentiation of current in diheteromeric 2BV618G
NMDARs (n=3), without alteration in reversal potential.
(B) The plot shows fold potentiation against holding potential for two different Mg2+
concentrations (1 mM and 10 mM). The dotted line marks 1, no potentiation. Only negative
holding potentials are shown as very small currents at positive holding potentials led to a wide
spread of potentiation values. At the holding potentials shown, 1 mM Mg2+ is associated with a
mean fold potentiation of 1.45 ± 0.05 and 10 mM Mg2+ with a mean fold potentiation of 4.6 ±
0.34. The degree of potentiation is voltage-independent (the increase in potentiation seen with
10 mM Mg2+ approaching a holding potential of zero likely reflects error due to small currents).
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4.5.2 Mg2+ potentiation kinetics
Mg2+ potentiation on and off rates are shown in Table 4.13. As they are quantifying a different process
to what is occurring in wild type diheteromers (potentiation rather than block), it is not meaningful to
compare them against wild type receptors.
Table 4.13: Kinetics of Mg2+ potentiation in GluN2B pore mutant diheteromers.
GluN2 subunits Tau fast (ms) n
Mg2+ on
GluN2BN615I 14 ± 3 6
GluN2BV618G 11 1
Mg2+ off
GluN2BN615I 11 ± 1 6
GluN2BV618G 9 1
Time courses were fitted well by a single exponential.
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4.6 Discussion
4.6.1 Summary of findings
This chapter employed a recently developed technique to dictate the subunit composition of NMDARs.
This allowed the generation of NMDARs containing zero, one or two mutant subunits, as required. The
key finding is that the disease–associated mutation GluN2AN615K has a dominant negative effect on
Mg2+ block when incorporated into triheteromers with wild type GluN2 subunits. This supports its role in
disease causation. It was also found that the GluN2AN615K mutation slows Mg2+ on and off rates, that
diheteromeric GluN2BN615I and GluN2BV618G mutant subunits cause potentiation of current by Mg2+, and
that none of the pore mutations influence glutamate deactivation rates.
4.6.2 GluN2AN615K reduces Mg2+ block in di– and triheteromeric NMDARs
The finding of substantially reduced Mg2+ block in GluN2AN615K diheteromers replicates previous work
(Endele et al., 2010), and the oocyte work reported in Chapter 3. As described more fully in Chapter 3’s
discussion, this effect is likely to be due to the substitution of a positively charged lysine residue in place
of a neutral asparagine at a residue previously found to be a strong determinant of Mg2+ block (Wollmuth
et al., 1998).
The finding that one GluN2AN615K subunit is enough to cause significantly reduced Mg2+ block in
triheteromers extends the work previously done in diheteromers by demonstrating that the GluN2AN615K
mutation alters NMDAR properties in the subunit composition most likely to arise physiologically:
GluN2AN615K/GluN2B-containing NMDARs. The dominant negative effect in partnership with either wild
type subunit demonstrates that the wild type residues are insufficient to fully counteract the repulsion
of Mg2+ by the introduced lysine residue. The effect of GluN2AN615K on Mg2+ block was less marked
in partnership with wild type GluN2A, which was an unexpected finding. The residues known to be
important for Mg2+ binding (the “N” site, “N+1” site, and “S/L” site) are identical in GluN2A and GluN2B.
Despite this, differences in Mg2+ block exist: GluN2A exhibits slightly faster Mg2+ off rates than GluN2B
(Clarke et al., 2013; Clarke and Johnson, 2008). The impact of subunit identity may therefore arise via
some as yet unidentified difference in sequence between the two subunits which influences Mg2+ block.
Interestingly, a recent investigation of the impact of human GRIN2A mutations on Zn2+ sensitivity
in diheteromeric and triheteromeric NMDARs also found that the influence on triheteromers varied
with whether the wild type partner was GluN2A or GluN2B, with a GluN2A partner associated with
Zn2+ sensitivity that was closer to wild type (Serraz et al., 2016). The interpretation of this finding is
complicated by the different Zn2+ sensitivities of wild type GluN2A and GluN2B subunits. However, it
may point to an underlying principle of subtle differences in conformation between assemblies of GluN2
subunits which are the same or different. This possibility could be investigated by introducing a GluN2A
mutation at the equivalent site in a GluN2B subunit (for example, GluN2BN616K), and comparing Mg2+
block in GluN2BN616K/GluN2B receptors versus GluN2BN616K/GluN2A receptors (if same versus different
subunit identity was important in mediating the impact of the mutation, the GluN2B only receptors would
show a smaller reduction in Mg2+ block than the GluN2B/GluN2A receptors).
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4.6.3 GluN2AN615K slows Mg2+ block on and off rates
GluN2AN615K was found to slow Mg2+ block kinetics when expressed as part of diheteromeric or
triheteromeric NMDARs. This slowing likely reflects the alteration in Mg2+ binding residues. No previous
work has addressed Mg2+ block kinetics in the GluN2AN615K mutant subunit, but the off rates of wild
type subunits (driven by hyperpolarisation rather than concentration change) have been previously found
to be well fitted by two exponentials with τ fast of around 1 ms (Clarke et al., 2013) and a τslow of 1.2
ms. This study’s estimate of a τ fast of 22 ms in wild type NMDARs is substantially higher than that
detected by voltage steps, probably because the time for solution exchange (0.7–0.9 ms, from with Mg2+
to without Mg2+ or vice versa) is much longer than the time taken to change holding potential. Although
the time constants identified here are longer than those identified previously by a different method, the
comparisons between subunits still stand.
A slowing of Mg2+ on and off rates is of physiological relevance as this could influence the
coincidence detection properties of the NMDARs required for spike-timing-dependent synaptic plasticity:
a longer period of post-synaptic depolarisation would be required to ensure removal of Mg2+ block before
current could pass through NMDARs containing mutant subunits. Similarly, once a post-synaptic cell
was no longer depolarised, the unblocked NMDARs would take longer to reblock, potentially passing
current stimulated by uncoordinated activity. It would be interesting to explore this further, potentially by
computational modelling.
4.6.4 GluN2BN615I and GluN2BV618G cause Mg2+ current potentiation
The finding that the GluN2B pore mutant diheteromers caused potentiation of currents in the presence
of Mg2+ was very unexpected. The results in Chapter 3 showed an overall reduction in Mg2+ block in a
mixed population of NMDARs containing wild type and mutant subunits. This was initially interpreted as
the majority of receptors showing a reduction in block, but is also consistent with a minority of receptors
showing potentiation of current. Previously published work reported a reduction in Mg2+ block to 15%
(n=3) in GluN2BN615I diheteromers and 49% (n=3) in GluN2BV618G diheteromers, with a wild type block
of 96% (Lemke et al., 2014). However, inspection of the representative traces suggests that these data
refer to differences in peak responses and the steady state response for GluN2BN615I is in fact larger in
the presence of Mg2+ (see Figure 4.19).
The mechanism of how the GluN2B pore mutations allow Mg2+ to potentiate current has not been
confirmed in this study. Preliminary investigations suggested that the effect is dependent on the
concentration of Mg2+ but is not due to Mg2+ itself being conducted, or more Ca2+ being conducted.
This suggests that Mg2+ may be influencing open probability, or the conductance of Na+, or the potency
of glutamate. A little discussed finding is that GluN2B diheteromers have previously been shown to
demonstrate potentiation by Mg2+, in a manner non-additive with spermine (Paoletti et al., 1995). As
the channel is normally blocked by Mg2+ at resting membrane potentials, this potentiation normally only
emerges at positive membrane potentials. An intriguing possibility is that the GluN2B pore mutations
are preventing Mg2+ block and thus exposing Mg2+ potentiation via the spermine site at all potentials.
It is now known that spermine potentiates current through NMDARs by binding to the subunit-interface
between GluN2B and GluN1 and stabilising the N termini in a way that increases open probability (Mony
et al., 2011; Sirrieh et al., 2015). It is also known that spermine potentiation is not present in NMDARs
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Figure 4.19: Mg2+ block in GluN2B pore mutants: previous work
Taken from (Lemke et al., 2014). Representative traces showing Mg2+ block in wild type 2B and
2BN615I diheteromers, with data quantified in the bar chart.
containing the “b” splice variants of GluN1 and is pH-sensitive and voltage-independent. The findings
in this study are consistent with these properties, in that the GluN1-1a splice variant was used, and the
potentiation is not voltage-dependent. Further, the 4.6-fold mean potentiation seen here with 10 mM
Mg2+ is very similar to the 3.9 mean potentiation observed by Paoletti et al. (1995) at the same Mg2+
concentration. It would therefore be possible to test the hypothesis that the potentiation of current by
Mg2+ observed in diheteromeric GluN2B pore mutant NMDARs is via Mg2+ acting at the spermine site
by: testing the pH sensitivity of the potentiation, the influence of GluN1 splice variant a versus b, and by
introducing additional mutations into the spermine site.
It proved more difficult to generate triheteromers containing GluN2B pore mutants than triheteromers
containing GluN2AN615K. This may simply be a chance finding arising due to the small number of cells
recorded in the GluN2B mutant groups. Alternatively, the GluN2B pore mutants with modified C termini
may have a faster deactivation rate than wild type, as suggested by the finding that GluN2BN615IC1C2
receptors had a slightly faster deactivation rate than GluN2BN615I receptors. It is also possible that the
GluN2B mutations may in some way inhibit the assembly or trafficking of subunits with modified C termini,
allowing undesired diheteromers to have an increased escape probability. Further work to explore this
would be initially to repeat the experiments with a larger sample size, and potentially to explore the impact
of varying the ratios of GluN2 subunits transfected (potentially increasing the ratio of GluN2B pore mutant
subunits to wild type subunits would increase the probability of their expression). In any case, findings in
GluN2B diheteromers are still of high physiological relevance, as GluN2B diheteromers are the dominant
form of forebrain NMDARs during early development (Monyer et al., 1994).
4.6.5 None of the pore mutants affected glutamate deactivation rates
It was found that none of the pore mutations affect glutamate deactivation rates. This is unsurprising, as
none of the mutations affect residues previously implicated in NMDAR deactivation (see Section 1.4.3 in
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the Introduction). This suggests that alterations in deactivation following glutamate exposure are not part
of the mechanism by which these mutations may cause disease, unlike what has been found for another
disease-associated NMDAR mutation (Yuan et al., 2014).
4.6.6 Limitations
Although representing a significant advance in the understanding of NMDARs, both the recently
published approaches allowing expression of triheteromeric NMDARs have limitations (Hansen et al.,
2014; Stroebel et al., 2014). Both methods require substantial modifications of the NMDAR C termini,
which means this approach cannot be used to explore triheteromeric properties related to C terminus
function. Hansen’s approach requires replacement of the GluN2B C termini with that of GluN2A, in order
to reduce steric complications created by the substantial differences in sequence between subunits in
this domain. Stroebel’s approach requires complete removal of both C termini. It is therefore possible
that the findings in this chapter are not relevant to the in vivo effect of the mutations studied because
of the modified C termini employed to generate the receptors for study. However, it is reassuring to
note that swapping GluN2A and GluN2B C termini has previously been found not to influence receptor
deactivation rates and open probability (Punnakkal et al., 2012), suggesting that the C terminus has more
of a permissive than a modulatory role in these receptor properties. The findings in this chapter are also
limited in that other NMDAR subunit partnerships have not been investigated. For example, GluN2AN615K
with GluN2C or GluN2D, although there is little evidence so far that these subunit combinations arise
frequently physiologically.
4.6.7 Conclusion
This chapter has provided further evidence that the GluN2AN615K, GluN2BN615I and GluN2BV618G
mutations influence fundamental properties of physiological configurations of NMDARs in a way
consistent with causing the neurodevelopmental disorders experienced by their carriers. To achieve




Validation and initial functional




5.1 Chapter summary and key findings
1. Two genetically modified rats were created: one carrying LoxP sites flanking exon 8 of Grin2a
(Grin2aflox/flox) and one carrying a deletion of exon 8 of Grin2a (Grin2a-/-). The genetic alterations were
confirmed by sequencing.
2. The Grin2aflox/flox rat was functionally validated: the LoxP sites alone do not influence Grin2a
expression but do allow Grin2a knock-out in the presence of Cre recombinase.
3. The Grin2a-/- rat was functionally validated: homozygous animals show greatly reduced Grin2a
mRNA expression, absent GluN2A protein and reduced incorporation of GluN2A into functional
NMDARs as assessed electrophysiologically. Heterozygotes show intermediate mRNA, protein and
functional levels.
4. A preliminary assessment of the physiological consequences of Grin2a knock-out and
haploinsufficiency was performed. Neurons cultured from Grin2a-/- and Grin2a-/+ rats showed lower
current density and altered coordinated activity compared to Grin2a+/+ rats. There was no effect on
mEPSCs, mIPSCs or excitotoxicity.
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5.2 Introduction
5.2.1 Generation of genetically modified rat lines
The findings of previous chapters have demonstrated that GluN2AN615K is a mutation which profoundly
influences crucial NMDAR properties in a dominant negative fashion. These findings support the
hypothesis that GluN2AN615K causes the epileptic encephalopathy experienced by its carrier. However,
they do not prove this. Proof would be provided by a demonstration that removing or negating the
consequences of the point mutation prevents or even reverses the neurodevelopmental disorder. No
way to prevent the consequences of the point mutation has been identified for use in its human carrier
(dextromethorphan could potentially be helpful, but would not fully block the functioning of the mutant
subunits without also affecting wild type subunits). However, an animal model genetically engineered
to carry the GluN2AN615K mutation offers a way in which the impact of the presence and absence of
the mutation can be assessed using genetic techniques. Specifically, the Cre-Lox system can be used,
whereby the mutation is placed between two 5’-3’ orientated LoxP sites and so can be excised when the
DNA is exposed to Cre recombinase. By varying the timing of exposure to Cre recombinase, the impact
of the mutation on development could be assessed, as could any critical window for any reversibility seen.
A major benefit to an animal model would be the opportunity to investigate the consequences of the
mutation at a whole organism level, allowing in depth investigation of electrophysiological, circuit level
and behavioural phenotypes with the aim of identifying pathological mechanisms. Genetically modified
animal models also allow the effect of the mutation to be assessed when expressed at genomically
driven levels, rather than overexpressed via viral promoters in plasmids or viruses. A rat was chosen
as the model organism as they have a relatively complex behavioural repertoire, allowing more accurate
assessment of phenotypes such as intellectual disability. In addition, they have brains large enough for
structural and functional brain imaging to be performed in vivo.
A commercial organisation were employed to perform the genome editing using CRISPR/Cas9
technology. This is a recently developed approach (reviewed by Hsu et al. (2014)) where single cell
embryos are injected with single guide RNAs (sgRNA) which bind to the desired genomic DNA site with
high specificity, allowing recruitment of the Cas9 endonuclease, which cuts the DNA (in this case creating
a double stranded break), which then stimulates the cell’s own DNA repair pathways. The cell can
repair DNA using either non-homologous end joining, which often results in small insertions or deletions
and hence often gene knock-out, or homology directed repair, which, if exogenous template DNA is
provided, can allow point mutations to be inserted. Figure 5.1 shows the desired genome modifications
and strategy for achieving them.
To achieve the animal model desired here (Grin2aT1845A(flox)/+), modification of a relatively large
region of DNA was required: replacement of all of exon 8 (330 bp) with a donor exon containing the
mutation, and insertion of LoxP sites into intronic regions 340 and 500 base pairs away from the exon.
This required two double stranded breaks to be made and totalled 1170 bp of replacement. It transpired
that this was too ambitious. Although a number of founder mutants were obtained where both LoxP
sites were inserted, none of them also had the point mutation. It seemed that the genome editing was
occuring in a two step process (see Figure 5.2A). First, one double stranded break would occur and
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Figure 5.1: Genome modification approach to generate Grin2aT1845A(flox)/+
This schematic shows the genome modification strategy designed to insert a floxed exon
carrying the point mutation of interest into the rat genome. Grin2aT1845A(flox)/+ encodes the
mutation required to generate GluN2AN615K. Single cell embryos were injected with two
single guide RNAs which bound to 5’ and 3’ of Grin2a exon 8. These recruited the Cas9
endonuclease, which created double stranded breaks, stimulating the cell’s own DNA repair
pathways. Exogenous donor DNA was provided via a plasmid, containing a replacement exon
(with point mutation) and left and right homology arms (green) flanking the double stranded
breaks. It was anticipated this would be used to repair the double strand breaks using homology-
directed repair. Yellow marks intronic DNA not included within the donor DNA.
required to repair as far as the exon and the point mutation would not be inserted. Second, a double
stranded break would occur on the other side of the exon and the same process occur. The outcome
was a floxed exon but no point mutation: Grin2aflox/+.
In some cases two double stranded breaks did occur simultaneously, but were repaired using non-
homologous end joining, not homology-directed repair (see Figure 5.2B). This resulted in deletion of exon
8: Grin2a-/+.
The attempt to generate a Grin2aT1845A(flox)/+ rat therefore resulted in the generation of two other
genetically modified rat models: a Grin2aflox/+ and a Grin2a-/+ rat. Although this was not what was
intended, these rat models are still potentially useful tools for addressing the overall question of this
thesis: what are the functional consequences of mutations in GRIN2A and GRIN2B associated with
mental disorder? This is because a large number of gene disrupting mutations in GRIN2A have been
identified heterozygously in people with epilepsy-aphasia syndromes (see Section 1.6). Further, a locus
near GRIN2A was identified as significantly associated with schizophrenia by genome wide association
study (Ripke et al., 2014). Although the nature of the impact of this locus on GRIN2A (if any) remains to
be identified, the most likely impact is that it is modifying the expression of GRIN2A in some way, most
likely by reducing it (as there is already evidence of NMDAR hypofunction in schizophrenia (Snyder and
Gao, 2013)). Thus, the Grin2a-/+ rat is a useful model for investigating the pathophysiology of epilepsy-
aphasia syndromes, with potential relevance also to schizophrenia. The Grin2aflox/+ rat is useful as it
allows the creation of a Grin2a knock-out at a range of developmental time points or in a subset of
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Figure 5.2: Genome modification events that generated Grin2aflox/+ and Grin2a-/+
This schematic shows the genome modifying events that were presumed to occur when
genomes were exposed to the reagents designed to generate the Grin2aT1845A(flox)/+ rat.
(A) Shows the events underlying generation of the Grin2aflox/+ rat. Following exposure to
sgRNAs, double stranded breaks probably occurred at separate times, allowing recruitment
of different sections of the donor DNA for repair, and resulting in insertion of only the sections
closest to the double stranded breaks (including the LoxP sites).
(B) Shows the events underlying generation of the Grin2a-/+ rat. Following exposure to sgRNAs,
double stranded breaks probably occurred at the same time, allowing the 5’ and 3’ ends of
the cuts to be joined together using non-homologous end joining. This resulted in a 1065 bp
deletion, including exon 8.
5.2.2 Experiments performed with genetically modified rat lines
Before any experiments regarding the role of Grin2a in neurodevelopmental disorder could be performed,
it was first necessary to validate both models. This was done by sequencing the targeted genomic region,
and by quantifying mRNA and protein levels. In the case of the Grin2aflox/flox model, a virus was used to
confirm Cre-Lox mediated Grin2a knock-out.
In the case of the Grin2a-/+ model, a reduction in GluN2A subunit functional incorporation was
confirmed electrophysiologically. In Chapter 3 the GluN2A:GluN2B ratio was assessed using sensitivity
to the GluN2B selective negative allosteric modulator, ifenprodil. A different approach was taken in this
chapter: potentiation by spermine was used to assay the incorporation of GluN2A into surface NMDARs
instead. Spermine is an endogenous polyamine that binds to the subunit interfaces between GluN2B
and GluN1 N-terminus domains, increasing open probability of GluN2B diheteromeric NMDARs (Mony
et al., 2011; Sirrieh et al., 2015).
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A spermine potentiation assay was used here because new evidence suggested it should
theoretically be more sensitive than ifenprodil inhibition. The recently developed ability to generate
triheteromeric NMDARs (see Chapter 4 Introduction) allowed determination of their sensitivity to
compounds modulating NMDARs. It was found that GluN2A/2B triheteromers had a sensitivity to
ifenprodil intermediate between GluN2A and GluN2B (but closer to GluN2A) whereas triheteromers
showed a potentiation by spermine identical to that of GluN2A (Stroebel et al., 2014). Thus, a given
proportion of GluN2A expression should result in a bigger shift in spermine potentiation than in ifenprodil
sensitivity, and be easier to detect.
The first part of the chapter addresses the validation of the new rat models. The remaining sections
describe a preliminary asessment of functional consequences of GluN2A knock-out. The four functional
domains investigated were current density, mEPSCs and mIPSCs, synchronised network activity, and
excitotoxicity. A brief rationale for each of these areas is given below.
The magnitude of NMDA-evoked currents in cultured neurons normalised to cell size (current density)
was assessed as it is a simple and important property which gives a measure of how many NMDARs
a cell is expressing. If a cell is expressing fewer/more NMDARs this may have knock-on effects for all
the processes NMDARs can influence. The hypothesis was that GluN2A knock-out would result in lower
current density, because other NMDAR subunits would not be sufficiently upregulated to compensate.
mEPSCs are currents caused by activation of glutamate receptors by quantal release of glutamate
at individual synapses. They are predominantly mediated by AMPA receptors (AMPARs). Increased
amplitude indicates more AMPARs at a given synapse. Increased frequency represents more active
synapses per cell, or a higher pre-synaptic vesicle release probability. mEPSCs were assessed because
NMDARs can regulate AMPARs membrane trafficking to synapses, with different NMDAR subunits having
different effects on AMPAR trafficking. Previous work in acute hippocampal slices found that removal of
GluN2A increased mEPSC amplitude, but did not affect frequency (suggesting that GluN2A’s normal role
would be to inhibit strengthening of synapses) (Gray et al., 2011). However, a study in hippocampal
organotypic slices found that overexpression of GluN2A decreased mEPSC frequency, but did not affect
amplitude (suggesting that GluN2A’s normal role would be to inhibit formation of new synapses) (Gambrill
and Barria, 2011). The hypotheses for this study were therefore that cells cultured from Grin2a-/+ rats
would show mEPSC amplitudes that were increased, or unaffected, and mEPSC frequencies that were
increased, or unaffected.
mIPSCs are currents caused by activation of GABA receptors by quantal release of GABA at
individual synapses. They are predominantly mediated by GABAA receptors. mIPSCs were assessed
because NMDARs can influence many aspects of inhibition in neural networks (see Figure 5.3). Inhibition
in the forebrain is a very complex topic, with the combined activities of many different types of interneuron
to consider. However, overall, previous work suggests that reduced NMDAR activation in the commonest
type of interneuron (parvalbumin-positive) is associated with a reduction in inhibitory output (for review
see Moreau and Kullmann (2013)).
There has been little work on the role of individual NMDAR subunits in inhibition. There is some
evidence suggesting GluN2A may be particularly important in driving inhibition as parvalbumin-positive
interneurons in culture show a five-fold higher GluN2A:GluN2B ratio than neighbouring pyramidal cells
(Kinney et al., 2006). Further, in Grin2a knock-out mice, NMDA evokes 50% less striatal GABA release
than in wild type animals (Miyamoto et al., 2001). The hypothesis for this study was therefore that
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Figure 5.3: NMDAR hypofunction impairs inhibitory circuits
This figure shows potential routes NMDAR hypofunction may impact on parvalbumin-positive
(PV) interneurons, adapted from Moreau and Kullmann (2013). In summary, less NMDAR
activity is associated with less inhibition.
(a) Denotes a pyramidal cell synapsing onto a PV interneuron. Less NMDAR activation has
been associated with a reduction in synthesis of PV (a calcium binding protein) and GAD67 (an
enzyme which synthesises GABA).
(b) Denotes a pyramidal cell forming a weak synapse onto a PV interneuron because of reduced
NMDAR-mediated synaptic potentiation.
(c) Denotes a pyramidal cell forming a weak synapse onto another pyramidal cell because of
reduced NMDAR-mediated synaptic potentiation - overall circuit hypoactivity.
(d) Marks a PV interneuron synapsing weakly onto a pyramidal cell because of less pre-synaptic
NMDAR activity resulting in reduced GABA synthesis and release.
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Grin2a-/+ rats would show less inhibitory activity in the form of lower amplitude and lower frequency
mIPSCs.
Network activity following disinhibition is another way to assess the impact of GluN2A knock-out on
inhibitory networks. Live-cell calcium imaging was used to measure neural activity via calcium transients
as scores of cells can be recorded from simultaneously, unlike with standard patch-clamping approaches.
Removal of inhibition by blocking GABAA receptors with bicuculline typically results in rebound activity
in the form of large spikes of calcium synchronised across the neurons present. With the hypothesis that
GluN2A knock-out would result in less inhibitory input to pyramidal cells, the prediction was that removal
of inhibition would result in less disinhibition i.e. lower spike amplitude and frequency.
The final functional assessment performed was of excitotoxicity. There is a large literature linking
NMDAR activation to excitotoxic cell death, with the C-terminus of GluN2B identified as more efficient
at mediating the pro-death response than that of GluN2A (Martel et al., 2012). The hypothesis for the
relative excitotoxic vulnerability for GluN2A knock-out cells therefore depended on whether knock-out
cells expressed a compensatory increase in GluN2B subunits, or not (as indicated by current density). If
there was no increase in GluN2B expression, the absence of GluN2A should not result in an increased
risk of cell death. If, however, there was an increase in GluN2B expression, an increased vulnerability to
cell death would be predicted.
The key findings of this chapter are the validation of two new rat models (Grin2aflox/+ and Grin2a-/+),
and that preliminary functional investigations suggest that GluN2A knock-out reduces current density in
culture, and also influences disinhibition.
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5.3 Confirmation of targeted genome modification by sequencing
The commercial organisation who created the genetically modified rat lines unfortunately made a number
of errors when using sequencing to confirm the modifications had occurred, including falsely attributing
an off target insertion of the donor DNA as a targeted insertion. It was therefore necessary to rigorously
confirm the nature of the genetic alterations as part of this study.
The approach taken was to amplify a section of genomic DNA which started and ended in intronic
regions which were not included in the donor DNA: a “trans donor PCR” (see Figure 5.4). This would
avoid false positives generated from off target donor insertions. However, this was difficult to do because
it required amplification of a large section of DNA (2.4 kb in the case of floxed exons, 1.3 kb in the case of
deleted exons) and so was in competition with several smaller non-specific products. A number of PCR
optimisation strategies were trialled, including adding Mg2+ to the PCR mix and using GC-rich buffer, but
the only modifications of benefit were allowing sufficient elongation time (3 minutes) and using a high
processivity enzyme (see Methods Section 2.5.2 for details).
The presence of non-specific products also made it difficult to sequence the segment of interest.
Gel extraction and cloning of individual PCR fragments did not help, presumably because of the low
abundance of the product of interest relative to other products. The approach which worked best was
to perform a nested PCR, whereby the region was initially amplified from genomic DNA with one pair
of primers, then DNA oligomers and salts removed from the PCR product and a second PCR run with
primers internal to the first pair (see Figure 5.4). Using this approach it was possible to sequence the
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Figure 5.4: Sequencing strategy and results for genetically modified rat lines
This schematic shows the sequencing strategy for the genetically modified rat lines: a nested
PCR with two pairs of primers starting and ending in endogenous intronic DNA (yellow),
spanning the region for which replacement donor DNA provided (green). Pink and purple lines
mark the location of variations from the donor DNA found in animals. The pink variations were
found in all animals, suggesting the donor DNA was not recruited for repair at those points.
The purple lines were found only in wild type animals, suggesting the donor DNA was used
for homology-directed repair at least as far as those points. The approximate distance from
the double stranded breaks to these points are marked: the donor DNA was used for repair at
least 220 bp to 3’ of the 5’ double stranded break, and for at most 100 bp to 5’ of the 3’ double
stranded break.
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Figure 5.4 also highlights a number of differences between the donor DNA and the genomic DNA
which give an insight into the DNA repair events which occurred. Four single nucleotide variations were
found in all animals sequenced (wild type and mutant), but not in the donor DNA. One was only 100 bp
from a double strand break, showing that the donor DNA was no longer being recruited for repair by that
point (assuming the donor DNA was correctly synthesised). In contrast, a number of variations were
found to 5’ of the exon in wild type animals which were not present in the donor DNA or in animals which
had the 5’ LoxP site integrated, suggesting that the donor DNA was still being used for repair up until that
point.
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5.4 Validation of Grin2aflox/flox rat model
5.4.1 The Grin2aflox/flox rat is not a Grin2A hypomorph
Inserting LoxP sites into genes can occasionally be associated with a reduction in gene expression
(creation of hypomorphic alleles). GluN2A protein levels in Grin2aflox/+ and Grin2aflox/flox were therefore
compared to wild type levels. This was done via immunoblots of cortical extracts from adolescent rats
and in extracts from cultured cortical neurons at ages where GluN2A expression is high (see Figure 5.5).
No difference in expression was seen.
5.4.2 Exposure to Cre recombinase results in knock-out of GluN2A in Grin2aflox/flox rat
cultured neurons
The ability of the Grin2aflox/flox rat to be conditionally converted to a Grin2a-/- rat was tested next. This
was done by exposing wild type and Grin2aflox/flox cultured cortical neurons to a Cre-expressing virus
(an adeno-associated virus (serotype 2) expressing a Cre–eGFP fusion protein driven by the CMV
promoter). Excision of Grin2a exon 8 was then assessed using PCR (with the same primers as for
genotyping (primer pairs 1 in Table 2.6), and GluN2A protein levels assessed by immunoblot (see Figure
5.6). The conditional knock-out was confirmed by the emergence of a Grin2a deletion band and reduction
in GluN2A protein levels following exposure to Cre in the Grin2aflox/flox rats but not in the wild type rats.
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Figure 5.5: GluN2A protein levels are normal in Grin2aflox/flox rat
(A) Representative immunoblot showing GluN2A levels (N terminus antibody) and loading
control (β actin) in neocortical extracts derived from wild-type, Grin2aflox/+ and Grin2aflox/flox
littermate rats aged P28.
(B) Representative immunoblot showing GluN2A levels (N terminus antibody) and loading
control (β actin) in extracts from DIV 17-18 cortical cells cultured from wild type and Grin2aflox/flox
embryos.
(C) The bar chart shows GluN2A protein levels normalised to β actin in neocortical extracts
from rats aged P28-31. The ratios have also been normalised to wild type ratios from the same
blot. Four littermate WT/het/hom trios were assessed. A one-way ANOVA showed no significant
effect of genotype (F(2,9) = 0.287, p = 0.76). Thus GluN2A levels were the same in wild type (1
± 0.24), Grin2aflox/+ (1.46 ± 0.65) and Grin2aflox/flox rats (1.13 ± 0.35).
(D) The bar chart shows GluN2A protein levels normalised to β actin in extracts from DIV 17-18
cultured cortical cells. The ratios have also been normalised to wild type ratios from the same
blot. A t-test showed no significant effect of genotype. Thus GluN2A levels were the same in




































Figure 5.6: GluN2A is deleted following Cre recombination in Grin2aflox/flox rat
(A) Agarose gel showing PCR products from genomic DNA extracted from DIV 18 cultured
cortical cells from wild type and Grin2aflox/flox rats, with and without exposure to Cre recombinase
on DIV 3. Primers were designed to create “WT bands” (binding either side of the 5’ LoxP
site) and “del bands” (binding either side of the deleted region). Without Cre exposure, all
animals show a WT band product (with the Grin2aflox/flox product slightly larger than the wild
type, reflecting the presence of LoxP sites) and low abundance non-specific bands with the
deletion primers. With Cre exposure, the wild type cells continue to show a WT band and no
new deletion band emerges. However, the Grin2aflox/flox cells show a marked reduction in WT
band intensity, and a prominent new deletion band, demonstrating excision of exon 8.
(B) Immunoblot showing GluN2A levels (N terminus antibody) and loading control (β actin) in
extracts from DIV 18 cultured cortical cells from wild type and Grin2aflox/flox rats, with and without
exposure to Cre recombinase on DIV 3.
(C) The bar chart shows GluN2A protein levels normalised to β actin in extracts from DIV 18
cultured cortical cells from one wild type and three Grin2aflox/flox rats, with and without exposure
to Cre recombinase on DIV 3. The ratios have been normalised to the wild type level without
exposure to Cre. A paired t-test showed a significant reduction (t(2) = 4.81, p = 0.041) in
GluN2A levels in Grin2aflox/flox exposed to Cre recombinase (0.09 ± 0.03, n = 3 ) compared to
Grin2aflox/flox without exposure to Cre (0.74 ± 0.11, n = 3).
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5.5 Validation of Grin2a-/+ rat model
The genetic data suggests that humans with gene disrupting mutations in one copy of GRIN2A
experience GluN2A haploinsufficiency, and that this may contribute towards the pathogenesis
of neurodevelopmental disorders. However, most genes can be heterozygously knocked out
without phenotypic consequence, as the gene product remaining is sufficient for normal function
(haplosufficiency). It was therefore necessary to both confirm that the Grin2a-/- rat is a true knock-
out, and that the Grin2a-/+ rat showed intermediate, haploinsufficient, values at both biochemical and
functional levels.
First, qPCR was used to quantify mRNA levels in cultured neurons with primers bridging exons prior
to the deletion (Figure 5.7). This was done at two ages, to confirm the developmental regulation of Grin2a
transcription. The qPCR first confirmed an approximately three-fold increase in Grin2a transcription from
DIV 7 to DIV 15 in cells cultured from wild type rats. The qPCR also demonstrated that mRNA levels
were substantially reduced but not completely absent in the Grin2a-/- rats, suggesting that the mRNA is
transcribed, but is unstable and probably undergoing nonsense mediated decay. At the later time point,
it was also possible to confirm that the heterozygous rats showed an intermediate amount of Grin2a
mRNA.
Next, GluN2A protein levels were assessed, at DIV 7 and DIV 15 in cultured cells and at P27-
P28 in necortical extracts (Figure 5.8). Quantification of the GluN2A levels in neocortex confirmed that
Grin2a-/- rats showed no GluN2A expression, whereas heterozygotes showed intermediate amounts.
Quantification of GluN2A levels in cultured cells again identified a several-fold increase in GluN2A
expression from DIV 7 to DIV 15 in wild type cells, with absent levels in homozygous animals and
intermediate levels in heterozygotes. A N terminus antibody to GluN2A was used in order to allow any
truncated products to be identified: there were none.
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Figure 5.7: Grin2a mRNA levels are reduced in Grin2a-/+ and Grin2a-/- rats
The bar chart shows Grin2a mRNA levels in cultured cortical neurons from wild type, Grin2a-/+
and Grin2a-/- rats at DIV 7 and DIV 15. Levels were normalised to Gadph, and then to wild
type ratios at DIV 15. A two-way ANOVA showed a significant main effect of genotype (F(2,48)
= 38.1, p = 1.25e-10), age (F(1,48) = 49.6, p = 6.4e-9) and a significant interaction (F(2,48) =
11.3, p = 9.6e-5). Planned post-hoc t–tests (Bonferroni corrected) showed that wild type rats
showed a significant increase in Grin2a mRNA levels from DIV 7 to DIV 15 (DIV 7: 0.35± 0.09,
DIV 15: 1 ± 0.07 (n=8), t(12.9) = 5.5, pcorr = 0.00042). At DIV 15, there was also a significant
reduction in Grin2a levels in heterozygotes compared to wild type (het: 0.54 ± 0.07, t(15.0) =
4.5, pcorr = 0.0017) and in homozygotes compared to heterozygotes (hom: 0.24 ± 0.02, t(8.9)
= 4.2, pcorr = 2.84e-5). There was also a significant reduction in homozygotes compared to wild
type (t(7.8) = 10.5, pcorr = 0.0092).
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Figure 5.8: GluN2A protein levels are reduced in Grin2a-/+ and Grin2a-/- rats
(A) Representative immunoblot showing GluN2A levels (N terminus antibody) and loading
control (β actin) in neocortical extracts derived from wild type, Grin2a-/+ and Grin2a-/- littermate
rats aged P28.
(B) Representative immunoblot showing GluN2A levels (N terminus antibody) and loading
control (β actin) in extracts from DIV 17-18 cortical cells cultured from wild type and Grin2a-/-
embryos.
(C) The bar chart shows GluN2A protein levels normalised to β actin in neocortical extracts
from rats aged P27-28. The ratios have also been normalised to wild type ratios from the same
blot. Five littermate WT/het/hom trios were assessed. A one-way ANOVA showed a significant
effect of genotype (F(2,12) = 41, p = 4.33e-6). Planned post-hoc t–tests (Bonferroni corrected)
showed a significant reduction in Grin2A levels in heterozygotes compared to wild type (WT:
1 ± 0.10, het: 0.38 ± 0.09, t(7.9) = 4.5, pcorr = 0.0062) and in homozygotes compared to
heterozygotes (hom: 0.01 ± 0.01, t(4.0) = 4.3, pcorr = 0.038). There was also a significant
reduction in homozygotes compared to wild type (t(4.0) = 9.8, pcorr = 0.0018).
(D) The bar chart shows GluN2A protein levels normalised to β actin in extracts from DIV 17-
18 cultured cortical cells. The ratios have also been normalised to wild type ratios from the
same blot. A two-way ANOVA showed a significant main effect of genotype (F(2,28) = 13.7,
p = 7e-5), age (F(1,28) = 20.3, p = 0.00011) and a significant interaction (F(2,28) = 8.7, p =
0.0011). Planned post-hoc t–tests showed that wild type rats showed a significant increase in
GluN2A levels from DIV 7 to DIV 15 (DIV 7: 0.13 ± 0.07, DIV 15: 1 ± 0.23 (n=6), t(5) = 17.1,
pcorr = 5e-5). At DIV 15, there was also a significant reduction in GluN2A levels in heterozygotes
compared to wild type (het: 0.34 ± 0.07 (n=5), t(4) = 6.6, pcorr = 0.011) and in homozygotes
compared to wild type (hom: 0.02 ± 0.02 (n=6), t(5) = 71.4, pcorr = 4.1e-8).
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Functional incorporation of GluN2A subunits into surface expressed NMDARs was then assessed
electrophysiologically. This was done by assessing spermine potentiation. GluN2B diheteromers
are potentiated by spermine, whereas GluN2A diheteromers and GluN2A/2B triheteromers show no
potentiation (Stroebel et al., 2014) (see Section 5.2.2 for the rationale for choosing this assay). Thus,
as GluN2A expression increases, spermine potentiation should decrease. This was confirmed using
transient transfection to overexpress wild type GluN2A subunits (see Figure 5.9). The impact of
GluN2AN615K overexpression on spermine potentiation was also assessed (in case this assay were to
be used with a Grin2aT1845A(flox)/+ rat in due course). The representative traces in Figure 5.9 show the
response to 100 µM and 200 µM spermine but only the data from 100 µM spermine are used for analysis
(as the currents are smaller they are less prone to loss of voltage-clamp). Figure 5.10 shows that both
GluN2A subunits cause a reduction in spermine potentiation.
Next, spermine potentiation was used to track the increase in GluN2A expression with age in wild
type rat cultured cortical neurons. Figure 5.11 shows that spermine potentiation drops by the third week
in culture, reflecting the onset of GluN2A expression (as also demonstrated by mRNA and protein in the
sections above). No further drop in potentiation was seen in the fourth week in culture.
Based on the developmental time course in Figure 5.11, two time points were selected to assess
GluN2A incorporation in cells cultured from genetically modified rat embryos: DIV 7-8 (when minimal
GluN2A expression is expected) and DIV 15-16 (when wild type cells would be expected to show a clear
onset of GluN2A expression). Figure 5.12 shows that spermine potentiation is higher in Grin2a-/+ and
Grin2a-/- cells compared to wild type cells. This confirms that the loss of GluN2A is impacting NMDAR
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Figure 5.9: Representative spermine potentiation traces from neurons expressing wild
type GluN2A and GluN2AN615K NMDARs
(A) Representative whole-cell voltage-clamp recording from untransfected DIV 9 neurons,
showing potentiation of current evoked by saturating NMDA (150 µM) by spermine (100 µM
and 200 µM). Holding potential –30 mV. Responses are normalised to the peak amplitude.















































Figure 5.10: Spermine potentiation is reduced in neurons transfected with wild type
GluN2A or GluN2AN615K
The bar chart shows fold potentiation by spermine (100 µM) for DIV 9 untransfected neurons
and neurons transfected with an inert control (β globin), 2A and 2AN615K NMDAR subunits.
A one-way ANOVA showed a significant main effect of transfected subunit (F(3,31) = 16.5,
p < 1.4e–6). Planned post-hoc independent t–tests showed no significant difference in
spermine potentiation between untransfected neurons and neurons transfected with β globin
(Untransfected: 2.3 ± 0.2 (n=9), β globin 2.6 ± 0.2 (n=8)). However, there was a highly
significant reduction in spermine potentiation in neurons transfected with 2A ((2A : 1.3 ± 0.1
(n=10), t(14.1) = 7.1, pcorr = 2.0e-5) and 2AN615K (2AN615K : 1.4± 0.1 (n=8), t(12.1) = 6.6, pcorr =
9.1e–5), when compared to a β globin transfection. Finally, there was no significant difference































Figure 5.11: GluN2A expression is demonstrated by a reduction in spermine potentiation
by three weeks in vitro in cultured neurons
The bar plot shows fold potentiation by spermine (100 µM) for untransfected wild type neurons
at a range of ages. A reduction in spermine potentiation (indicating an increase in GluN2A
expression) is evident from the third week in culture onwards. A one-way ANOVA showed a
significant main effect of day in vitro (F(2,98) = 9.2, p < 1.5e–9). Planned post-hoc independent
t–tests showed a significant difference in spermine potentiation between DIV 7-11 and DIV 14-
18 neurons (DIV 7-11: 2.8± 0.2 (n=33), DIV 14-18: 2.0± 0.1 (n=40), t(40) = 4.8, pcorr = 0.0019).
However, there was no significant difference between DIV 14-18 and DIV 21-28 neurons (DIV

































Figure 5.12: Spermine potentiation is increased in Grin2a-/+ and Grin2a-/- rats
The bar chart shows spermine potentiation in cultured cortical neurons from wild type, Grin2a-/+
and Grin2a-/- rats at DIV 7-8 and DIV 15-16. A two-way ANOVA showed a significant main
effect of genotype (F(2,148) = 19.1, p = 4.1e-8) and age (F(1,148) = 13.7, p = 0.0003) but no
significant interaction (F(2,148) = 1.2, p = 0.30). Planned post-hoc t–tests (Bonferroni corrected)
showed that wild type rats showed a significantly lower spermine potentiation than Grin2a-/+
rats (WT: 2.51 ± 0.09 (n=50), het: 3.13 ± 0.13 (n=50), t(88.4) = 3.8, pcorr = 0.00091) and than
Grin2a-/- rats (hom: 3.52± 0.14 (n=54), t(92.4) = 6.2, pcorr = 7.2e-8). The difference in spermine
potentiation between Grin2a-/+ and Grin2a-/- rats was not significant after correction for multiple
comparison. Spermine potentiation at DIV 15-16 was significantly lower than at DIV 7-8 (DIV
15-16: 2.80 ± 0.11 (n=74), DIV 7-8 3.32 ± 0.10 (n=80), t(150.2) =3.5, pcorr = 0.0022) (pooled
across genotypes) (not marked on plot).
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Finally, a smaller sample of cells was used to compare the two methods of assessing the degree
of GluN2A expression: ifenprodil sensitivity against spermine potentiation. Ifenprodil sensitivity was
assessed by comparing NMDA-evoked current density before and after exposure to 1 minute of ifenprodil
(3 µM) (as in Section 3.4.1 but without the application of Mg2+). Figure 5.13 shows that both approaches
were able to distinguish homozygous from wild type cells, but only spermine potentiation was able
to separate heterozygous from wild type cells, and identify the developmental change in GluN2A
expression. Thus spermine potentiation is more sensitive than ifenprodil inhibition in detecting reductions






















































Figure 5.13: Spermine potentiation is better than ifenprodil sensitivity for detecting
Grin2a-/+ haploinsufficiency
A The bar chart shows spermine potentiation in cultured cortical neurons from wild type,
Grin2a-/+ and Grin2a-/- rats at DIV 7-8 and DIV 15-16. A two-way ANOVA showed a significant
main effect of genotype (F(2,75) = 12.1, p = 2.8e-5) and age (F(1,75) = 5.4, p = 0.023) but no
significant interaction. Planned post-hoc t–tests (Bonferroni corrected) showed that wild type
rats showed a significantly lower spermine potentiation than Grin2a-/+ rats (WT: 2.62 ± 0.11
(n=26), het: 3.38 ± 0.21 (n=25), t(37.2) = 3.2, pcorr = 0.01) and than Grin2a-/- rats (hom: 3.79
± 0.19 (n=30), t(46.2) = 5.2, pcorr = 1.5e-5). The difference in spermine potentiation between
Grin2a-/+ and Grin2a-/- rats was not significant. Spermine potentiation at DIV 15-16 was not
significantly lower than at DIV 7-8 after correction for multiple comparisons.
B The bar chart shows ifenprodil sensitivity in cultured cortical neurons from wild type, Grin2a-/+
and Grin2a-/- rats at DIV 7-8 and DIV 15-16. A two-way ANOVA showed a significant main
effect of genotype only (F(2,78) = 21.2, p = 4.5e-8). Planned post-hoc t–tests (Bonferroni
corrected) showed that wild type rats showed a significantly lower ifenprodil sensitivity than
Grin2a-/- rats (WT: 77 ± 1 (n=26), hom: 86 ± 1 (n=34), t(88.4) = 3.8, pcorr = 4.5e-6) but were
not significantly different to Grin2a-/+ rats. However, Grin2a-/+ rats showed a signficantly lower
ifenprodil sensitivity than Grin2a-/- rats (het: 79 ± 1 (n=24), t(92.4) = 6.2, pcorr = 0.0001).
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5.6 Functional assessment of Grin2a-/+ rat model
The previous section demonstrated that Grin2a-/- rats lack GluN2A, and that Grin2a-/+ rats are
haploinsufficient. Attention was then turned to a preliminary investigation of some potential functional
consequences of low or absent levels of GluN2A.
Although the behaviour of the Grin2a-/- and Grin2a-/+ rats was not formally assessed, no differences
were observed during general husbandry: the animals were able to eat and drink as normal, breed as
normal, and showed no overt neurological phenotype.
The first potential functional consequence to be quantified was current density. This was assessed
simply by exposing cultured neurons to saturating NMDA until the current response plateaued, then
dividing by the cell’s size as estimated by capacitance. Figure 5.14 shows that there is no difference
between genotypes at young ages, when there is minimal GluN2A expression, but lower current density
in Grin2a-/+ and Grin2a-/- cells at older ages, when wild type cells have started expressing higher levels
of GluN2A. This shows that any compensatory increase in expression of other GluN subunits is not
sufficient to match the current normally mediated by GluN2A-containing NMDARs.
167


























Figure 5.14: Current density is reduced in Grin2a-/+ and Grin2a-/- rat neurons after two
weeks in culture
The bar chart shows current density in cultured cortical neurons from wild type, Grin2a-/+ and
Grin2a-/- rats at DIV 7-8 and DIV 15-16. A two-way ANOVA showed a significant main effect
of genotype (F(2,235) = 5.6, p = 0.0043), age (F(1,235) = 66.1, p = 2.5e-14) and a significant
interaction (F(2,235) = 6.0, p = 0.0029). Planned post-hoc t–tests (Bonferroni corrected) showed
that wild type rats showed a significant increase in current density from DIV 7 to DIV 15 (DIV 7:
24± 1 (n=38), DIV 15: 43± 3 (n=38), t(54.5) = 6.6, pcorr = 7.6e-8). At DIV 15, there a significant
reduction in current density in heterozygotes compared to wild type (het: 33 ± 2 (n=35), t(65.9)
= 3.0, pcorr = 0.013) and in homozygotes compared to wild type (hom: 32 ± 2 (n=42), t(70.1)
= 3.3, pcorr = 0.0059). There was no significant difference in current density at DIV15 between
Grin2a-/+ and Grin2a-/- cells. Points for individual cells not shown due to large n.
The next properties to be assessed were the frequencies and amplitudes of mEPSCs and mIPSCs,
and the excitation:inhibition ratio. Figure 5.15 shows a representative recording of mEPSCs made in
a cortical neuron cultured from a wild type rat. Complete inhibition by the AMPAR antagonist CNQX
confirmed these events to be AMPAR mediated. Figure 5.16 shows the amplitudes and frequencies of
mEPSCs in wild-type, Grin2a-/+ and Grin2a-/- rats. There is no difference in either parameter between
genotypes.
mIPSC are presented next. Figure 5.17 shows a representative recording of a mIPSC made in a
cortical neuron cultured from a wild type rat. Complete inhibition by the GABAAR antagonist bicuculline
confirmed these events to be GABAR mediated. Figure 5.18 shows the amplitudes and frequencies of










Figure 5.15: Representative trace showing AMPAR mediated mEPSCs
(A) Representative whole-cell voltage-clamp recording from DIV 18 cortical neuron cultured
from a wild type rat. The application of the AMPA receptor antagonist CNQX (20 µM) abolishes
the mEPSCs. Holding potential –65 mV.























































































Figure 5.16: mEPSC amplitudes and frequencies in cultured neurons are unaffected by
Grin2a knock-out
(A) Cumulative probability plot of mEPSC amplitudes measured in DIV 18-20 neurons cultured
from wild type, Grin2a-/+ and Grin2a-/- rats.
(B) The bar chart shows mean mEPSC amplitudes. A one-way ANOVA showed no significant
effect of genotype on mEPSC amplitude (WT: 19 ± 2 (n=25 cells from 8 animals), het: 15 ± 1
(n=18 cells from 8 animals), hom: 18 ± 2 (n=21 cells from 8 animals)).
(C) Cumulative probability plot of mEPSC inter event intervals measured in DIV 18-20 neurons
cultured from wild-type, Grin2a-/+ and Grin2a-/- rats.
(D) The bar chart shows mean mEPSC frequencies. A one-way ANOVA showed no significant
effect of genotype on mEPSC frequency (WT: 7 ± 1 , het: 5 ± 1, hom: 8 ± 1). Sample sizes









Figure 5.17: Representative trace showing GABAR mediated mIPSCs
(A) Representative whole-cell voltage-clamp recording from DIV 18 cortical neuron cultured
from a wild type rat. The application of the GABA receptor antagonist bicuculline (50 µM)
abolishes the mIPSCs. Holding potential –65 mV.
























































































Figure 5.18: mIPSC amplitudes and frequencies in cultured neurons are unaffected by
Grin2a knock-out
(A) Cumulative probability plot of mIPSC amplitudes measured in DIV 18 neurons cultured from
wild type, Grin2a-/+ and Grin2a-/- rats.
(B) The bar chart shows mean mIPSC amplitudes. A one-way ANOVA showed no significant
effect of genotype on mIPSC amplitude (WT: 13± 3 (n=5 cells from 1 animal), het: 11± 2 (n=4
cells from 3 animals), hom: 13 ± 2 (n=5 cells from 3 animals)).
(C) Cumulative probability plot of mIPSC inter event intervals measured in DIV 18 neurons
cultured from wild-type, Grin2a-/+ and Grin2a-/- rats.
(D) The bar chart shows mean mIPSC frequencies. A one-way ANOVA showed no significant
effect of genotype on mIPSC frequency (WT: 0.59 ± 0.16 , het: 0.27 ± 0.10, hom: 0.50 ±
0.15). Sample sizes as for amplitudes (see (B)).
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Finally, excitation:inhibition ratios for miniature synaptic events are presented. These were calculated
from cells in which both mEPSCs and mIPSCs were recorded. Figure 5.19 shows the ratios of amplitudes





































Figure 5.19: Ratio of mEPSC:mIPSC amplitudes and frequencies in cultured neurons are
unaffected by Grin2a knock-out
(A) The bar chart shows the ratio of mean mEPSC:mIPSC amplitudes, recorded in the same
cell. A one-way ANOVA showed no significant effect of genotype on the ratio (WT: 1.2 ± 0.1
(n=5 cells from 1 animal), het: 1.5 ± 0.5 (n=3 cells from 3 animals), hom: 0.9 ± 0.2 (n=4 cells
from 3 animals)).
(B) The bar chart shows the ratio of mean mEPSC:mIPSC frequencies, recorded in the same
cell. A one-way ANOVA showed no significant effect of genotype on the ratio (WT: 10 ± 3, het:
10 ± 3, hom: 6 ± 2). Sample sizes as for amplitudes (see (A)).
The degree of inhibition can also be indirectly measured by the degree of disinhibition. This was the
approach taken next. Live-cell calcium imaging with a fluorescent dye was used to concurrently measure
the calcium levels in 50 cells, before and after disinhibition via application of bicuculline. Figure 5.20
shows representative traces. Calcium imaging traces are normally presented as multiples of Ca2+’s
dissociation constant from the dye (Kd), with the fluorescence levels calibrated individually for each
cover slip. This allows comparisons of Ca2+ concentrations between cover slips. However, the calcium
transients generated in the presence of bicuculline matched the saturating response the indicator dye
could generate, preventing their accurate quantification. Thus, only the raw fluoresence levels are
presented as traces here. The basal calcium levels are reported as multiples of Kd, but the amplitude
of the bicuculline induced Ca2+ transients cannot be calculated and so have not been analysed. The
analysis of frequency and duration of transients is unaffected by the difficulty in assessing high Ca2+
concentrations.
Figures 5.21 and 5.22 show the quantification of key calcium imaging parameters for neurons
cultured from wild type, Grin2a-/+ and Grin2a-/- rats. Figure 5.21 shows firstly that there is no difference
in culture density between the genotypes. This is important to exclude as cell density can affect network
activity (Pacico and Mingorance-Le Meur, 2014). Secondly, there is no difference in basal Ca2+ levels
between genotypes, and none of the genotypes exhibited any spontaneous Ca2+ transients during the
wash period.
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Figure 5.22 shows that nearly all cover slips showed coordinated spikes of elevated Ca2+ levels in
the presence of bicuculline. However, Grin2a-/- cover slips on average showed a lower frequency of
spikes than wild type. Heterozygous neurons showed an intermediate frequency of spikes, but this
was not significantly different to the other genotypes. Finally, some of the homozygous cover slips
showed an altered spike morphology, with a quick succession of spikes preventing return to baseline
(see traces in Figure 5.20). This was quantified by measuring spike duration, defined as consecutive









Figure 5.20: Representative traces showing Ca2+ levels in response to bicuculline in
neurons cultured from wild type, Grin2a-/+ and Grin2a-/- rats
(A) Representative trace showing fluorescence intensity of Ca2+ sensitive dye (Fluo-3) recorded
from DIV 17 cultured cortical neurons during washing with aCSF (artificial cerebrospinal fluid)
then bicuculline (50 µM). The thick black line is the average for the cover slip. The thin grey
lines show responses of individual cells.
(B) As for (A) but cells cultured from Grin2a-/+ rat.
(C) As for (A) but cells cultured from Grin2a-/- rat.
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Figure 5.21: Basal Ca2+ levels and cell density in cultured neurons are unaffected by
Grin2a knock-out
(A) The bar chart shows cell counts from the cover slips above, counting all cells in a field of
view of set area (307 µm2). A one-way ANOVA showed no significant effect of genotype on cell
density (WT: 108 ± 13, het: 196 ± 12, hom: 221 ± 15).
(B) The bar chart shows basal Ca2+ levels in DIV 17 neurons cultured from wild type, Grin2a-/+
and Grin2a-/- rats. The Ca2+ levels shown are means of 50 cells per cover slip, and were
averaged over 50 seconds during washing with aCSF. A one-way ANOVA showed no significant
effect of genotype on basal Ca2+ levels (WT: 0.26 ± 0.04 (n=13 cover slips from 4 animals),











































Figure 5.22: Bicuculline-evoked coordinated Ca2+ spikes are less frequent in neurons
cultured from Grin2a-/- rats
(A) The bar chart shows frequency of bicuculline evoked spikes in cover slips cultured from wild
type, Grin2a-/+ and Grin2a-/- rats. A one-way ANOVA showed a significant effect of genotype on
spiking frequency (F(2,37) = 5.1, p = 0.0107). Post-hoc t–tests (Bonferroni corrected) showed
that cells cultured from wild type animals spiked together more frequently than those cultured
from Grin2a-/- animals (WT: 44± 3 (n=13 cover slips from 4 animals), hom: 27± 4 (n=16 cover
slips from 6 animals), t(26.4) = 3.8, pcorr = 0.0024)). Cells cultured from Grin2a-/+ rats did not
show spike frequency significantly different to either wild type or Grin2a-/- rats (het: 37 ± 6,
(n=11 cover slips from 5 animals)).
(B) The bar chart shows durations of bicuculline evoked spikes in cover slips cultured from wild
type, Grin2a-/+ and Grin2a-/- rats. A one-way ANOVA showed no effect of genotype on spike
duration (WT: 6.0 ± 0.5, het: 7.2 ± 0.7, hom: 7.4 ± 0.9). Sample sizes as in (A) except one
fewer Grin2a-/- cover slip, as it demonstrated no spikes.
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The final potential functional consequence of low or absent levels of GluN2A to be assessed was
excitotoxicity. This was measured by exposing cells to a range of NMDA concentrations for one hour,
then fixing and staining with a DNA binding dye (DAPI) the next day. Cells which were alive at the time
of staining show diffuse, even, nuclear DNA, whereas cells which were dead at the time of staining
show condensed, pyknotic nuclei. Figure 5.23 shows representative images and quantification of the
percentage of dead cells at each NMDA concentration for neurons cultured from wild-type, Grin2a-/+ and






















Figure 5.23: Cell death in cultured neurons is unaffected by Grin2a knock-out
(A) The image shows a representative x20 field of view from a cover slip of wild type DIV 17
cultured cortical neurons fixed and stained with DAPI 23 hours after exposure to NMDA 30 µM.
The white triangle marks a dead cell, the grey triangle a cell that was living at the time of
staining. The white bar marks 50 µm. All images have had brightness of faint objects enhanced
by using ImageJ’s (Schneider et al., 2012) non-linear intensity adjustment function with gamma
set to 0.5.
(B) As (A) but neurons cultured from Grin2a-/+ rat.
(C) As (A) but neurons cultured from Grin2a-/- rat.
(D) The bar chart shows % cell death in DIV 17 neurons cultured from wild-type, Grin2a-/+ and
Grin2a-/- rats. A two-way ANOVA showed no significant effect of genotype on cell death but a
significant effect of NMDA concentration (F(5,66) = 66, p < 2e-16).
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5.7 Discussion
5.7.1 Summary of findings
This chapter first described the validation of two new rat models allowing the constitutive and conditional
knock-out of Grin2a. It then described some initial functional investigations into the consequences of
Grin2a knock-out, identifying a reduction in current density and altered inhibition in cultured neurons.
Grin2a knock-out was not found to affect frequency or amplitude of miniature synaptic events, or
excitotoxicity. Heterozygous Grin2a knock-out resulted in functional haploinsufficiency, including reduced
current density, but did not impact on any other functional property assessed.
5.7.2 Validation of Grin2aflox/flox and Grin2a-/- model
Investigation of the Grin2aflox/flox rat confirmed the appropriate exon is floxed and that exposure to Cre
results in excision of the exon. It also confirmed that the LoxP sites do not influence GluN2A expression
in the absence of exposure to Cre. It is useful to confirm that Grin2a can be conditionally knocked
out in these rats when cultured. However, the knock-out would need to be revalidated in any further
experimental conditions, for example, if a virus for in vivo injection was used, or if the line were crossed
with a Cre line.
Similarly, it is useful to have confirmed that Grin2a is constitutively knocked out in the cortices and
cultured cortical neurons of the Grin2a-/- rats. However, conceivably different tissue types could process
the modified Grin2a transcript differently, so it would be important to confirm knock-out in the particular
region of interest for future experiments, for example, the hippocampus.
To my knowledge, these are the first rat models of Grin2a knock-out. However, a mouse Grin2a
knock-out was generated in the 1990s. Table 5.1 summarises findings in the mouse model. Overall,
Grin2a knock-out is associated with a relatively mild phenotype. A range of reductions in synaptic
plasticity have been identified, as have some specific mild learning impairments. Three studies observed
increased motor activity in unfamiliar environments, and the initial publication reporting the line described
them as “jumpy” (Sakimura et al., 1995). No studies have reported spontaneous seizures (and none have
been observed in the Grin2a-/- rats maintained during this study).
5.7.3 Grin2a-/+ and Grin2a-/- neurons have reduced current density
A reduction in NMDA-evoked current density in cultured neurons aged older than two weeks was
identified in heterozygous and homozygous knock-out rats. This is of interest for two reaons. Firstly,
it shows that cultured neurons do not wholly compensate for the absence of GluN2A by increasing
expression of other GluN2 or GluN3 subunits. It is possible that there is some increase in other GluN
subunits but any increase is insufficient to match the loss of GluN2A. A more complete picture of changes
in other GluN subunits could be provided by performing immunoblots for the other GluN subunits in
Grin2a-/+ and Grin2a-/- rats.
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Table 5.1: Phenotypes observed in Grin2a-/- mice
Phenotype Study
Basic phenotypic assessment
Normal skeletal structure, eye structure, International Mouse Phenotyping Consortium
haematology, biochemistry, (www.mousephenotype.org)
startle response, tremor,
open field behaviour, time on rotarod
Altered synaptic plasticity
Reduced in hippocampus Kiyama et al. (1998); Sakimura et al. (1995)
Ito et al. (1996); Longordo et al. (2009)
Kannangara et al. (2015)
Reduced in visual pathways Cho et al. (2009); Philpot et al. (2007)
Zhao and Constantine-Paton (2007)
Reduced in cerebellum Andreescu et al. (2011)
Altered behaviour
Impaired spatial reference memory Miyamoto et al. (2001); Sakimura et al. (1995)
Kannangara et al. (2015)
Impairments in other types of memory
Reduced spatial working memory Bannerman et al. (2008)
Reduced context dependent fear conditioning, Kiyama et al. (1998)
particularly when short exposure to context
Reduced motor learning (phase reversal Andreescu et al. (2011)
adaptation of vestibulo-ocular reflex)
Reduced eye blink conditioning Kishimoto et al. (1997)
Reduced visual discrimination learning Brigman et al. (2008)
Impaired set shifting Marquardt et al. (2014)
Altered motor activity
Increased motor activity in new environment Miyamoto et al. (2001); Tomiyama et al. (2013)
Boyce-Rustay and Holmes (2006b)
Reduced motor coordination (time on rotarod) Boyce-Rustay and Holmes (2006a)
Other phenotypes
Dendritic alterations in immature cells Kannangara et al. (2014)
in dentate gyrus
Smaller injury size following transient Morikawa et al. (1998)
(but not prolonged) ischaemia
Increased NMDA-evoked release Miyamoto et al. (2001)
of dopamine in striatum
Decreased NMDA-evoked release Miyamoto et al. (2001)
of GABA in striatum
Less sensitivity to seizure following Sakamoto et al. (2002)
electrical stimulation of inferior colliculus
All phenotypes reported as Grin2a-/- mice relative to wild type
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A reduction in current density is also of interest because this will impact on NMDAR signalling. A
given stimulus will evoke less response in the heterozygotes or homozygotes than in wild type. This
would be expected to influence excitability via smaller changes in membrane potential due to NMDAR
activation, and potentially to impact on synaptic plasticity via less Ca2+ entry. These possibilities could
be explored by making recordings from acute slices in vitro in regions such as the hippocampus and
assessing NMDAR-mediated EPSP and response to paradigms designed to evoke NMDAR-mediated
synaptic plasticity, such as long term potentiation and depression. Indeed, previous work with Grin2a-/-
mice has shown a range of reductions in synaptic plasticity (see Table 5.1).
5.7.4 Grin2a knock-out does not influence properties of miniature synaptic events
No effect of Grin2a knock-out was found on the amplitude or frequency of mEPSCs or mIPSCs, or their
ratio, in mature cultured cortical neurons. This is in contrast to what has been found previously, albeit
those findings have opposed each other. One group conditionally knocked out GluN2A in mice using viral
injections on P0/P1 and recording from CA1 pyramidal neurons in acute slices on P17. They identified
a reduction in mEPSC amplitude in the absence of GluN2A, but no effect on frequency (Gray et al.,
2011). The other group made recordings in hippocampal organotypic slices, overexpressing GluN2A
after biolistic transfection 60-72 hours prior to recording. They identified a reduction in mEPSC frequency
with overexpression of GluN2A but no effect on amplitude (Gambrill and Barria, 2011). A few differences
between the current study and the previous work stand out. Firstly, both the previous studies were done
in hippocampal preparations, whereas this study was performed in cortical neurons. Secondly, neither
previous study caused GluN2A alterations in all the cells in the preparation, whereas this study generated
cells where the entire network experienced a complete absence of GluN2A. Finally, this study was
performed in dissociated cultures, meaning that normal regional architecture was abolished, in contrast
to slices. Regional differences, network level compensation, or altered networks following dissociation,
could all therefore explain the lack of differences found in this study compared to previous work.
To investigate the impact of Grin2a knock-out in a more physiological manner, it would be useful
to assess mEPSCs and mIPSCs in acute slices from Grin2a-/- rats. It would also be interesting to
investigate the possibility of network compensation further, as “synaptic scaling” is known to operate
widely in cultured neocortical neurons - modulating network activity induces compensatory changes
in mEPSC or mIPSC amplitude via bidirectional changes in AMPAR or GABAAR density respectively
(reviewed in Turrigiano (2011)). If homeostatic plasticity has occurred in Grin2a-/- cultures to maintain
mEPSC frequency and amplitude similar to wild type, it could be hypothesised that the system will have
less reserve to deal with a second pertubation to synaptic activity, such as the overnight application of
TTX, and differences between genotypes could potentially be revealed in this way.
5.7.5 Grin2a knock-out reduces disinhibition
Knock-out of Grin2a was found to reduce the frequency of coordinated calcium transients following
blockade of inhibitory neurotransmission by bicuculline in mature cultured cortical neurons. This could
be due to a reduction in inhibitory inputs to Grin2a-/- cells resulting in less disinhibition when inhibition is
removed. Although some previous work supports the idea that NMDARs are important for inhibitory
function (Moreau and Kullmann, 2013), no evidence to directly support this was provided here. A
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reduction in coordinated activity following bicuculline could also arise from an overall reduction in network
coordination. Further work to explore the causes of the altered network coordination would include
assessing the number of interneurons in Grin2a-/- rats, with parvalbumin-positive interneurons being of
most interest, and using multi-electrode arrays to make field recordings from cultures or acute slices
at rest and following stimulation. The multi-electrode array recordings could allow coordinated network
activity to be assessed in a more precise manner than is possible with Ca2+ imaging, where the need to
avoid photo bleaching limits the sampling frequency (in this study, to once per second).
Coordinated neural activity, particularly gamma oscillations, have been linked to a range of cognitive
functions, and reductions in coordination identified in a range of neurodevelopmental disorders (reviewed
by Uhlhaas and Singer (2012)). If Grin2a knock-out does indeed cause a reduction in coordinated
network activity, this may be of great relevance to the pathophysiology of epilepsy-aphasia syndromes.
It would be interesting to make EEG recordings from Grin2a-/+ rats and see if there is any evidence
of alterations in coordination, particularly in the gamma band. It would also be interesting to look for
EEG findings typical of those found in epilepsy-aphasia syndrome: paroxysmal centrotemporal spikes,
particularly during sleep (Berroya et al., 2005; Smith and Hoeppner, 2003). Unexpectedly, the only study
which has addressed seizures in Grin2a knock-out mice found that they showed a higher resistance to
seizures evoked by direct electrical stimulation of the inferior colliculus (stimulating the same pathway as
audiogenic seizures) (Sakamoto et al., 2002).
5.7.6 Grin2a knock-out does not influence excitotoxicity
Knock-out of Grin2a was found not to influence the vulnerability of cells to death induced by prolonged
elevated ambient levels of NMDA. This is consistent with previous work highlighting the C terminus of
GluN2B as critical in mediating cell death under these conditions (Martel et al., 2012). The finding that
the current density in Grin2a-/- was significantly lower than in wild type cells suggests that minimal, if
any, compensatory increase in GluN2B expression occurred in Grin2a-/- cells. If their GluN2B expression
levels were similar to those of wild type cells, it would be expected that their vulnerability to NMDA
evoked cell death would be similar also. Although some previous work using pharmacological blockage
concludes GluN2A is neuroprotective (for example, (Terasaki et al., 2010; von Engelhardt et al., 2007)),
the findings of this study suggest it is neutral with regard to excitotoxicity.
5.7.7 Limitations
The major limitations of this chapter are with regard to the relevance of the findings in Grin2a-/+ rats to
GRIN2A disrupting mutations in humans with epilepsy-aphasia syndromes. Firstly, the only assessment
of functional consquences performed here has been in dissociated cultured cortical neurons. This system
was chosen as it was a relatively simple way to quickly assess a range of parameters. However,
assessment of functional impact at the whole organism or regional level would be much preferable,
and offers a rich vein of future work in this area. The second limitation is that not all the functional
consequences detected in homozygous knock-outs have been detected in heterozygotes. Although
functional consequences in homozygotes are of physiological interest, to be relevant to disease they
should also be detectable in heterozygous knock-outs.
182
5.7.8 Conclusion
This chapter has validated two new rat models: a constitutive and conditional knock-out of Grin2a. It
established that Grin2a-/+ rats experience haploinsufficiency, and that this is associated with a reduction
in NMDA-evoked current density. This chapter has therefore taken some preliminary steps towards using






6.1.1 Summary of key findings
This thesis assessed the functional consequences of four missense mutations in the type 2A and 2B
subunits of the NMDA receptor, and performed a validation and preliminary functional investigation of
rat models where the 2A subunit was knocked-out heterozygously or homozygously. The key findings
of this thesis are: three of the four missense mutations were found to significantly alter physiologically
fundamental properties of the NMDAR: compared to wild type, GluN2AN615K was found to reduce Mg2+
block, GluN2BN615I and GluN2BV618G to cause potentiation by Mg2+, and GluN2AN615K and GluN2BN615I
showed reduced conductance. GluN2AR586K was not found to influence the parameters assessed. When
GluN2AN615K was expressed alongside wild type subunits in the same NMDA receptor, it was found to
have a dominant negative effect. In the rat Grin2a knock-out model, heterozygous neurons had lower
GluN2A protein expression and current density, and homozygous neurons showed reduced coordinated
neural activity.
6.1.2 How might these mutations contribute to neurodevelopmental disorders?
The overall aim of this thesis was to use the knowledge generated from functional investigations of
mutations in NMDARs found in humans with neurodevelopmental disorders to better understand the
pathogenesis of neurodevelopmental disorders. What progress has been made towards this aim?
Firstly, three of the four missense mutations were found to cause marked disruption to a NMDAR
property which is already known to be integral to important brain functions: Mg2+ block. In the case of
GluN2AN615K, this effect was found to be dominant negative. Mg2+ block is essential to the NMDAR’s role
as a molecular coincidence detector and hence its roles in synaptogenesis and synaptic plasticity (see
Section 1.4.7 and 1.4.8). As these processes are thought to represent the cellular basis of learning and
memory, a mutation which altered them could plausibly lead to neurodevelopmental disorder, particularly
intellectual disability.
Secondly, two of the four missense mutations were found to reduce single channel conductance:
the rate of flow of ions through the channel. As most, if not all, of the NMDAR’s signalling is ionotropic,
reductions in this would influence many NMDAR functions. For example, less excitatory drive could
disrupt the rhythm of neural oscillations. Less Ca2+ entry during an activation could result in inappropriate
intracellular signals for regulation of AMPA receptor density or gene expression.
Thirdly, the heterozygous Grin2a-/+ rat was found to show reduced current density. As with the point
mutations, this could result in alterations in excitatory drive and Ca2+ dependent signalling. The alteration
in coordinated neural activity seen in the homozygous Grin2a-/- rat suggests changes in excitatory drive
may be important.
The identification of altered functional consequences associated with these mutations is thus
consistent with them having a role in causing neurodevelopmental disorders. However, this thesis has
not been able to prove this. No reversal of the altered property with subequent reversal of phenotype
has been attempted. It remains possible that the altered properties identified are not important in
causing disease, or that additional altered properties that have not been assessed are also important.
The hypothesised impact on circuit level functions such as plasticity has not been assessed. Any
compensation which could occur during development of a whole organism has also not been assessed.
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Finally, the impact of the mutations in NMDARs expressed in human cells, rather than heterologously in
rodent cells, has not been evaluated.
Despite these limitations I believe the severity of the alteration in NMDAR properties observed
makes it highly likely that these mutations do influence risk for neurodevelopmental disorder in their
carriers. Overall, the functional consequences of these mutations highlight synaptic plasticity, neural
oscillations and possibly synaptogenesis as candidate mechanisms which are disrupted in epileptic
encephalopathies and epilepsy-aphasia syndromes.
6.1.3 Do functional consequences of mutations in NMDARs indicate a shared
aetiology for NMDAR-synaptopathies?
The NMDAR mutations studied in this thesis are not the only ones to have been functionally investigated.
Is there a pattern of functional alteration common to all NMDAR mutations found in people with
neurodevelopmental disorders? Table 6.1 presents a summary of the functional consequences of the
19 other mutations for which functional investigations have been published so far. As in this thesis,
these investigations have all been peformed in heterologous systems and extrapolation to humans
brains needs to be done cautiously. The table shows that the functional consequences of the mutations
influence a range of receptor properties, and in opposing overall directions (activating/“gain of function”
or inhibiting/“loss of function”). There is no one consequence of mutations in either gene, unsurprisingly
given their diverse locations. In the small number of mutations assessed so far in GRIN2B, there is a
pattern of activating mutations being associated with epilepsy, and inhibitory mutations being associated
with intellectual disability, but more mutations would need to be tested before this pattern could be viewed
as definite. However, there is clearly no one overall consequence for GRIN2A mutations associated with
epilepsy-aphasia syndromes, as these disorders are associated with mutations which both increase and
decrease overall channel activation.
The different directions of effect for GRIN2A mutation functional consequences may reflect the
fact that most of the mutations have undergone targeted rather than consistent functional evaluation,
and may affect more than one property without this being known. For example, opposing effects on
different properties have been identified in this thesis for GluN2AN615K and GluN2BN615I. A thorough
evaluation of each mutation and synthesis of effects may lead to the identification of an overall pattern
of increased or decreased function. Alternatively, there may be some specific shared consequence of
all the mutations which remains to be identified, for example, an interaction with a particular intracellular
protein. However, it remains possible that similar symptoms can be caused by a disruption of neural
homeostasis in opposite directions. This has already been proposed in the aberrant protein synthesis
theory of intellectual disability and autism, where too much or too little protein synthesis give a similar
phenotype (Auerbach et al., 2011). Similarly to GRIN2A, the same type of epilepsy has been observed in
people carrying mutations of opposing effect in the case of the nicotinic acetylcholine receptor (causing
autosomal dominant nocturnal frontal lobe epilepsy) and the type 1.1 voltage gated sodium channel
(causing Dravet syndrome) (Avanzini et al., 2007).
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Table 6.1: Functional consequences of mutations identified in GRIN2A and GRIN2B
Study Disorder Protein domain Mutation Consequence
GluN2A
Activating
Lemke et al. (2013) Epilepsy-aphasia N terminus GluN2AA243V Zn2+ inhibition
syndrome reduced
Lesca et al. (2013) Epilepsy-aphasia Ligand binding GluN2AR518H Channel opening time
syndrome domain (S1) increased four fold
Carvill et al. (2013) Epilepsy-aphasia Ligand binding GluN2AT531M Channel opening time
syndrome domain (S1) increased four fold
Endele et al. (2010) Epileptic Pore (M2) GluN2AN615K Ca2+ permeability
encephalopathy reduced three fold
Lesca et al. (2013) Epilepsy-aphasia Pore (M3) GluN2AF652V Channel opening time
syndrome increased two fold
Yuan et al. (2014) Epileptic Ligand binding GluN2AL812M Glutamate and glycine
encephalopathy domain (S2-M4 linker) (di- and tri-het) potency increased,





Serraz et al. (2016) Epilepsy-aphasia N terminus GluN2AP79R Protein expression
syndrome (di- and tri-het) reduced. Zn2+ inhibition
reduced four fold but
H+ inhibition increased.
Serraz et al. (2016) Epilepsy-aphasia N terminus GluN2AC231Y Protein expression
syndrome markedly reduced
Serraz et al. (2016) Epilepsy-aphasia N terminus GluN2AR370W Zn2+ inhibition
syndrome (di- and tri-het) increased > ten fold
Serraz et al. (2016) Epilepsy-aphasia Ligand binding GluN2AC436R Protein expression
syndrome domain markedly reduced
No effect
Serraz et al. (2016) Epilepsy-aphasia N terminus GluN2AF183I No effect on expression,
syndrome GluN2AI184S glutamate affinity,
GluN2AC243V glycine affinity,
GluN2AC290V open probability,
GluN2AG295S Zn2+ or H+ inhibition
GluN2B
Activating
Lemke et al. (2014) Epileptic Pore (M2) GluN2BN615I Ca2+ permeability
encephalopathy increased three fold
Lemke et al. (2014) Epileptic Pore (M2) GluN2BV618G Ca2+ permeability
encephalopathy increased three fold
Inhibitory
Endele et al. (2010) Intellectual disability N terminus GluN2BR682C Glycine affinity
(moderate) two fold reduction
Adams et al. (2014) Intellectual disability Ligand binding GluN2BE413G Glutamate affinity
(severe) domain (S1) reduced 50-fold
Di- and tri-het refers to diheteromers and triheteromers. Where not specified, only diheteromers
were investigated. Findings which have been replicated in this thesis are not included in the
table.
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6.1.4 Do functional consequences of mutations in other genes indicate a shared
aetiology for epileptic encephalopathies?
How do the findings of this thesis relate to other causes of the same disorders? The three missense
mutations studied here are all associated with epileptic encephalopathy. Do other causes of epileptic
encephalopathy demonstrate alterations at the circuit level similar to those proposed for these mutations?
For example, do they show alterations in synaptic plasticity or neural oscillations? The answer to this
question is uncertain. As the majority of genetic causes of epileptic encephalopathies have only been
identified within the last five years, the major animal models in this field represent acquired epilepsy,
seeking to model the impact of early life infection, hypoxia or stress, on the brain and assessing
predominantly seizure phenomenology and behavioural outcomes rather than neural circuit effects
(reviewed in Galanopoulou and Moshe (2015), Shao and Stafstrom (2016) and Auvin et al. (2016)).
One of the main animal models of epileptic encephalopathy is intra-peritoneal injection of NMDA,
which in addition to causing truncal flexion seizures is acutely associated with impairments in learning
and coordination (Shao and Stafstrom, 2016). Interestingly, maternal exposure to prenatal stress or
stress hormones shortens the latency of time to seizure following injection (Shao and Stafstrom, 2016).
Using this model, it was recently found that rats which had undergone NMDA injection as juveniles
showed enhanced hippocampal LTP as adults (Tsuji et al., 2016). Thus, exposure to excess NMDAR
activation during development is associated with seizures, cognitive impairment and later alterations in
synaptic plasticity. This supports the theory that activating NMDAR mutations could also cause these
effects, but does not speak to any convergence across multiple causes of epileptic encephalopathy.
The animal models of genes found to be mutated in epileptic encephalopathies available so far
provide some evidence of convergence on interneuron dysfunction. Mutations in the transcription factor
ARX (West syndrome) are associated with interneuron migration abnormalities (Marsh et al., 2009), and
mutations in the sodium channel gene SCN1A (Dravet syndrome) are associated with impaired firing
of fast-spiking interneurons (Yu et al., 2006). This resonates with the proposed importance of NMDAR
subunits for interneuron function (see Section 5.2.2 in Chapter 5’s Introduction) and with the abnormalities
in disinhibition observed in homozygous Grin2a-/- rats in Chapter 5. However, further investigation with
different genes is needed to clarify the importance of interneuron dysfunction more generally in epileptic
encephalopathies.
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6.1.5 How can the findings of this thesis be used clinically?
Is there any clinical utility to the findings of this thesis? Firstly, are there any pharmacological treatments
available which could reverse the functional alterations seen? Unfortunately, in the case of the missense
mutations, existing pharmacological treatments are unlikely to be of benefit. This is partly because
the nature of the direction of useful modification is unclear - if a channel is open too much (i.e. has
loss of Mg2+ block), blocking it could be helpful. However, if it is allowing too little current to pass (i.e.
a reduction in single channel conductance), potentiating it could be helpful. Which, if any, of these
interventions is of benefit could potentially be established in an animal model, but not in heterologous
systems without robust validation of a “cellular phenotype” which relates to clinical symptoms. Further,
because the mutations are carried heterozygously, the impact of any drug on the wild type subunit needs
to be considered. Improving the function of the mutant while disrupting the function of the wild type
subunit is unlikely to be of overall benefit. This would likely be a problem if dextromethorphan were used
to block receptors containing GluN2AN615K subunits as the difference in potency between GluN2AN615K
and wild type subunits is not large.
Despite these difficulties, a treatment based on correcting the consequence of a missense point
mutation in a NMDAR subunit has been trialled and found to be of benefit (Pierson et al., 2014). In this
case, a child with epileptic encephalopathy was found to heterozygously carry the GluN2AL812M mutation.
Electrophysiological assessment showed this mutation to result in overactivation of NMDARs with all the
parameters assessed. Memantine potency was reduced about three fold by the mutation compared to
wild type, but maximal effective block was the same. Aged nine years old, the child was therefore given
a trial of memantine with the aim of reducing activity of receptors containing his mutated subunits. The
trial reduced the frequency of his seizures to a third of what they had been, and abolished his myoclonic
jerks, but did not influence his cognition. Thus, in this case knowledge of the functional consequences
of a point mutation did allow useful, personalised treatment. This allows optimism that were a drug to be
identified which reduced the effects of the missense mutations studied here, it could still be of benefit in
someone with established symptoms.
Considering the mutations which probably result in an absent protein, modelled by the Grin2a-/+ rat,
the picture is a little simpler. Here, the problem is not enough GluN2A activity, and this could potentially
be improved by positive allosteric modulators which are selective for GluN2A over GluN2B, for example,
GNE-6901 or GNE-8324, members of a recently identified new class of modulator which stabilise the
GluN1/GluN2A ligand binding domain subunit interface in an open conformation (Hackos et al., 2016).
Alternatives would include UBP512, although at the required concentrations this also inhibits GluN2C and
GluN2D (Costa et al., 2010). Positive allosteric modulators which enhance both GluN2A and GluN2B
activity, for example pregnenolone sulphate (Malayev et al., 2002) or UBP710 (Costa et al., 2010),
could potentially also be useful, although may increase the risk of GluN2B-mediated excitotoxicity. It
would be important to establish the efficacy of these drugs on GluN2A/GluN2B triheteromeric receptors
before using them in animals, and indeed the GNE compounds have already been shown to potentiate
GluN2A/GluN2B triheteromers, although to a lesser extent than their potentiation of GluN2A diheteromers
(Hackos et al., 2016).
A new field of treatment possibilities for genetic disorders is provided by gene therapy: editing,
replacing or blocking the expression of a mutated gene (Naldini, 2015). Major obstacles remain to its
implementation in vivo, and there are concerns about the ethics of irreversible treatments. However, there
are some relatively simple, reversible forms of targeted gene therapy which have already shown benefit
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in vitro in disorders caused by ion channel mutations. For example, allele-specific RNA interference
was used to specifically downregulate a heterozygous mutant allele encoding a potassium channel
which causes heart arrhythmias (Matsa et al., 2014). This approach could potentially benefit carriers
of dominant negative mutations such as GluN2AN615K. Those with GRIN2A nonsense mutations could
potentially benefit from trialling an antibiotic such as gentamicin. This has been used to induce
read through of a premature stop codon in a GABAA receptor subunit associated with the epileptic
encephalopathy Dravet’s syndrome, showing partial rescue in vitro (Huang et al., 2012).
The second domain of clinical utility of these results is in diagnosis, prognosis, and reproductive
planning. Knowing that the GluN2AN615K, GluN2BN615I and GluN2BV618G mutations are associated with
marked functional consequences, but GluN2AR586K is not, is useful to clinical geneticists and families who
are either trying to understand the cause of a disorder in a child or plan regarding future pregnancies.
This information may also be relevant to similar but non-identical mutations, as it highlights which residues
can tolerate a change, and which cannot without altering important properties.
6.1.6 What future work would be useful?
The results of this thesis suggest a range of future experiments. Continuing to work with heterologous
expression systems, it would be interesting to assess single channel conductance in NMDARs containing
GluN2BV618G mutant subunits, and in triheteromeric versions of all three of the mutant subunits. Ca2+
permeabiility of diheteromeric mutant subunits has been assessed by others, but this would also be
interesting to examine in triheteromers. These experiments would improve mechanistic understanding of
the consequences of the mutations.
To allow assessment of circuit level dysfunction and behaviour, the GluN2AN615K, GluN2BN615I and
GluN2BV618G could all be usefully explored in animal models. Circuit level function could be assessed
by making multi-electrode array recordings from acute slice preparations, amongst other approaches.
Animal models would also allow pharmacological agents to be trialled, and the effect of removing the
mutation could be tested if genetic reversibility were included within the model design.
The Grin2a-/+ rat has been validated and stands ready for a range of future experiments. Of
particular interest would be to assess the impact of GluN2A haploinsufficiency on EPSCs in principal
cells and interneurons in the hippocampus. This could help to clarify which cell type is more affected,
with the hypothesis that excitatory drive to interneurons would show a greater reduction. It would
also be interesting to assess synaptic plasticity in hippocampal slices, with the hypothesis that GluN2A
heterozygotes would show a reduction in LTP, as seen in mice (see Table 5.1 in Chapter 5’s discussion).
Network dynamics could also be investigated in hippocampal slices via multi-electrode array recordings.
Spontaneous and evoked activity could be assessed for frequency, power and burst profiles, with the
hypothesis that the GluN2A heterozgotes would show lower gamma power but greater propensity to
epileptiform activity in the presence of pro-convulsant agents.
Considering experiments at the whole organism level, seizure susceptibility would be important to
assess by monitoring response to a seizure inducing stimulus (e.g. noise), with the hypothesis that
GluN2A heterozygotes would show a lower seizure threshold. Analysing the EEG of alert, spontaneously
behaving animals during sleep and awake periods would be potentially very useful translationally - with
the hypothesis that GluN2A heterozygote rats would show spike and wave activity during the slow wave
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stages of their sleep cycle, and potentially some spikes over the motor cortex when awake (based on
what has been observed in humans). Cognitive dysfunction would also be important to assess. Grin2a-/-
mice show some mild impairments in spatial memory, fear conditioning and set shifting (see Table 5.1).
Grin2a-/- rats would be expected to share these deficits, but in addition allow a more complex repertoire
of cognitive testing than is easy to achieve in mice. For example, object-place recognition, which tests the
rat’s ability to distinguish objects based on a memory combining their familiary and their location when
first presented, and which has been shown to be NMDAR-dependent (Barker and Warburton, 2008).
Use of these more complex tests may be required to identify potentially subtle deficits in heterozygous
animals, given that many GRIN2A+/- humans do not show intellectual disability.
The Grin2aflox/flox rat has also been validated. When combined with exposure to Cre recombinase
this rat allows assessment of the importance of GluN2A in development and in particular cell types or
brain regions. Cre expression could be achieved by crossing the Grin2aflox/flox line with a Cre-expressing
genetically modified line, although there are not many of these available in rats yet. Alternatively, Cre
expression could be achieved using viruses injected in vivo or into organotypic slices. The use of cell
type specific promoters would allow the importance of GluN2A in interneurons to be addressed, with the
hypothesis that selective knock-out of GluN2A in interneurons alone would result in an epilepsy-related
phenotype. Injection of virus at different ages would allow the identification of any “critical period” after
which GluN2A removal does not result in impairment. The presence or absence of such a period would
have implications for the timing of any future treatments for GluN2A haploinsufficiency.
6.1.7 Conclusion
In conclusion, this thesis addressed the hypothesis that mutations in NMDAR subunits cause
neurodevelopmental disorders in humans. I found that three of the four missense mutations studied
caused substantial changes in physiologically pivotal NMDAR properties. I also found that a rat model
of gene disrupting mutations in the GluN2A subunit experienced haploinsufficiency with a reduction in
NMDAR currents. Overall, these findings strengthen the evidence that these NMDAR subunit mutations
cause neurodevelopmental disorders, and further emphasise NMDAR-related functions such as synaptic
plasticity as likely candidates for disruption during the pathogenesis of mental disorder.
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